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Summary 
Introduction 
Enteric infections remain a significant public health problem. Worldwide, the 
infectious diarrhea is the second leading cause of childhood morbidity and 
mortality, and raise one of the most common human suffering with high 
morbidity and associated long term sequelae. Furthermore long term 
diarrhea is associated to cognitive and development deficiency in early 
childhood ages (under five years age). Infectious diarrheal disease is 
associated with poverty, and child mortality from it is higher in low-income 
than in high-income countries and in populations in crisis situations. In 
particular, enteric infections (diarrheal disorders) were responsible for an 
estimated 4.6 million deaths worldwide from around 1 billion episodes of 
diarrhea annually in children. Despite the widespread use of oral 
rehydration therapies (ORT) and an increased understanding of the 
pathogenesis of diarrhea, 1.9 million children less than five years of age still 
die from these illnesses every year according to recent WHO and UNICEF 
reports. Enteric infections outbreaks occur through the ingestion of 
contaminated food or water (fecal-oral route transmission) or by direct 
contact (person to person). The main clinical symptomatology of enteric 
infections can include either gastrointestinal, systemic affectations or both 
successively. The main symptom of gastrointestinal affectation is diarrhea. 
Other frequent symptoms are fever, nausea, vomiting and abdominal pain, 
depending on microbial pathogen. Systemic affectations imply more serious 
syndromes including hemolytic uremic syndrome as the one produced by 
enterohaemorrhagic E. coli (EHEC), meningitis, malabsorption disorders, 
cardio-neurological alterations, arthritis and hepatitis. WHO defines 
diarrhea as the “passage of loose or watery stools at least three times in a 
24 h period”, the diarrhea occurs as a result of the failure or ineffectiveness 
of the digestive tract to perform its absorption function, by different 
mechanisms that contribute to loss of fluids and electrolytes following 
microbial infections. The etiological agents of enteric infections are 
bacteria, viruses, protozoa, fungi and helminthes. 
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In developing countries the most recurrence causative agents are bacteria. 
Escherichia coli is the predominant facultative anaerobe of the human 
colonic microbiota. Escherichia coli gradually emerged as a cause of 
diarrhea. Diarrheagenic E. coli (DEC) cause infection by a variety of 
complex mechanisms. These include adherence, production of toxigenic 
mediators, invasion of the intestinal mucosa, and transportation of bacterial 
proteins into the host cells. Diarrheagenic E. coli (DEC) is classified into six 
characterized categories: enteropathogenic E. coli (EPEC), 
enterohaemorrhagic E. coli (EHEC), enterotoxigenic E. coli (ETEC), 
enteroinvasive E. coli (EIEC),  enteroaggregative E. coli (EAEC), and 
diffusely adhering E. coli (DAEC). Enteropathogenic E. coli (EPEC) is the 
leading cause of morbidity and mortality of children under five years old in 
developing countries. Using a type-three secretion system the bacterial 
effector proteins are transferred to the host cell cytosol and affect multiple 
physiological functions, ultimately leading to diarrheal disease. EPEC 
attach to cells and form actin-rich structures called pedestals, which 
contain many proteins that play unknown functions during pedestal 
formation. Injected Tir binds to Intimin on the bacterial surface and 
promotes attaching of bacteria intimately and effacing lesion formation (loss 
of absorptive microvilli), leading to assembly of cytoskeleton intracellular 
actin on the cellular surface. Rearrangements of the actin cytoskeleton 
compose a pedestal-like structure where the bacterium tightly cups the 
cells, leading to degeneration of brush border microvilli and occurrence of 
diarrhea. Oral Rehydration Therapy (ORT) and nutritional support should 
be performed before any other therapeutic agent. Antibiotics are required 
for the treatment of bacterial gastroenteritis in those patients suffering from 
severe complications of gastroenteritis, including dissemination of the 
disease or sepsis. Generally, antimicrobial treatment tends to speed up the 
clinical resolution of diarrhea, prevents the progression of the disease and 
reduces the severity of associated symptoms as fever, vomiting and 
abdominal pain. 
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Antibiotics induce bacterial cell death based on the bacterial cell function 
that can be inhibited by the drug-target interaction. The mechanism 
includes interference with cell wall synthesis, interference with nucleic acid 
synthesis, inhibition of protein synthesis, metabolic pathway inhibition and 
alterations of cell membrane. Currently, there are many synthetic antibiotics 
for treatment of various diseases caused by microorganisms. Some of 
these microorganisms have become resistant to antibiotics, rendering them 
ineffective. The global emergence of bacterial resistance particularly E. coli 
to the antimicrobial agents has increased. The resistance to antimicrobials 
is due to several causes: genetic plasticity of the microorganisms, 
unnecessary and inappropriate use, including inadequate dosing, low 
quality drugs, and increased mobility of the world population. A great 
number of bacterial isolates are showing resistant to practically all available 
therapeutic agents. Therefore, the problem has been building up over 
decades, and today many common and life-threatening infections are 
becoming difficult or even impossible to treat, sometimes turning a common 
infection into a life-threatening one. So, there is a continuing need to search 
for new antibacterial agents to overcome antibiotic resistance. Medicinal 
plants remain an integrated part of cultures for diseases treatment since 
ancient times. For these reasons, focusing on alternative herbal medicine 
has been increased for discovering new therapeutic/antibacterial agents. 
Much more interest has been paid to extracts and biologically active 
compounds that were isolated from plant species. This interest in the use of 
phytocompounds was due to the emergence of side effects of synthetic 
compounds and the need to find new compounds, including new antibiotics 
to treat multiresistance bacteria. Therefore, plants can offer a new source 
of antibacterial agents. It is well known that phytochemical constituents and 
secondary metabolites are responsible for the activity of plants. The 
majority of these secondary metabolites work as a defense mechanism 
against predators and pathogens. The major groups of phytocompounds 
and bioactive constituents that work as antimicrobial agents are phenols, 
polyphenols, quinones, tannins, coumarines, flavonols, flavone, flavonoids, 
terpenoids, essential oils and alkaloids. There is an important direction that 
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can help us to overcome the problem of microbial resistance is to dedicate 
our efforts toward scientific research in order to discover new antimicrobial 
agents. In Europe, nearly 1500 species of medicinal and aromatic plants 
are widely used in Albania, Bulgaria, Croatia, France, Germany, Hungary, 
Poland, Spain, Turkey, and the United Kingdom. Many medicinal plants are 
used as antibacterial agents. It has been reported that Allium sativum, 
Zingiber officinale, Methanolic extract of Tussilago farfara, Equisetum 
arvense, Sambucus nigra, Aesculus hippocastanum and Taraxacum 
officinale possess antibacterial activity. Likewise, juices of blueberry, sour 
grape, Isabella grape, wild blackberry, essential oil of Rosmarinus officinalis 
and Salvia officinalis showed antibacterial activity. Moreover, essential oils 
obtained from Origanum vulgare showed effective antibacterial activity. 
Furthermore, methanol and aqueous extracts of the leaves of Syzygium 
cumini presented good antibacterial active agent. As well, ethanol extract 
and acetone extract of Cinnamonum zeylanicum and 
Trachyspermum ammi displayed good antibacterial activity. H. sabdariffa 
calyces extract has different biological potential activities. It can be used as 
an anti-obesity agent, treatment of atherosclerosis, diabetes, liver disease 
and metabolic syndrome. Furthermore, it can be used as antihypertensive 
and cardioprotective effects in type II diabetic patient with mild 
hypertension. Its aqueous and ethanol extracts can be used as food 
preservatives. It showed a dose dependent inhibitory effect against food 
spoilage of ground beef and apple juice by S. Typhimurium DT104, E. coli 
O157:H7, L. monocytogenes, S. aureus and B. cereus. Likewise, it inhibits 
the growth of MRSA, K. pneumoniae, P. aeruginosa and A. baumannii. Due 
to the important problem of children deaths in the developing country, it is 
essential to investigate the use of new natural phytocompounds as 
antibacterial agents. 
Objectives 
Enteric infections, which are food and water borne diseases, are a serious 
public health problem worldwide. Microorganisms are the main cause of 
enteric infections; therefore their control may significantly reduce the food 
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and water-borne enteric infections outbreaks. The public is becoming 
increasingly conscious of problems with the over prescription and misuse of 
traditional antibiotics, and the failure of treatments due to the appearance of 
new bacterial strains antibiotic resistant. The use of plant extracts and 
natural phytochemicals with proved antimicrobial properties can be of great 
significance in the therapeutic use. In recent years, secondary metabolites 
as phenolic compounds, terpenoids, flavonoids and alkaloids have received 
a great deal of attention due to their diverse biological functions. Some 
natural substances have effective antimicrobial properties and they have 
been used as alternative treatments. Today, the use of plants as treatment 
of illness is accepted worldwide. In developing countries, the use of 
medicinal plants has significantly increased due to the low income of the 
population. Herbs and spices are generally considered to be safe and have 
been proved to be effective against certain ailments. Therefore we aimed to 
study the antimicrobial properties of selected medicinal plant extracts, as 
follows: 
I. Evaluation of the in vitro antimicrobial activity of selected plant 
extracts, against Gram-negative and Gram-positive bacteria 
including some of the most frequent etiological agents of enteric 
infections and fungi. 
II. Characterization of the antimicrobial activity of the natural extract 
with best activity and the most sensitive/interesting microorganism. 
III. Determination of the in vitro cytotoxicity of the selected extract. 
IV. Analysis of the effect against enteropathogenic E. coli (EPEC) of the 
selected extract during in vitro infection of cell cultures.  
V. Chemical fractionation of the selected natural extract. 
VI. Assessment of the antibacterial activity of the fractions. 
Results 
In the present study, the aqueous extracts of five plants (Hibiscus 
sabdariffa, Cinnamomum zeylanicum, Origanum vulgare, 
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Rosmarinus officinalis and Thymus vulgaris) were screened for their 
antimicrobial activity against 12 pathogenic bacteria (Gram-positive 
and Gram-negative), and 3 fungi (yeasts). The antimicrobial activity 
was assayed by using broth microdilution assay and disc diffusion 
test. H. sabdariffa extract showed the highest antibacterial activity 
against Gram-positive and Gram-negative, with MICs ranged 
between 4-10 mg/mL and MBCs ranged between 5-25 mg/mL. In 
disc diffusion test, H. sabdariffa extract produce an inhibition halo of 
10.5 mm against EPEC. H. sabdariffa extract did not show fungicidal 
activity. Time killing studies showed bactericidal activity of 
H. sabdariffa extract (MBC 25 mg/mL) at 10 h against EPEC, with the 
endpoint at 23 h. This extract did not show cytotoxicity on 
macrophages but affected HeLa cells as previously reported.  
The H. sabdariffa extract induces bacterial filamentation in EPEC. 
This morphological change reduces the ability of bacteria to adhere 
to epithelial cells in vitro. The H. sabdariffa extract reduces numbers 
of the pedestals formation induced by EPEC during the in vitro HeLa 
cells infection, in a time dependent manner. The H. sabdariffa extract 
inhibits pedestals formation in case of simultaneous treatment (EPEC 
infection and H. sabdariffa treatment simultaneously). This inhibition 
can be due to the induction of the filamentous morphology which 
would reduce the ability of the bacteria to adhere to HeLa cells and 
consequently no pedestals were formed. The pedestals cannot be 
formed in HeLa cells that were pre-treated with H. sabdariffa extract, 
before infection by EPEC. These results suggest that H. sabdariffa 
could be used both as potential preventive and treatment agent of 
gastroenteritis produced by EPEC.  
The H. sabdariffa aqueous extract was fractionated using different 
organic solvent based on polarity. The acetone fraction (AC) was the 
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most active fraction with antibacterial activity, followed by further 
acetone extraction from ethanol extraction (AC-EtOH). They have 
antibacterial activity against tested bacteria at MIC 5 mg/mL and 
MBC at 5 mg/mL, except for EPEC with values of 8 mg/mL. The sub-
fractions 2, 3 and 4 of acetone fraction had MIC at 5 mg/mL and 
MBC at 5 mg/mL for all tested bacteria.  
This is the first study that demonstrates time kill kinetics of 
H. sabdariffa extract against EPEC, showing the effect of 
H. sabdariffa extract on pedestals formation induced by EPEC in 
HeLa cells and presents new active antibacterial fraction (acetone 
fraction). Furthermore, it opens door to investigate the molecular 
mechanism of H. sabdariffa extract as antibacterial agent and 
determining the active compounds of H. sabdariffa extract as 
antibacterial agent. 
Conclusions 
H. sabdariffa extract has antibacterial activity and could be used as 
antimicrobial agent for enteric infections, particularly produced by 
EPEC. The H. sabdariffa extract induces bacterial filamentation in 
EPEC and reduces the ability of bacteria to adhere to epithelial cells 
in vitro. This morphological change might be mediated through the 
interaction of active compounds with molecular targets from bacterial 
cell wall, leading to bacterial filamentation and death. H. sabdariffa 
extract could be used as potential protective agent against enteric 
infections particularly by EPEC. The antibacterial activity was present 
mainly in the 2, 3 and 4 acetone fractions. Therefore, the active 
compounds could be purified from these fractions in the future, in 
order to be used in pharmaceutical formulations for enteric infections. 
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Resumen 
Introducción 
Las enfermedades causadas por infecciones entéricas siguen siendo uno 
de los problemas más importantes de salud pública. La diarrea infecciosa 
es a nivel mundial la segunda causa de morbilidad y mortalidad infantil, con 
4,6 millones de muertes de los aproximadamente un billón de episodios de 
diarrea al año reportados en niños. Los trastornos diarreicos conllevan 
además un gran sufrimiento dejando secuelas a largo plazo, entre las que 
se encuentran la deficiencia cognitiva y de desarrollo en los primeros cinco 
años de la infancia. Las enfermedades diarréicas infecciosas están 
altamente ligadas con la pobreza, y la mortalidad infantil es mayor en los 
países con menor producto interior bruto, especialmente en situaciones de 
crisis. A pesar del uso generalizado de las terapias de rehidratación oral 
(TRO) y de un mayor conocimiento de la patogénesis de la diarrea 
infecciosa, 1,9 millones de niños menores de cinco años siguen muriendo 
de estas enfermedades cada año según informes recientes de la OMS y 
UNICEF. Los brotes de infecciones intestinales se producen a través de la 
ingestión de alimentos o agua contaminados (transmisión vía fecal-oral) o 
por contacto directo (persona a persona). Los principales síntomas clínicos 
de las infecciones entéricas incluyen los síntomas gastrointestinales o las 
afecciones sistémicas, pudiendo darse sucesivamente. El principal síntoma 
de afectación gastrointestinal es la diarrea. Otros síntomas frecuentes son 
fiebre, náuseas, vómitos y dolor abdominal, en función de los patógenos 
microbianos. Las afecciones sistémicas implican síndromes más graves, 
incluyendo el síndrome urémico hemolítico (como el causado por la 
bacteria EHEC), meningitis, trastornos de malabsorción, alteraciones 
cardio-neurológicas, artritis y hepatitis. La OMS define la diarrea como “la 
deposición, tres o más veces al día (o con una frecuencia mayor que la 
normal para la persona) de heces “sueltas o líquidas”. La diarrea se 
produce como resultado de la insuficiencia o ineficacia del tracto digestivo 
para realizar su función de absorción, esto ocurre mediante diferentes 
mecanismos que contribuyen a la pérdida de líquidos y electrolitos tras la 
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infección microbiana. Los agentes etiológicos de las infecciones entéricas 
son bacterias, virus, protozoos, hongos y helmintos. 
En los países en vías de desarrollo los agentes causantes de las 
infecciones entéricas más recurrentes son las bacterias. Escherichia coli es 
una bacteria anaerobia facultativa predominante en la microbiota intestinal 
del colon en los humanos que con el paso del tiempo se asoció a la 
aparición de diarreas. Las distintas cepas de E. coli diarreicas (DEC, de las 
siglas en inglés Diarrheagenic E. coli) infectan las células del hospedador 
mediante una variedad de mecanismos complejos, dentro de los cuales se 
incluyen la adhesión y/o la invasión de la mucosa intestinal, la producción 
de toxinas y la inyección de proteínas bacterianas en las células 
hospedadoras. Las bacterias E. coli diarreicas se clasifica en seis 
categorías: E. coli enteropatógena (EPEC), E. coli enterohemorrágica 
(EHEC), E. coli enterotoxigénica (ETEC), E. coli enteroinvasiva (EIEC), 
E. coli enteroagregativa (CEEA), y E. coli de adherencia difusa (DAEC). 
E. coli enteropatógena (EPEC) es la causa más importante de morbilidad y 
mortalidad en niños menores de cinco años en los países en vías de 
desarrollo. EPEC se adhiere a las células intestinales y mediante un 
sistema de secreción denominado tipo tres, inyecta las proteínas efectoras 
bacterianas que se transfieren al citosol de la célula hospedadora 
afectando a múltiples funciones fisiológicas que en última instancia 
conducen a la enfermedad diarreica. EPEC se adhiere a las células 
intestinales formando una lesión histopatológica caracterizada por la 
degeneración local de las microvellosidades de absorción, la adherencia 
íntima de la bacteria a la célula hospedadora y la formación de una 
estructura rica en filamentos de actina denominada pedestal. Los 
pedestales contienen además muchas otras proteínas celulares cuya 
función durante la formación de dicha estructura es desconocida. La 
proteína efectora Tir (de las siglas en inglés Translocated Intimin Receptor) 
es inyectada en la célula, se inserta en la membrana plasmática e 
interacciona con intimina, una proteína de la superficie bacteriana, 
promoviendo la fijación de las bacterias de manera íntima, y dando lugar al 
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ensamblaje de filamentos de actina en la superficie de la célula 
hospedadora. Esta reorganización del citoesquelto de actina de la célula 
da lugar a la formación del pedestal, donde la bacteria queda literalmente 
apoyada en la superficie celular de manera fija, lo que conduce a la 
degeneración de las microvellosidades del borde en cepillo y la ocurrencia 
de la diarrea. La terapia de rehidratación oral (TRO) y el suplemento 
nutricional se deben realizar antes de administrar ningún otro agente 
terapéutico. Los antibióticos se requieren para el tratamiento de la 
gastroenteritis bacteriana en aquellos pacientes que sufren complicaciones 
graves, como por ejemplo pacientes donde la enfermedad se ha expandido 
por el organismo provocando sepsis. Generalmente, el tratamiento 
antimicrobiano consigue prevenir la progresión de la enfermedad y reduce 
la gravedad de los síntomas clínicos asociados como fiebre, vómitos y 
dolor abdominal. 
Los antibióticos inhiben la función celular bacteriana como resultado dela 
interacción fármaco-diana, provocando así la muerte celular bacteriana. 
Los distintos mecanismos mediante los cuales actúan los antibióticos 
incluyen la inhibición de la síntesis de la pared celular, la inhibición de la 
síntesis de ácidos nucleicos y de proteínas, la inhibición de rutas 
metabólicas y alteraciones de la membrana celular. Actualmente, hay 
muchos antibióticos sintéticos para el tratamiento de diversas 
enfermedades causadas por microorganismos. Algunos de estos 
microorganismos se han vuelto resistentes a los antibióticos, haciéndolos 
ineficaces. La aparición de la resistencia bacteriana los agentes 
antimicrobianos, particularmente de cepas de E. coli, se ha incrementado a 
nivel global. La resistencia a los antimicrobianos se debe a varias causas: 
plasticidad genética de los microorganismos, el uso innecesario e 
inapropiado de los antimicrobianos (incluyendo la dosificación inadecuada 
y los medicamentos de baja calidad), y el aumento de la movilidad de la 
población mundial. Un gran número de cepas bacterianas están mostrando 
ser resistentes a prácticamente todos los agentes terapéuticos disponibles. 
De este modo, el problema ha ido aumentando durante décadas, y hoy en 
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día muchas infecciones comunes se están convirtiendo en infecciones 
difíciles o incluso imposibles de tratar, y así una infección común 
potencialmente mortal puede convertirse en una amenaza para la vida de 
la persona. Por lo tanto, hay una continua necesidad de buscar nuevos 
agentes antibacterianos para superar la resistencia a los antibióticos. El 
uso de plantas medicinales para el tratamiento de las enfermedades es 
una práctica arraigada en las distintas culturas desde la antigüedad. Por 
ello, últimamente se han incrementado los tratamientos de medicina 
alternativa a base de hierbas para el descubrimiento de nuevos agentes 
terapéuticos y antibacterianos. Debido a la aparición de efectos 
secundarios frente a determinados compuestos sintéticos y a la necesidad 
de encontrar nuevos compuestos para tratar bacterias multiresistentes, 
incluyendo nuevos antibióticos, los extractos y compuestos biológicamente 
activos aislados a partir de distintas especies de plantas (fitocompuestos) 
están despertando un gran interés. Por lo tanto, las plantas se presentan 
como una nueva fuente de agentes antibacterianos. La mayoría de los 
constituyentes fitoquímicos y metabolitos secundarios responsables de la 
actividad de las plantas, funcionan como un mecanismo de defensa contra 
patógenos y depredadores. Los principales grupos de fitocompuestos y 
componentes bioactivos que funcionan como agentes antimicrobianos son: 
fenoles, polifenoles, quinonas, taninos, cumarinas, flavonoles, flavonas, 
flavonoides, terpenoides, aceites esenciales y alcaloides. De este modo, 
dirigir nuestros esfuerzos hacia la investigación científica para descubrir 
nuevos agentes antimicrobianos nos puede ayudar a superar el problema 
de la resistencia microbiana. Cerca de 1.500 especies de plantas 
medicinales y aromáticas son ampliamente utilizadas en distintos países 
Europeos como Albania, Bulgaria, Croacia, Francia, Alemania, Hungría, 
Polonia, España, Turquía y el Reino Unido. Muchas plantas medicinales 
poseen actividad antibacteriana, como por ejemplo Allium sativum, Zingiber 
officinale, el extracto metanólico de Tussilago farfara, Equisetum arvense, 
Sambucus nigra, Aesculus hippocastanum y Taraxacum officinale. Del 
mismo modo, los zumos de arándano, uva agria, uva “Isabella”, mora 
silvestre, y el aceite esencial obtenido de Rosmarinus officinalis, Salvia 
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officinalis y Origanum vulgare muestran actividad antibacteriana. Los 
extractos acuoso y metanólico de las hojas de Syzygium cumini presentan 
un agente activo antibacteriano. Además, el extracto de etanol y el extracto 
de acetona de Cinnamonum zeylanicum y Trachyspermum ammi muestran 
también actividad antibacteriana eficaz. El extracto de los cálices de 
H. sabdariffa presenta un amplio rango de actividades biológicas, 
pudiéndose utilizar como tratamiento contra la obesidad, la aterosclerosis, 
diabetes, enfermedades del hígado y otros síndromes metabólicos. 
Además, se puede utilizar como antihipertensivos y presenta efectos 
cardioprotectores en los pacientes diabéticostipo II con hipertensión leve. 
Por otro lado, sus extractos acuosos y etanólicos se pueden usar como 
conservantes de alimentos, habiéndose demostrado un efecto inhibidor 
dependiente de la dosis en el deterioro de los alimentos tales como carne 
picada y zumo de manzana debido a S. Typhimurium DT104, E. coli 
O157:H7, L. monocytogenes, S. aureus y B. cereus. Asimismo, inhibe el 
crecimiento de MRSA, K. pneumoniae, P. aeruginosa y A. baumannii. La 
elevada mortalidad en niños en países en vías de desarrollo como 
resultado de infecciones entéricas pone de manifiesto la importancia de 
investigar nuevos principios activos y fitocompuestos naturales para 
descubrir nuevos agentes antibacterianos y su potencial uso terapéutico. 
Objetivos 
Las enfermedades entéricas cuya causa principal son las infecciones por 
microrganismos transmitidos por agua o alimentos contaminados, son un 
grave problema de salud pública en todo el mundo. El control de los 
microorganismos puede reducir significativamente los brotes de 
infecciones entéricas debidos a la ingestión de comida o agua 
contaminada. La humanidad es cada vez más consciente del grave 
problema que constituye el fracaso de los tratamientos actuales, debido a 
la aparición de nuevas cepas bacterianas resistentes a múltiples 
antibióticos. El uso de extractos de plantas y fitoquímicos naturales con 
propiedades antimicrobianas probadas puede por tanto ser de gran 
importancia en el uso terapéutico. En los últimos años, metabolitos 
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secundarios como compuestos fenólicos, terpenoides, flavonoides y 
alcaloides han recibido una gran atención debido a sus diversas funciones 
biológicas. Algunas sustancias naturales tienen propiedades 
antimicrobianas eficaces y han sido utilizados como tratamientos 
alternativos, habiéndose aceptado en todo el mundo el uso de 
determinadas plantas para el tratamiento de ciertas enfermedades. En los 
países en vías de desarrollo, el uso de plantas medicinales ha aumentado 
significativamente debido a los bajos ingresos de la población. Se ha 
demostrado que ciertas hierbas y especias consideradas generalmente 
como seguras, son eficaces contra ciertas dolencias. Por todo ello, en esta 
tesis nos propusimos estudiar las propiedades antimicrobianas de una 
selección de extractos de plantas medicinales, estableciéndose los 
siguientes objetivos: 
I. Evaluación de la actividad antimicrobiana in vitro de extractos de una 
selección de plantas sobre bacterias Gram-negativas y Gram-positivas 
causantes de infecciones entéricas y sobre hongos. 
II. Caracterización de la actividad antimicrobiana del extracto natural con 
mayor actividad sobre el microorganismo más sensible o interesante de los 
estudiados. 
III. Determinación de la citotoxicidad in vitro del extracto natural 
seleccionado. 
IV. Análisis del efecto sobre E. coli enteropatógena (EPEC) del extracto 
natural seleccionado mediante la infección in vitro de una línea celular 
estable de células humanas. 
V. Fraccionamiento químico del extracto natural seleccionado. 
VI. Evaluación de la actividad antibacteriana de las distintas fracciones. 
Resultados 
En el presente estudio, fueron seleccionados los extractos acuosos de 
cinco plantas (Hibiscus sabdariffa, Cinnamomum zeylanicum, Origanum 
vulgare, Rosmarinus officinalis y Thymus vulgaris) por su actividad 
antimicrobiana frente a diversas cepas de bacterias patógenas (12 Gram-
positivas y Gram-negativas en total), y 3 hongos (levaduras). La actividad 
antimicrobiana se analizó mediante dos ensayos microbiológicos, ensayo 
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de microdilución en caldo y prueba de difusión en disco. El extracto de 
H. sabdariffa mostró la mayor actividad antibacteriana sobre las bacterias 
Gram-positivas y Gram-negativas estudiadas, con CMI que oscilaron entre 
4-10 mg/ml y CMB oscilaron entre 5-25 mg/ml. En la prueba de difusión en 
disco, el extracto de H. sabdariffa produjo un halo de inhibición de 10.5 mm 
contra EPEC. Sin embargo, el extracto H. sabdariffa no mostró actividad 
fungicida. Además, las curvas de letalidad mostraron actividad bactericida 
del extracto de H. sabdariffa (CMB 25 mg/mL) sobre EPEC a partir de las 
10 horas y hasta las 23 horas. Este extracto no mostró citotoxicidad en 
macrófagos J774, pero presentó un effecto  anti-proliferativo de células 
como se ha descrito previamente en células de carcinoma epitelial humano 
(células HeLa) en cultivo. 
Se observó que el extracto de H. sabdariffa induce filamentación de la 
bacteria EPEC. Este cambio morfológico reduce la capacidad de las 
bacterias para adherirse a las células epiteliales cultivadas in vitro (células 
HeLa). Asimismo, se demostró que el extracto de H. sabdariffa reduce el 
número de pedestales formados por EPEC durante la infección de las 
células HeLa, de manera dependiente del tiempo de tratamiento. Además, 
en el caso de tratar simultáneamente las células con H. sabdariffa e 
infectarlas con EPEC se observó una inhibición en la formación de 
pedestales. Esta inhibición puede ser debida a la filamentación de EPEC 
en presencia del extracto, lo que reduciría la capacidad de las bacterias 
para adherirse a las células HeLa y en consecuencia la formación de 
pedestales. En este estudio se observó también que los pedestales no se 
formaron en las células HeLa que fueron tratadas con extracto de 
H. sabdariffa previamente a la infección por EPEC. Estos resultados 
sugieren que H. sabdariffa podría ser utilizado como potencial agente 
preventivo y como posible tratamiento de la gastroenteritis producida por 
EPEC. 
El extracto acuoso de H. sabdariffa se fraccionó utilizando varios 
disolventes organicos de distinta polaridad. La fracción de acetona (AC) 
fue la fracción con mayor actividad antibacteriana, seguida por extracción 
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adicional de acetona de la extracción de etanol (AC-EtOH). Ambos 
presentaron actividad antibacteriana sobre todas las bacterias estudiadas 
con valores de CMI de 5 mg/mL y CMB a 5 mg/mL, a excepción de EPEC 
con valores de 8 mg/mL de CMB. Las sub-fracciones 2, 3 y 4 de la fracción 
de acetona tenían CMI en 5 mg/mL y CMB a 5 mg/mL para todas las 
bacterias probadas. 
Este es el primer estudio que demuestra la cinética de las curvas de 
letalidad del extracto de H. sabdariffa sobre la bacteria EPEC. En este 
estudio se observa un claro efecto de dicho extracto sobre los pedestales 
formados tras la infección de EPEC en células HeLa y se descubre una 
nueva fracción activa con actividad antibacteriana (fracción de acetona). 
Nuestro trabajo abre así nuevas vías de estudio para investigar el 
mecanismo molecular del extracto de H. sabdariffa como agente 
antibacteriano y la determinación de los compuestos activos responsables 
de dicha actividad. 
Conclusiones 
El extracto de H. sabdariffa tiene actividad antibacteriana y podría ser 
utilizado como agente antimicrobiano en infecciones entéricas, 
particularmente producidas por EPEC. El extracto de H. sabdariffa induce 
la filamentación de la bacteria EPEC reduciendo la capacidad de las 
bacterias para adherirse a células epiteliales en cultivo. Este cambio 
morfológico podría estar mediada a través de la interacción de los 
compuestos activos de este extracto con dianas moleculares de la pared 
celular bacteriana, que conduce a la filamentación bacteriana y a la muerte 
de la bacteria. De este modo, el extracto de H. sabdariffa podría ser 
utilizado como potencial agente protector contra las infecciones entéricas 
provocadas particularmente por EPEC. Se corroboró que la actividad 
antibacteriana estaba presente principalmente en las fracciones 2, 3 y 4 de 
la fracción de acetona. Por lo tanto, los compuestos activos pueden ser 
purificados a partir de estas fracciones en el futuro, con el fin de ser 
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utilizado en formulaciones farmacéuticas para uso terapéutico de 
infecciones entéricas. 
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Abbreviations 
AC extract: Acetone soluble extract 
AC from EtOH extract: Acetone soluble extract from ethanol soluble 
extract 
AAF: aggregative adherence fimbriae 
A/E: Attaching and effacing 
AMR: Antimicrobial resistance 
AKT: Serine/Threonine-specific protein kinase 
BGA: Brilliant Green Agar 
BFP: bundle forming pilus 
CFU/ml: Colony Forming Unit/milliliter 
CFA: Colonization factor antigen 
cGMP: Cyclic guanosine monophosphate 
CDC: Centers for Diseases Control and Prevention  
DEC: Diarrheagenic Escherichia coli 
DAEC: Diffusely adhering Escherichia coli 
DRA: Down regulated in adenoma 
EtOAc extract: Ethyl acetate soluble extract 
EtOH extract: Ethanol soluble extract 
Esp: Escherichia coli secretion protein 
EU: European Union 
Erk: Extracellular signal-regulated kinase 
Ext: Extract 
FasL: Fas ligand 
Fra: Fraction 
GAPPD: Global Action Plan for the Prevention and control of Pneumonia 
and Diarrhea  
HUS: Haemolytic Uremic Syndrome 
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LB: Luria Bertani media 
LT: Heat labile enterotoxin 
LDL: Low density lipoprotein 
MAPK: Mitogen activated protein kinase 
MHA: Mueller Hinton Agar 
MHB: Mueller Hinton Broth 
MOI: Multiplicity of Infection 
MIC: Minimum Inhibitory Concentration 
MBC: Minimum Bactericidal Concentration 
MRSA: Methicillin Resistant Staphylococcus aureus 
NHE3: Sodium–hydrogen exchanger3 
NOD: Niucleotide-binding oligomerization domain 
NLRs: (NOD)-Like-receptors 
ORT: Oral rehydration therapy 
PI3K: Phosphoinositide 3-kinase 
SS: Salmonella-Shigella agar  
STEC: Shiga toxin-producing Escherichia coli  
Stx: Shiga toxin 
ST: Heat stable enterotoxin 
SGLT1: Sodium–glucose cotransport 1 
Tir: Translocated intimin receptor 
TLC: Thin Layer Chromatography 
TLRs: Toll-like receptors  
TPC: Total phenolic compounds 
TTSS: Type III secretion system 
TATFAR : Transatlantic Taskforce on AMR 
UPEC: Uropathogenic Escherichia coli 
UTI: Urinary tract infection 
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UNICEF: United Nations Children's Fund 
US: Untited States 
VRBG: Violet-Red-Bile-Glucose 
W/V: Weight/Volume 
WHO: World Health Organization 
XLD: Xylose Lysine Desoxycholate agar 
YPD: Yeast Extract-Peptone-Dextrose medium 
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Introduction 
1. Gastrointestinal Microbiology and enteric 
infections 
This is a fascinating time for gastrointestinal Microbiology. Enteric infections 
(whose etiological agents are bacteria, viruses, fungi and protozoa) remain 
a significant public health problem. Worldwide, the infectious diarrhea is the 
second leading cause of childhood morbidity and mortality, and raises one 
of the most common human suffering with high morbidity and associated 
long term sequelae. On the other hand, recent culture-independent 
metagenomic methods and the next-generation sequencing techniques 
along with bioinformatics developments have revealed an unprecedented 
microbial biodiversity in the human intestine and “our other genome”, the 
human microbiome. 
Advances in the past 10 years in the fields of gastrointestinal physiology, 
innate immunity and enteric bacterial virulence mechanisms highlight the 
multifactorial nature of infectious diarrhea. Moreover, the recognition of 
Helicobacter pylori and its role in gastric disease by Warren and Marshall 
earned a Nobel Prize in 2005 (Warren, 2005). The discovery of bacterial 
secretion systems and translocate effectors has unlocked numerous 
mechanisms of pathogenesis (Hodges and Hetch, 2012). The finding that 
eukaryotic cells perceive and respond to bacteria through the expression of 
Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain-
containing (NOD)-like-receptors (NLRs), is a major step toward 
understanding molecular interactions between the host and gut microbiota 
or microbial pathogens (Ishii et al., 2008). The discovery of quorum sensing 
as a means of inter-cell communication between bacterial populations 
(Anand and Griffiths, 2003; Waters and Basler, 2005) and even with host 
(Holm and Vikström, 2014) cells has provided insight into pathogenic 
mechanisms. The multiple-sited impact of the commensal gut microbiota on 
whole host metabolism (Burcelin, et al., 2011; Arumugam, et al., 2011), as 
well as its role in human health (Clemente, et al., 2012), and many 
diseases states, including inflammatory and irritable bowel syndromes, 
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obesity (Spor, et al., 2011), even brain disorders (Borre, et al., 2014), is 
now accepted and will undoubtedly lead to new therapeutic strategies. And 
the recently discovered Human Microbiome (Huttenhower, et al., 2012) will 
allow a better understanding of the role of this complex intestinal 
community in human health and disease.  
On the clinical side, for the time being, we are witnessing the emergence of 
more virulent strains of enteric pathogens as well as the failure of 
antimicrobial treatments owing to the appearance of new bacterial antibiotic 
resistances and antibiotic overuse. The use of active natural 
phytocompounds with proved antimicrobial and antiquorumsensing 
activities could be significant for the treatment and prevention of 
gastro-enteric infections. The benefits of probiotics and nutraceuticals in the 
treatment of medical disorders are being studied nowadays (Gerritsen, et 
al., 2011; Rauch and Lynch, 2011; Rahal et al., 2012). Furthermore, we are 
becoming increasingly aware of the presence of gut pathogens through the 
widespread outbreaks of foodborne diseases and the relevance of water 
and food safety controls in human health. 
2. Global burden of infectious diarrhea 
First estimates of the global incidence of childhood mortality and morbidity 
became available in the early 1980s. The most important infectious causes 
of childhood morbidity and mortality are pneumonia and diarrhea (as it has 
been already mentioned) (Fig. 1). 81% of deaths associated with 
pneumonia and 72% of those associated with diarrhea occur in the first 
2-5 years of life (Walker et al., 2013), suggesting that an increased 
emphasis on prevention and treatment in neonates and young children is 
crucial. Both diseases are associated with poverty, and child mortality from 
them is higher in low-income than in high-income countries and in 
populations in crisis situations. In particular, enteric infections (diarrheal 
disorders) were responsible for an estimated 4.6 million deaths worldwide 
from around 1 billion episodes of diarrhea annually in children. Despite the 
widespread use of oral rehydration therapies (ORT) and an increased 
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understanding of the pathogenesis of diarrhea, 1.9 million children less 
than five years of age still die from these illnesses every year according to 
recent WHO and UNICEF reports (WGO, 2012).  
 
 
Figure 1. Report of the World Health Organization (WHO) 2011. Diagram of 
World Health Organization showing that diarrhea, the main symptom of enteric 
infections, represents the second leading cause of death among children less 
than five years worldwide in 2010. The figure represents 10 % of total death 
among children younger than five years of age.  
Adapted from WHO-UNICEF Child Health Epidemiology Reference Group 
(CHERG) Estimates, 2013 
 
In the developed world, deaths caused by diarrheal illness are rare, and the 
effects of these illnesses are often measured in financial terms (Thapar and 
Sanderson, 2004). It is usually a mild disease in most of European 
countries but it is still accompanied by large number of hospital admissions 
and not negligible number of deaths. Approximately 179 million cases of 
acute enteric infection occur in the United States each year (Wikswo and 
Hall, 2012). It is a major source of morbidity and hospitalization in children 
younger than five years, accounting for 200 000 hospital admissions with 
approximately 300 deaths and greater than 1.5 million visits to primary care 
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providers annually in US. These hospitalizations lead to $250 million in 
direct medical costs and $1 billion in indirect costs (Churgay and Aftab, 
2012). It is estimated that 80% of children death in South Asia and Africa 
due to infectious diarrhea (WHO/UNICEF, 2009).  
Enteric infection afflicts people of all ages around the world. Although 
etiological agents are not found in many cases, the nature of most acute 
diarrheal diseases is suggested by epidemiologic behaviour showing case 
clustering spread in families and occurrence among travellers.  
Gastroenteritis is a clinically significant disease. Clinical studies in 
Fortaleza Brazil and other countries show clearly that patients with diarrhea 
persisting longer than 7-14 days demonstrate short fall in growth and 
cognitive development (Niehhaus, 2002; Nataro, 2013). The prevalence of 
infectious diarrhea is estimated at 1 to 1.5 episodes per person per year, 
and although most cases are self-limited, the severity of illness can vary 
markedly depending on characteristics of both the pathogen and the host. 
Management of each episode, therefore, varies based on cause, severity of 
disease, the host and the host’s comorbid illnesses.  
Prompt recognition, diagnosis and treatment of infectious diarrhea may 
have significant public health implications. The primary care action is 
crucial in early control of local outbreaks as well as in preventing secondary 
transmission, especially in health care workers, day care workers and food 
handlers. Stool testing for diagnosis of specific pathogens can abbreviate 
illness, reduce morbidity, decrease development of antimicrobial resistance 
through pathogen-directed treatment, and help identify and trace public 
health outbreaks. With the development of new tools of diagnosis essential 
information has been gained in our understanding of the etiology, 
pathogenesis, epidemiology and control of enteric infections. Therefore, 
global Cooperation is needed to limit the spectrum of the enteric infections. 
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3. Route of enteric infections transmission 
Enteric infections outbreaks occur through the ingestion of contaminated 
food or water (fecal-oral route transmission) or by direct contact (person to 
person) (Bartlett, 1996). 
4. Symptomatology of enteric infections 
The anamnesis (clinical symptoms and clinical patient history) of enteric 
infections shows the main clinical symptomatology can include either 
gastrointestinal, systemic affectations or both successively (Table 1).  
 
Table 1. Clinical symptoms of enteric infections 
 
Gastrointestinal affectation Systemic affectation 
Diarrhea 
Nausea 
Vomiting 
Abdominal pain 
Fever 
Hemolytic uremic syndrome 
(EHEC), meningitis, 
malabsorption disorders, cardio-
neurological alterations, 
arthritis and hepatitis. 
Chronic sequelae  
The main symptom of gastrointestinal affectation is diarrhea. Other 
frequent symptoms are fever, nausea, vomiting and abdominal pain, 
depending on microbial pathogen (Table 1). Systemic affectations imply 
more serious syndromes including hemolytic uremic syndrome (as EHEC), 
meningitis, malabsorption disorders, cardio-neurological alterations, arthritis 
and hepatitis. Chronic sequeale are present in 2-3% of food borne and 
water borne enteric diseases. 
Definitions of diarrhea include increases in volume or fluidity of stools, 
changes in consistency, and increased frequency of defecation. The 
measurement of stool fluid content is impractical and assessment of stool 
frequency is preferred for diagnostic purposes. WHO defines diarrhea as 
the “passage of loose or watery stools at least three times in a 24 h period”, 
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but emphasizes the importance of change in stool consistency and 
appearance rather than frequency, and the usefulness of parental insight in 
deciding whether children have diarrhoea or not (WHO, 1995). Blood in 
stool could indicate an acute diarrheal illnesses or dysentery, irrespective of 
frequency (Baqui, 1991; WHO, 1994). Diarrheal disorders can further be 
divided into acute and chronic, allowing some categorization of causes 
and associated management. Acute diarrheas, the most usual form of 
diarrheal illness, have an abrupt onset, resolve within 14 days, and are 
mostly caused by infections. Chronic diarrheas last for at least 14 days. 
Persistent diarrheas usually arise secondary to infections in the presence 
of complications such as malnutrition; whereas the remaining chronic 
diarrheas are mainly due to congenital defects of digestion and absorption. 
Persistent and chronic diarrheas often overlap. 
The diarrhea occurs as a result of the failure or ineffectiveness of the 
digestive tract to perform its absorption function, by different mechanisms 
that contribute to loss of fluids and electrolytes following microbial 
infections. These events are linked to specific toxins and other virulence 
factors (Viswanathan et al., 2009). 
4.1 Classification of diarrhea 
Diarrhea can be classified according to different criteria (Vu HT, 2012): 
A. Duration: 
 
• Acute diarrhea: When the symptoms usually continue less than 
two weeks and can be cured after three or four weeks. 
• Chronic diarrhea: When the diarrhea continue more than 4 weeks. 
 
B. Physiopathology: 
 
• Osmotic: It can be caused by ingestion of non-absorbable solutes 
or by disease states that interfere with normal solute absorption. 
• Secretory: It results from a disturbance in the balance between 
absorption (primarily via villous epithelial cells) and secretion 
(primarily via crypt cells). 
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• Inflammatory: It occurs when there is a damage to mucosal lining 
or brush border which leads to loss of protein rich fluids and 
decrease ability to absorb these lost fluids. 
• Penetrating: It includes the bacteria that penetrate to the 
submucosa  
• Steatorrhea: It is characterized by the presence of excess of fat in 
feces. It includes any process that affects the digestion and 
absorption of fat as coeliac disease and pancreatic insufficiency. 
• Motility disturbance/functional: Intestinal motility disturbance can 
cause increase of the intestinal passages and decrease the time 
mucosal contact for absorption.  
• Antibiotic–associated diarrhea: It results from an imbalance in the 
intestinal microbiota caused by antibiotic therapy. Another 
consequence of antibiotic therapy leading to diarrhea is overgrowth 
of potentially pathogenic organisms such as Clostridium difficile. 
 
C. Etiopathogenesis:  
 
• Non infectious diarrhea can be caused by some diseases as 
irritable bowel syndrome, hyperthyroidism, diabetes, colorectal 
cancer, etc.; as well as chemical compounds. 
• Infectious diarrhea, produced by enteric pathogens including 
bacteria, viruses, fungi and protozoa. 
 
5. Etiological agents of enteric infections 
As it has been already mentioned, the etiological agents of enteric 
infections are bacteria, viruses, protozoa, fungi and helminthes (Table 2). 
Medically, diarrhea is subdivided into non-inflammatory and inflammatory, 
mainly based on the presence of leucocytes in feces. However, considering 
a more recent view of inflammation, it should be taken into account that all 
pathogens are able to induce an inflammatory response in the intestine due 
to the recognition of their Pathogen-Associated Molecular Pattern (PAMPs) 
detected by Pattern Recognition Receptors (PRRs), found in epithelial and 
immune cells. 
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Table 2. Etiological agents of infectious diarrhea 
               (modified from Mensa et al., 2014) 
 
Secretory (“non-
inflamatory”) diarrhea1 “Inflammatory” diarrhea
2 
 It induced by enterotoxins that act 
directly on the secretory 
mechanisms in feces. It does not 
contain leucocytes cells 
It can be mediated by cytotoxines and 
invasiveness inducing destruction of 
mucosal cells leading to the 
inflammatory response 
Bacteria Staphylococcus aureus 
Bacillus. cereus 
Clostridium perfringens 
Escherichia coli (enterotoxigenic*, 
enteropathogenic, 
enteroaggregative* and diffusely 
adhereing) 
Vibrio cholerae 
Aeromonas hydrophila 
Salmonella spp. no Typhi* 
Tropheryma whipplei 
Campylobacter jejuni 
Escherichia coli 
(enterohemorragic and invasive) 
Shigella spp* 
Vibrio spp 
Yersinia enterocolitica 
Clostridium difficile 
Plesiomonas shigelloides* 
Klebsiella oxytoca 
Listeria monocytogenes 
Mycobacterium spp 
Laribacter hongkongeniss 
Enterocolitis neutopenic 
Viruses 
Rotavirus* 
Norovirus* 
Astrovirus 
Adenovirus 
Hepatitis A 
Cytomegalovirus 
Herpes simplex virus (HHV1) 
Enteric Adenovirus (serotypes 40, 41) 
Sapovirus 
Enterovirus 
Pestivirus 
Picornavirus 
Torovirus 
Protozoa Cryptosporidium parvum 
Cyclospora cayetanensis 
Giardia lamblia 
Cytoisospora belli 
Entamoeba histolytica* 
Schistosoma mansoni 
Balantidium coli 
Dientamoeba fragilis 
Fungi and 
helminthes 
Microsporidia Trichinella spiralis Strongyloides stercoralis 
(*) Microorganisms more frequently involved in travel-diarrhea 
(1) Watery diarrhea with copious stools without blood. Afebrile course, except in 
cases of viral infection. Absence of leukocytes on microscopic examination 
of the feces. Usually due to increased fluid secretion into the small intestine 
due to the effect of neurotoxins or enterotoxins, or mucosal surface invasion 
caused by virus or protozoa. 
(2) Frequent and little bulkystools, often with fever. There may be tenesmus and 
diarrhea may contain blood or mucus and leukocytes. It is generally due to 
inflammation of the lining of the colon by microbial invasion or effect of 
cytotoxins. 
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5.1 Escherichia coli  
Escherichia coli is the predominant facultative anaerobe of the human 
colonic microbiota. E. coli is the type species of the genus Escherichia, 
which contains mostly motile gram-negative bacilli within the family 
Enterobacteriaceae (Nataro, 1998). The genus Escherichia, originates from 
the german pediatrician Theodor Escherich, who discovered the bacteria in 
1885. The species coli, means “from the colon”, which is the 
microorganism’s natural habitat. Most strains of E. coli live and grow 
harmlessly in the gastrointestinal tract (commensal microbiota)of animals 
and humans (Ingerson-Mahar, 2011). Infections due to pathogenic E. coli 
may be limited to the mucosal surfaces or can be spread throughout the 
human body. These pathogenic strains of E. coli are broadly categorized as 
either diarrheagenic E. coli or extraintestinal pathogenic E. coli (ExPEC) 
(Wiles, et al., 2008). 
Three general clinical syndromes result from infection with inherently 
pathogenic E. coli strains (Nataro, 1998; Ausina and Moreno, 2006):  
5.1.1 Enteric infection 
5.1.2 Urinary tract infection 
5.1.3 Sepsis / neonatal Meningitis  
5.1.1 Enteric infection by Escherichia coli 
Escherichia coli gradually emerged as a cause of diarrhea. Diarrheagenic 
E. coli (DEC) cause infection by a variety of complex mechanisms. These 
include adherence, production of toxigenic mediators, invasion of the 
intestinal mucosa, and transportation of bacterial proteins into the host cells 
(Khan and Steiner, 2002). Diarrheagenic E. coli (DEC) is classified into six 
characterized categories (Fig. 2): enteropathogenic E. coli (EPEC), 
enterohaemorrhagic E. coli (EHEC), enterotoxigenic E. coli (ETEC), 
enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAEC), and 
diffusely adhering E. coli (DAEC) (Nataro and Kaper, 1998). Each type has 
unique features in its interaction with eukaryotic cells to induce diarrhea.  
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A. Enteropathogenic E. coli (EPEC) adheres to small bowel 
enterocytes and destroys the normal microvillar architecture 
inducing the characteristic attaching and effacing (A/E) lesion and 
cytoskeletal changes including the accumulation of polymerized 
actin beneath the adherent bacteria. EPEC as infectious agent may 
cause persistent and chronic diarrhea in children lasting longer than 
1 week (Nataro, 2006). 
B. Enterohaemorrhagic E. coli (EHEC) also induces the attaching and 
effacing (A/E) lesion, but in the colon. The distinguishing feature of 
EHEC is the elaboration of Shiga toxin (Stx), systemic 
malabsorption that leads to potentially life-threatening 
complications. EHEC causes bloody diarrhea (haemorrhagic colitis), 
non-bloody diarrhea and haemolytic uremic syndrome (HUS). 
C. Enterotoxigenic E. coli (ETEC) adheres and colonizes the surface of 
small bowel mucosa and induce watery diarrhea by the secretion of 
heat-labile (LT) and/or heat-stable (ST) enterotoxins. 
D. Enteroaggregative E. coli (EAEC) The basic strategy of EAEC 
infection is the colonization in the intestinal mucosa predominantly 
that of the colon, followed by secretion of enterotoxins and 
cytotoxins. Studies on human intestinal explants indicate that EAEC 
induces mild, but significant, mucosal damage. These effects are 
most severe in colonic sections. Mild inflammatory changes are 
observed in animals. Models and evidences indicate that some 
EAEC strains may be capable of limited invasion of the mucosal 
surface. The most dramatic histopathological finding in infected 
animal models is the presence of a thick layer of auto-aggregating 
bacteria adhering loosely to the mucosal surface. 
E. Enteroinvasive E. coli (EIEC) invades the colonic epithelial cells 
followed by lyses of the endocytic vacuole, then, the bacteria move 
through the cell by nucleating actin microfilaments. The bacteria 
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may move laterally through the epithelium by direct cell-to-cell 
spread or may exit and re-enter the baso-lateral plasma membrane. 
F. Diffusely adhering E. coli (DAEC) is characterized by the 
development of finger like projection of epithelial cells, which wrap 
around the bacteria but without complete internalization. Then 
activates signal transduction cascades that are necessary to induce 
diarrhea (Kaper, Nataro et al., 2004). The complete pathogenesis of 
DAEC to induce diarrhea is not completely understood yet. 
 
Figure 2. Categories of Diarrheagenic Escherichia coli. 
Diarrheagenic Escherichia coli are classified in six categories. Each category 
has unique feature in its interaction with eukaryotic cells to induce diarrhea.  
(a) Enteropathogenic E. coli (EPEC) (b) Enterohaemorrhagic E. coli                    
(EHEC) 
(c) Enterotoxigenic E. coli (ETEC)   (d) Enteroaggregative E. coli (EAEC) 
e) Enteroinvasive E. coli (EIEC)      (f) Diffusely adhering E. coli (DAEC). 
 
AAF: aggregative adherence fimbriae. BFP: bundle-forming pilus. CFA: 
colonization factor antigen. DAF: decay-accelerating factor. EAST1: 
enteroaggregative E. coli ST1. LT: heat-labile enterotoxin. ShET1: Shigella 
enterotoxin 1. ST: heat-stable enterotoxin. 
Adapted from (Kaper, Nataro, et al., 2004) 
 
5.1.2 Urinary tract infection 
Urinary tract infections (UTIs) are very severe health problems worldwide. 
UTIs can be classified depending on the part of urinary tract. Lower urinary 
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tract infection is called cystitis and represents 95%, and the upper urinary 
tract infection is called acute pyelonephritis which is a complication that 
involves kidneys. 80 % of UTIs are caused by UPEC (Zalewska-Piatek, 
2011).  
5.1.3 Sepsis/neonatal Meningitis 
Meningitis is defined as an inflammation of the membrane that surrounds 
the brain and the spinal cord. Meningitis symptoms are characterized by 
fever, neck stiffness, and mental status changes (Chavez-Bueno and 
McCracken, 2005). Escherichia coli K1 is the most prominent Gram-
negative bacterium that causes meningitis in neonates with rates of fatality 
ranging from 5 to 30% of infected infants (Mittal, et al., 2011). 
5.2 Enteropathogenic E. coli (EPEC) 
Enteropathogenic E. coli (EPEC) infection is a major cause of infantile 
diarrhea in the developing world. Using a type-three secretion system the 
bacterial effector proteins are transferred to the host cell cytosol and affect 
multiple physiological functions, ultimately leading to diarrheal disease. 
EPEC attach to cells and form actin-rich structures called pedestals, which 
contain many proteins that play unknown functions during pedestal 
formation (Nieto-Pelegrin 2014). Injected Tir binds to Intimin on the 
bacterial surface and promotes attaching of bacteria intimately and effacing 
lesion formation (loss of absorptive microvilli), leading to assembly of 
cytoskeleton intracellular actin on the cellular surface. Rearrangements of 
the actin cytoskeleton compose a pedestal-like structure where bacterium 
tightly cups the cells, leading to degeneration of brush border microvilli 
(Figs. 4). Some translocated effectors that alter the transepithelial 
resistance include E. coli secreted protein F (EspF), Mitochonderial-
associated protein (Map) and E. coli secreted protein G (EspG) (EPEC 
secreted protein G). EspF decreases both sodium-hydrogen exchanger 3 
(NHE3) and sodium–glucose cotransport 1 (SGLT1) activity in addition to 
disruption of tight junctions. Map acts along with EspF to decrease SGLT1 
activity and tight junction function. EspG1 and EspG2 decrease Cl−/OH− 
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exchange by down regulated in adenoma (DRA) exchanger and also impair 
tight junctions. The combined activities of these proteins and other effectors 
on ion transport alter the osmotic gradient leading to subsequent movement 
of water into the intestinal lumen causing diarrhea (Fig. 3) (Viswanathan, 
2009). 
 
Figure 3. Schematic representation of the mechanism of action of 
enteropathogenic Escherichia coli infection. After initial adherence, EPEC 
causes the localized effacement of microvilli and intimately attaches to the host cell 
surface forming the characteristic attaching and effacement (A/E) lesion. EPEC 
secretes the virulence factor Tir (translocated intimin receptor) through a Type-III 
Secretion System (T3SS) into the cytoplasm of the target cell. Tir is then serves as 
the receptor for the bacterial surface protein intimin in the plasma membrane of the 
host cell. The binding induces a clustering in the membrane that activates the 
cellular machinery for actin polymerization to form the pedestal on which EPEC 
sits. EspF causes the loss of intestinal barrier function through disruption of tight 
junctions and induces host cell death by apoptosis. 
Adapted from http://what-when-how.com/acp-medicine/infections-due-to-
Escherichia-coli-and-other-enteric-gram-negative-bacilli-part-1/  
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6. Outbreaks of enteric infections worldwide 
In the period of 1950-54, enteric infections constituted the main cause of 
death among infants between 4 weeks and 1 year of age, in Venezuela. It 
represented the 52% of total death at this age; followed by respiratory tract 
 
 
Figure 4. Kinetics of EPEC-induced microvilli damage. Scanning electron 
micrograph (SEM) showing (A) One attached bacterium to Caco 2 cells after 5 min 
infection. (B) Small microcolonies are formed after 30 min of EPEC infection. (C) 
Bacteria appearing to sink (arrowheads) into the brush border. (D) Importantly, loss 
of microvilli from around the infection site occurs at later times, with microvilli 
appearing to be pulled toward the bacteria (arrows). (E and F) Extensive loss of 
microvilli from around the infection site by 2 h with practically all microvilli lost by 
4 h. 
Adapted from (Dean et al., 2006) 
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diseases that represented 22% of total death, then the infectious diseases 
that represented more than 6%.  
Among infants under 5 years of age, in the same period, gastroenteritis 
was the major cause of death and represented 36% of total death followed 
by pneumonia which represented 15% of total death (Curiel and Ochoa, 
1959).  
Another example of the devastation that enteric infections can took place in 
the city of Surat (Gujarat State, India), between the 29 of October and the 3 
of December in 1965, a total of 418 persons were hospitalized, of which 
344 were children under two years of age. It was reported that 34 out of 81 
examined specimens contained E. coli O86:B7 and one sample contained 
O126:B16. The route of transmission could not be determined 
(Pal, et al., 1969). 
In 1963, the Newfoundland public health laboratories recorded an epidemic 
infantile gastroenteritis that led to 100 death cases of a total of 1071 
affected children. 76% of this infantile enteric infection outbreak was due to 
enteropathogenic E. coli strain O111:B4 infection. This strain was isolated 
from aproximadtely 500 samples (Severs, et al., 1966) 
During the period of 1995 to 2000 in European countries the enteric 
infections outbreaks were estimated by European surveillance systems 
(Table 3), including diagnostic reference laboratories, local public health 
staff, food inspectorates, physicians and systematic national surveillance. 
The gastroenteritis outbreaks were calculated in each country annually the 
outbreaks by national population. The data are shown in table 3. 
 
 
 
 
 
IN
TR
OD
UC
TI
ON
 
70 
 
 
Table 3. Outbreaks of enteric infections in European countries during 
1995-2000 (Lopman, et al., 2003) 
Country Numbers of outbreaks / million in population 
Denmark 37 
England and Wales 1643 
Finland 125 
Italy 2 
Slovenia 45 
Spain 236 
Sweden 856 
Netherland 301 
The most frequently reported etiological pathogens for those enteric 
infections outbreaks were viral agents. 
During 2001-2002, the Centers for Disease Control and Prevention (CDC) 
reported 31 outbreaks of gastroenteritis that occured in 19 states of United 
State due to drinking polluted water by sewage (waterborne disease 
outbreak). These outbreaks caused 7 deaths, 51 hospitalizations from 1020 
affected people. During the period from 30th of May 2004 to 8th of 
September 2004, was reported an outbreak of gastroenteritis between 
resident and visitors to South Bass Island, Ohio. Among 1450 total affected 
people, 21 people (1%) were hospitalized and no deaths. The symptoms 
reported by patients were diarrhea (83%), abdominal crambs (80%), 
nausea (77%), vomiting (50%), fever (45%) and bloody diarrhea (5%). The 
etiological agents of the outbreak were Campylobacter jejuni, norovirus, 
Giardia intestinalis, and Salmonella Typhimurium; that were identified in 16, 
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9, 3, and 1 people, respectively of a total of 1 450 persons 
(O'Reilly, et al. 2007). 
Furthermore, it was reported by the American National Outbreaks 
Reporting System (NORS), the first illness onset of person-to-person 
contact of acute gastroenteritis during January 2009 up to December 2010 
in United States (Fig. 5).  
 
Figure 5. Numbers and percentages of outbreaks of acute 
gastroenteritis transmitted by person-to-person contact. National 
Outbreak Reporting System, United States, 2009–2010 reported that 
norovirus is the most common cause of gastroenteritis outbreaks while 
Shigella is the second common cause. 
Norovirus outbreaks represented the highest number and percentage 1 270 
(56%) etiology which were reported. Shigella was the second most 
commonly reported etiology, although it accounted for only 86 (4%) of all 
reported outbreaks. Other single-etiology outbreaks were suspected or 
confirmed to be caused by Salmonella (n=16), rotavirus (n=10), Shiga 
toxin-producing E. coli (STEC) (n=11), Giardia lamblia (n=5), 
Cryptosporidium spp. (n=9), Clostridium difficile (n=1) (Wikswo, 2012).  
IN
TR
OD
UC
TI
ON
 
72 
 
Furthermore, in Spain, it was determined the size and epidemiological 
characteristics of foodborne outbreaks due to Norovirus in Catalonia 
between October 2004 and October 2005. They observed that from 181 
outbreaks reported during the study period, 72 were caused by Salmonella 
and 30 by norovirus (NoV); the incidence rates were 14.5 and 9.9 per 
100 000 person-year, respectively (Martinez, et al., 2008).  
One of the most recent and important outbreaks happened in Germany in 
2011, where E. coli O104:H4 strain caused a large outbreak of hemolytic 
uremic syndrome (HUS) and bloody diarrhea. The isolated strain 
possesses new combination of pathogenic features that combines some of 
the virulence factors of both EHEC (Stx but not the type III secretion and 
Tir/Intimin system) and EAEC (especially the adherence mechanisms) 
(Scheutz, Nielsen et al., 2011). The outbreak affected 4 000 people 
including 900 with HUS, which resulted in 54 deaths (Karch, et al., 2012). 
7. Treatments of enteric infections 
Enteric infections remain a common health problem worldwide. Oral 
Rehydration Therapy (ORT) and nutritional support should be performed 
before any other therapeutic agent. The most suitable treatment for viral 
gastroenteritis and parasitic gastroenteritis is ORT which includes 
rehydration and maintenance of fluids with oral rehydration solutions beside 
the appropriate nutrition (King, et al., 2003; Santosham, et al., 2010). 
Before widespread use of oral rehydration solutions, the treatment of 
diarrhea was restricted to intravenous fluid replacement that required 
patient visits to a health care facility to access the appropriate equipment. 
The new methods for prevention, management and treatment of diarrhea, 
including an improved oral rehydration formulation, zinc supplementation 
and rotavirus vaccines make now the time to revitalise efforts to reduce the 
diarrhea mortality worldwide (Santosham, et al., 2010). 
Antibiotics are required for the treatment of bacterial gastroenteritis in 
those patients suffering from severe complications of gastroenteritis, 
including dissemination of the disease or sepsis. Generally, antimicrobial 
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treatment tends to speed up the clinical resolution of diarrhea, prevents the 
progression of the disease and reduces the severity of associated 
symptoms as fever, vomiting and abdominal pain (Diniz-Santos, 
et al., 2006).  
Antibiotics induce bacterial cell death based on the bacterial cell function 
that can be inhibited by the drug-target interaction. The mechanism 
includes interference with cell wall synthesis, interference with nucleic acid 
synthesis, inhibition of protein synthesis, metabolic pathway inhibition and 
alterations of cell membrane (Kohanski, 2010). 
The use of probiotics has gained an important attention in recent years for 
their potential use as anti-gastroenteritis treatments. Probiotics are defined 
as live microorganisms that are administered in the adequate amounts to 
induce health benefits to the host. These benefits include: prevention of 
pathogen proliferation and function, stimulation of the host´s immune 
function and promotion of mucosal barrier integrity. However, their 
beneficial mechanisms of action are not completely known and further 
studies are needed (Britton and Versalovic, 2008).  
7.1 Treatment of enteric infections produced by 
Escherichia coli 
Diarrhea that is caused by enterotoxigenic E. coli, enteropathogenic E. coli, 
enteroaggregative E. coli and diffusely adhering E. coli can be treated by 
antibiotics to quickly relieve symptoms, such as 2nd or 3rd generation 
cephalosporin antibiotics, aztreonam beta-lactams associated with 
beta-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam). But the 
more severe diarrhea that is caused by enteroinvasive E. coli and 
enterohaemorragic E. coli can be treated by Ciprofloxacine 500 mg/12h 
oral, 3-5 days or with other alternative treatment such as clotrimoxazol 
160-800 mg/12h oral for 5 days, or azithromycin 500 mg/day for 3-5 days 
(Vu HT et al., 2012). 
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7.2 Problems of the use of antibiotics 
Currently, there are many synthetic antibiotics for treatment of various 
diseases caused by microorganisms. Some of these microorganisms have 
become resistant to antibiotics, rendering them ineffective. The resistance 
to antimicrobials is due to several causes: genetic plasticity of the 
microorganisms, unnecessary and inappropriate use, including inadequate 
dosing, low quality drugs, and increased mobility of the world population 
(Bisi-Johnson, 2012). A great number of bacterial isolates are showing 
resistant to practically all available therapeutic agents. Therefore, the 
problem has been building up over decades, and today many common and 
life-threatening infections are becoming difficult or even impossible to treat, 
sometimes turning a common infection into a life-threatening one 
(WHO, 2012). 
The CDC estimates that, more than two million people get sick every year 
by antibiotic-resistant infections in United States, with at least 23,000 
deaths (Frieden, 2013). Pathogenic bacteria show an enormous array of 
resistence mechanisms against antibiotics. The mechanisms of microbial 
resistance include:  
1- Decreased uptake of the antimicrobial: reducing entry of the 
antimicrobial agent by alteration of cell permeability; or expulsion of 
the antimicrobial from the cell, via general or specific efflux pumps. 
2- Conversion of active drugs to inactive derivatives by enzyme(s) 
produced by resistant organisms. 
2- Synthesis of alternative enzymes for the enzymes that the 
antimicrobial agents inhibit. 
3- Modification and mutation of the antimicrobial targets. 
4- Overproduction of the antimicrobial agent targets.  
7.2.1 Antimicrobial resistance of Escherichia coli 
It is reported that diarrheagenic E. coli (DAE) are important pathogens that 
have shown an increased resistance to many antibiotics. In 2008, at 
University of Uyo Teaching Hospital and University of Uyo Health Center in 
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Auna General Hospital, Akwa Ibom State, Nigeria, 75.4 % of isolated DAE 
showed high antibiotic resistance against tetracycline, 73.9 % were 
resistant to ampicillin, 68.1 % were resistant to gentamycin, and 46.4 % 
showed moderate resistance to chloramphenicol and 43.5 % were resistant 
to cephalothine (Akinjogunla, 2009).  
A recent study showed that most of DAE isolated from fecal samples of 
children under five years of age, were resistant to ampicillin, erythromycin, 
nalidixic acid and cephalexin. The sensitivity pattern against azithromicin, 
cotrimoxazole and ciprofloxacin was moderately resistant, while that of 
mecillinam, ceftriaxone and gentamicin was quite satisfactory 
(Roy, et al., 2013). 
Likewise, in USA Escherichia coli was isolated from human and food 
animal samples during 1950-2002 to determine the changes in 
antimicrobial drug resistance. A total of 1 729 E. coli isolates were tested 
for susceptibility to 15 antimicrobial drugs. E. coli isolates showed 
a significant increase of resistance for ampicillin, sulphonamide, 
tetracycline and gentamicin. It was concluded that multidrug resistance in 
E. coli increased from 7.2 % during 1950s to 63.6 % during 2000s 
(Tadesse, et al., 2012). 
Moreover, another study identified the degree of E. coli resistance to 
amoxicillin/clavulanic acid, ceftriaxone, gentamicin, tetracycline, 
ciprofloxacin, and sulfamethoxazole/trimethoprim. E. coli strains 
(9 enterotoxigenic E. coli (ETEC) and 5 enteropathogenic E. coli (EPEC) 
were isolated from the cloacae of chickens that showed resistance to at 
least one of the commonly used antibacterial agents. They observed that, 
all 9 ETEC were resistant to tetracycline, 3 were resistant to 
sulfamethoxazole/trimethoprim and 1 to ciprofloxacin. All 5 EPEC were 
resistant to tetracycline, 4 were resistant to gentamicin, 4 were resistant to 
sulfamethoxazole/trimethoprim and 3 to ciprofloxacin. Therefore, this study 
confirm that E. coli has antibacterial resistance that can be a health hazard 
to human since chicken and eggs are very common foods 
(El-Rami,  et al., 2012).  
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All mentioned studies prove that there is a continuing need to search for 
new antibacterial agents to overcome antibiotic resistance. Therefore we 
will try to shed light on the current efforts for saving life and to specifically 
overcome the bacterial resistance problem. 
7.3 New approaches for saving lifes  
Several national, regional and global initiatives are engaged in tackling 
Anti-microbial Resistance (AMR), and more specifically antibiotic 
resistance. In 1998, the World Health Assembly of the WHO urged member 
states to promote suitable directions to face antibiotic resistance. In 2000, 
WHO considered the rise of AMR a universal crisis, and in 2001 it started to 
release its first universal strategy for its containment. In 2009, 
a Transatlantic Taskforce on AMR (TATFAR) was organized to increase 
EU and US collaboration, and it has focused on improving the pipeline for 
new drugs. In the same year, the Swedish government promoted the issue 
during its EU presidency, particularly in relation to drug development.  
In 2010, the European Commission launched a Joint Programme initiative 
on AMR to enhance a more cohesive approach to research and integrate 
relevant scientific fields to create a shared vision. This was followed by 
a 12-point EU Commission in 2011 ‘Action Plan against the Rising Threats 
from Antimicrobial Resistance. Similarly, 2011 saw a six-point policy 
package from WHO. The 2011 World Health Day was based on the 
premise of ‘no action today, no cure tomorrow’. In 2012, the first meeting of 
medical societies in India resulted in a roadmap to tackle resistance in 
India. Moreover in 2013, the United Kingdom published a roadmap. 
Furthermore, a number of other initiatives have been developed (Merrett, 
2013). Briefly, there is an important direction that can help us to overcome 
the problem of microbial resistance is to dedicate our efforts toward 
scientific research in order to discover new antimicrobial agents.  
The integrated Global Action Plan for the Prevention and control of 
Pneumonia and Diarrhea (GAPPD) proposed three sides of a framework to 
reduce the diarrheal morbidity and mortality (Fig. 6). The first side of 
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framework is to protect children by establishing good health practices from 
birth, including breastfeeding for six months, complementary feeding and 
vitamin A supplementation. The second side of the framework is to prevent 
diarrhea illness in children with vaccines, using safe drinking water and 
sanitation, washing hands with soap, reducing household air pollution. The 
third framework is to treat children who are ill with appropriate treatments, 
improved care seeking and referral, case management at the health facility 
and community level, supplies with low-osmolarity ORS, zinc, antibiotics 
and oxygen and continued feeding (WHO/UNICEF, 2013). 
 
Figure 6. Protect, prevent and treat framework. The integrated Global Action 
Plan for the Prevention and control of Pneumonia and Diarrhea (GAPPD) proposed 
three sides of a framework to reduce the diarrheal morbidity and mortality. 
Adapted from (WHO/UNICEF, 2013) 
 
7.4 Global use of medicinal plants 
Medicinal plants have been employed to treat diseases since ancient times, 
and their use had remained an integral part of many cultures worldwide. 
From the total number of known plant species on Earth (estimated as 
250 000–500 000), only a small fraction have been investigated for their 
antimicrobial activity and only 1–10% of plants are used. Among 109 new 
antibacterial drugs approved during the period 1981–2006, 69% originated 
from natural products, and 21% of antifungal drugs were natural derivatives 
or compounds simulating natural products (Savoia, 2012).  
The WHO estimates that 80% of people living in developing countries 
utilize traditional medicine. Developed countries also use medicinal plants. 
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In Germany, 600-700 plant-based medicines are plentiful for prescription 
and they can be prescribed by 70% of German physician (Ehrlich, 2011).  
In the last two decades in United States, there is a public dissatisfaction 
with the cost of medical prescriptions, which led to an interest in returning 
to use herbal medicine (Motaleb, et al., 2011). The use of medicinal plants 
is widespread in China, India, Japan, Pakistan, Sri Lanka and Thailand. In 
China approximately 40% of the total medicinal consumption is attributed to 
traditional medicines. In Japan, herbal medicinal preparations are more in 
demand than pharmaceutical preparations.  
In Europe, nearly 1 500 species of medicinal and aromatic plants are widely 
used in Albania, Bulgaria, Croatia, France, Germany, Hungary, Poland, 
Spain, Turkey, and the United Kingdom (Hoareau,1999). In 19Th century, 
medicinal plants were the main source to sustain health. In 1828, the 
German chemist Friedrich Wohler tried to synthesize the ammonium 
cyanate from silver cyanide and ammonium chloride, but accidently 
synthesized urea. Urea was the first synthetic organic compound, and 100 
years following the Wohler`s discovery, the phytomedicine was forgotten 
due to the synthetic compound revolution. Then, in 1980s started a 
resurgence of interest in the use of plants as a source of bioactive 
phytocompounds.  
Much more attention has been recently paid to extracts and biologically 
active compounds that were isolated from plant species. This interest in the 
use of phytocompounds was due to the emergence of side effects of 
synthetic compounds and the need to find new compounds, including new 
antibiotics to treat multiresistant bacteria. Therefore, plants can offer a new 
source of antibacterial agents (Ahmed, 2006). 
It is well known that phytochemical constituents and secondary metabolites 
are responsible for the biological activity of plants. The majority of these 
secondary metabolites work as a mechanism of resistance against 
predators and pathogens (Zahin, et al., 2010). The major groups of 
phytocompounds and bioactive constituents that work as antimicrobial 
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agents are phenols, polyphenols, quinones, tannins, coumarines, flavonols, 
flavone, flavonoids, terpenoids, essential oils and alkaloids (Cowan, 1999). 
7.5 Plants as anti-enteric infections agents 
Many medicinal plants are used as antibacterial agents. It has been 
reported that Allium sativum (garlic) and Zingiber officinale (ginger) possess 
antibacterial activity against multi-drug resistant pathogens and they can be 
used for prevention of drug resistant microbial diseases. Their antibacterial 
activity were tested against five Gram-negative (E. coli, Enterobacter spp., 
P. aeruginosa, Proteus spp., Klebsiella spp.) and two Gram-positive 
(S. aureus and Bacillus spp.) multidrug resistant bacteria isolates 
(Karuppiah and Rajaram, 2012). Allium sativum offers a hope for 
developing alternative drugs and a good potential as antitubercular drug 
(Gupta, et al., 1999; Dini, et al., 2011). 
Another study investigated the antibacterial activity of the aqueous garlic 
extract, apple vinegar and apple vinegar-garlic extract combination against 
5 Gram-positive and 9 Gram-negative bacteria. It showed that aqueous 
extract of garlic and apple vinager-garlic extract combination possess wide 
spectrum activity against all tested bacterial isolates while the apple vinager 
possess slight antibacterial activity (Hindi, 2013). 
Methanolic extracts of Tussilago farfara, Equisetum arvense, Sambucus 
nigra, Aesculus hippocastanum and Taraxacum officinale were investigated 
for antibacterial activity against E. coli strains resistant to ampicillin and 
chloramphenicol (Hleba, et al., 2013). It was studied, on one side, 10 E. coli 
strains isolated from milk from conventional breeding of cow, and on the 
other, 10 E. coli isolated from ecological breeding. All medicinal methanolic 
extracts possess antibacterial activity against 10 E. coli that were isolated 
from the conventional breeding of cow. In addition, the other 10 E. coli that 
were isolated from ecological breeding of mare (adult female of horse) were 
susceptible to Tussilago farfara medicinal plants (Hleba, et al., 2013). 
Likewise, the antibacterial activity of commercial fruit juices as pineapple, 
blueberry, pink pear, sweet aji, corozo, starfruit, Santander’s medlar, sour 
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grape, Isabella grape, and wild blackberry and the ethanolic extracts of 
bryophytes, two mosses (Sphagnum magellanicum and Hypnum amabile) 
and two liverworts (Metzgeria decipiens and Trichocolea tomentosa) was 
assessed against B. subtilis, S. aureus, P. aeruginosa and E. coli and 
compared to ampicillin and clindamycin antibiotics. This study showed that 
the juices of blueberry, sour grape, Isabella grape and wild blackberry and 
all ethanolic extracts of bryophytes were active against at least two of the 
evaluated bacteria with different percentage of inhibition 
(Rodríguez-Rodríguez, et al., 2012). 
Essential oils of Rosmarinus officinalis and Salvia officinalis showed 
antibacterial activity against Escherichia coli, Salmonella Enterica 
ser.Typhi, S. enterica ser. Enteritidis, and Shigella sonnei 
(Bozin, et al. 2007). The ethanolic extract of R. officinalis was active against 
Methicillin- Resistant S. aureus (MRSA) (Jarrar, et al., 2010). Moreover, 
essential oils from Origanum vulgare were bactericidal against S. aureus, 
B. subtlis, L. monocytogenes, C. perfringens, C. botulinum, E. coli, 
P. aeruginosa, S. enterica ser. Typhimurium, C. jejuni and V. cholerae, with 
minimum inhibitory concentrations (MIC) ranging from 0.1 to 4 mg/mL 
(Derwish, et al., 2010). 
Furthermore, the antimicrobial activity of crude methanol and aqueous 
extracts of the leaves of Syzygium cumini was evaluated against Gram-
negative bacteria such as S. ser. Enteritidis, S. ser. Typhi A, S. ser. 
Paratyphi A, S. ser. Paratyphi B, P. aeruginosa and E. coli; and Gram-
positive bacteria B. subtilis, and S. aureus. The results of this study showed 
that both extracts inhibited the tested Gram-negative and Gram-positive 
bacteria, but the methanol extract was more potent than the aqueous 
extract (Gowri and Vasantha, 2010). As well, ethanol extract of cinnamon 
bark (Cinnamomum zeylanicum) and ajowan fruits (Trachyspermum ammi) 
showed antibacterial activity against Pseudomonas spp., while acetone 
extract of spices displayed highest activity against E. coli. This study 
suggests that the ethanol extract of C. zeylanicum and T. ammi revealed a 
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significant scope to develop a novel broad spectrum of antibacterial herbal 
formulations (Usha, et al., 2012).  
7.5.1 Hibiscus sabdariffa 
Hibiscus sabdariffa belongs to the Malvaceae family. The genus Hibiscus 
includes from herbaceous annuals or perennials to small shrubs and small 
trees. The leaves are alternate, simple, ovate tolanceolate, often with 
serratedor lobedmargin. The flowersare large, conspicuous, trumpet-
shaped, with five petals, white tones of roses, red, purple or yellow, orange, 
4-15 cm in size. The fruit is a capsule containing several seeds in each 
locule. They are typical in subtropical and tropical areas around the world, 
with an origin centered mainly in South East Asia. It was introduced and 
cultivated since ancient times for use as ornamental, food and medicinal 
plant. 
The world's largest producers are China and Thailand. The production is 
lower in Mexico, Egypt, Senegal, Tanzania, Mali and Jamaica, and the best 
quality in the world comes from Sudan, though sparingly. In the delta of the 
Gangesin India, where it is called mesta, is grown for its fiber plant stem, 
very tough. In Brazil it is grown organically in the area of Minas Geraisas 
Flor dos Hibiscus, where they have developed a variety of organic 
products. The plant grows as a home garden plant in the tropical countries, 
including Caribbean, México, Central America, India, Africa, Brazil, 
Australia, Hawaii, Florida and Phillipines. In Sudan, it is a major crop of 
export (Mahadevan, et al., 2009). In English, it is called Roselle, Sorrel, 
Red sorrel, Jamaica sorrel, Indian sorrel, Guinea sorrel, Sour-sour 
(Mahadevan, et al., 2009).  
The deep red sour drink is prepared from dry calyces and is called roselle 
(a name for the flower) or rosella (Australia), karkadeh in Egypt, Sudan, 
Italy and Russia, agua de Jamaica or flor de Jamaica in Latin America, 
Arhul ka phool in India, Chai Kujarat in Iraq, Chai Torsh in Iran, 
gumamela in the Philippines, bissap, tsoborodo or wonjo in West Africa, 
sorrel in Jamaica, Barbados and Trinidad and Tobago, zobo juice in 
Nigeria, red sorrel in the wider Caribbean, and other names in other 
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regions, including the U.S., where it is sometimes known as simply 
Jamaica (Omemu, et al., 2005). 
The aqueous brew has a tart, cranberry-like flavor, and sugar is often 
added to sweeten the beverage. It contains vitamin C and minerals and is 
used traditionally as a mild medicine. In west Sudan a white hibiscus flower 
is favored for its bitter taste and is customarily served to guests. Hibiscus 
brew contains 15-30% organic acids, including citric acid, malic acid, and 
tartaric acid. It also contains acidic polysaccharides and flavonoid 
glycosides, such as cyanidin and delphinidin, which give it its characteristic 
deep red colour (Ali, et al., 2005). 
7.5.1.1 Medicinal uses of Hibiscus sabdariffa 
H. sabdariffa calyces extract has different biological potential activities 
(Fig. 7). It can be used as an anti-obesity agent as was showed in an in 
vivo study using rats that were fed with basal diet and in parallel the same 
basal diet supplemented with H. sabdariffa extract. The rats were fed with 
basal diet supplemented with H. sabdariffa extract showed decrease in 
weight gain and in food consumption (Carvajal-Zarrabal, et al., 2009).  
 
Figure 7. Hibiscus sabdariffa plant and its biological potential activities.  
              (Modified from Da-Costa-Rocha 2014). 
It has been shown that the aqueous extract of H. sabdariffa inhibits 
adipocyte differentiation through the modulation of the PI3-K/Akt and ERK 
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pathway that plays important roles during adipogenesis (Kim, et al., 2007). 
Also the aqueous and ethanol extracts can be used as food preservatives. 
In fact both extracts showed a dose dependent inhibitory effect against food 
spoilage of ground beef and apple juice by S. Typhimurium DT104, E. coli 
O157:H7, L. monocytogenes, S. aureus and B. cereus (Chao and 
Yin, 2009). Likewise, it inhibits the growth of MRSA, K. pneumoniae, 
P. aeruginosa and A. baumannii (Liu, et al., 2005). 
Another study reported that H. sabdariffa polyphenol extract reduced 
kidney mass in streptozotocin induced diabetic nephropathy in rats. 
Additionally it reduced triglyceride, total cholesterol and LDL serum content 
in streptozotocin treated rats (Lee, et al., 2009). Moreover it could be used 
as anticancer agent acting on the p53 signaling and p38 MAPK/FasL 
cascade pathway. Interestingly, it was shown to induce apoptosis in human 
gastric carcinoma cells (Lin, Huang, et al., 2005). Several H. sabdariffa 
extracts displayed different activities against atherosclerosis, diabetes, liver 
disease and other metabolic syndrome (Lin, Chen, et al., 2011). It has been 
suggested its use as protective agent against acetaminophen induced liver 
cell death mediated by oxidative stress (Liu, Wang, et al., 2010). 
The red sour tea is antihypertensive and cardioprotective in type II diabetic 
patient with mild hypertension (Mozaffari-Khosravi, et al., 2009). Moreover, 
there is a report that supports using H. sabdariffa as an antihypertensive 
agent. Whereas crude methanolic extract of H. sabdariffa induced 
relaxation (vasodilator) of isolated aortas from spontaneously hypertensive 
rats. The relaxation effect acts via endothelium-dependent and independent 
vasodilator pathways through activation of endothelium-derived nitric 
oxide/cGMP-relaxant pathway (Ajay, et al., 2007). 
H. sabdariffa ethanol and aqueous extracts are antipyretics in experimental 
animals (Reanmongkol and Itharat, 2007).  
Due to important problem of children deaths in the developing countries, it 
is interesting to investigate the use of natural products as antibacterial 
agents.  
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Objectives 
Enteric infections, which are food and water borne diseases, are a serious 
public health problem worldwide. Microorganisms are the main cause of 
enteric infections; therefore their control may significantly reduce the food 
and water-borne enteric infections outbreaks. The public is becoming 
increasingly conscious of problems with the over prescription and misuse of 
traditional antibiotics, and the failure of treatments due to the appearance of 
new bacterial strains antibiotic resistant. The use of plant extracts and 
natural phytochemicals with proved antimicrobial properties can be of great 
significance in the therapeutic use. In recent years, secondary metabolites 
as phenolic compounds, terpenoids, flavonoids and alkaloids have received 
a great deal of attention due to their diverse biological functions. Some 
natural substances have effective antimicrobial properties and they have 
been used as alternative treatments. Today, the use of plants as treatment 
of illness is accepted worldwide. In developing countries, the use of 
medicinal plants has significantly increased due to the low income of the 
population. Herbs and spices are generally considered to be safe and have 
been proved to be effective against certain ailments. Therefore we aimed to 
study the antimicrobial properties of selected medicinal plant extracts, as 
follows: 
I. Evaluation of the in vitro antimicrobial activity of selected plant 
extracts, against Gram-negative and Gram-positive bacteria 
including some of the most frequent etiological agents of enteric 
infections and fungi. 
II. Characterization of the antimicrobial activity of the natural 
extract with best activity and the most sensitive/interesting 
microorganism. 
III. Determination of the in vitro cytotoxicity of the selected extract. 
IV. Analysis of the effect against enteropathogenic E. coli (EPEC) of 
the selected extract during in vitro infection of cell cultures.  
V. Chemical fractionation of the selected natural extract. 
VI. Assessment of the antibacterial activity of the fractions. 
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Materials and Methods 
1. Plant materials 
Dried red calyces of Hibiscus sabdariffa var. ruber (red) were purchased 
from a local herbalist of Hurghada city (Egypt) which is imported from 
Sudan. Leaves and stem of Rosmarinus officinalis, leaves of Origanum 
vulgare, leaves of Thymus vulgaris and grounded bark of Cinnamomum 
zeylanicum or Cinnamomum verum (were obtained from a local herbal 
shop in Madrid, Spain. The botanical materials were identified in Dpt. of 
Plant Biology II, Faculty of Pharmacy, University Complutense of Madrid.  
2. Preparation of the plant extracts 
For H. sabdariffa, 10 g sample of the grounded dried red calyces were 
soaked in 100 mL of Milli Q sterile water for 24 h at RT. 10 g sample of the 
ground plants of R. officinalis, O. vulgare, T. vulgaris and C. zeylanicum, 
were soaked in 100 mL of Milli Q sterile water at 65 ºC for 30 min. Each 
aqueous plant extract was decanted and filtered using 0.22 µm sterile 
single use filters (Millipore Corporation, Bedford, MA, USA). The filtrates 
were lyophilized using a freeze-dryer (Freeze-drying works by freezing the 
material and then reducing the surrounding pressure to allow the frozen 
water in the material to sublimate directly from the solid phase to the gas 
phase) which it works at very low temperature (-40 ºC) and pressure. The 
lyophilized extracts were kept at 4 ºC, in the dark, until use. 
3. Determination of total phenolic compounds (TPCs) 
content 
Dried plants were prepared in sterile distilled water at 5-10% w/v as 
previously described. The total phenolic compounds contents were 
determined using the Folin-Ciocalteu method (Ainsworth and Gillespie, 
2007) using gallic acid (Sigma) as standard. Folin-Ciocalteu reagent (VWR 
International Eurolab) is formed from a yellow color mixture of 
phosphotungstic acid, H3PW12O40, and phosphomolybdic acid, H3PMo12O40, 
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which, after oxidation of the phenols, is reduced to a mixture of blue oxides 
of tungsten, W8O23, and molybdenum, Mo8O23. The blue coloration 
produced has a maximum absorption in the region of 750 nm, and is 
proportional t  o the total quantity of phenolic compounds originally present. 
The aqueous crude extract solution (10, 20 and 100µL) was oxidized with 
500 µL of Folin-Ciocalteou reagent (VWR international Eurolab). Then the 
mixture was kept for a 2-5 min period. The reaction was neutralized by the 
addition of 400 µL of sodium carbonate Na2CO3 (75 g/L) (Panreac). The 
absorbance of the resulting blue color was measured at 750 nm after 
incubation in dark for 60 min at RT. The total phenolic content was 
expressed as mg gallic acid equivalents (GAE)/L (Sigma) (standard curve 
was prepared using concentration 2, 5 mg/L). 
4. Bacterial strains and growth conditions 
Stock cultures were maintained at 4 ºC on slopes of nutrient agar. Cultures 
for experiments were prepared by picking a colony from 24 h Mueller-
Hinton agar (MHA) (Conda-Pronadisa) plate and it was re-suspended in 
Mueller-Hinton broth (MHB) medium (5 ml). Culture was grown aerobically 
for 20 h and at 37 ºC with shaking at 200 rpm. The cultures were diluted 
with fresh MHB to achieve absorbances at 600 nm; corresponding to 
4 x 105 colony forming units (CFU/mL) based on 0.3 absorbance units 
(600 nm) to 2.5 x 108 CFU/mL. The strains of bacteria used in these studies 
were kindly provided by Dpt. of Microbiology II, UCM, unless otherwise 
clearly indicated. The Gram-positive tested bacteria are Staphylococcus 
aureus ATCC 29213, Methicillin Resistant S. aureus MRSA, Enterococcus 
faecalis ATCC 29212; Listeria monocytogenes ATCC 7644, Listeria 
monocytogenes isolated from meat (both Listeria were kindly provided by 
Dr. A. Zamora, Food Science and Food Hygiene Institut, Veterinary Military 
Centre of Defense, Madrid, Spain). The Gram-negative bacteria are 
Klebsiella pneumoniae KPBL, clinical isolate of Pseudomonas aeruginosa 
and Burkholderia cenocepacia J2315, Escherichia coli ATCC 25922, 
clinical isolate of Uropathogenic E. coli (UPEC); Enteropathogenic E. coli 
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(EPEC 0127:H6 strain E2348/69) (this strain was provided by 
Dr. Brett B. Finlay. University of British Columbia, Vancouver, Canada). 
Salmonella enterica serovar Typhimurium, S. enterica serovar Enteritidis 
(both Salmonella were kindly supplied by the National Center for 
Microbiology, Virology and Immunology Health.Carlos III Institut (Instituto 
de salud Carlos III), Madrid, Spain).  
5. Fungal growth conditions 
The fungal strains used in these studies were kindly provided by Dpt. of 
Microbiology II, UCM, unless otherwise clearly indicated. Fungal strains: 
Candida albicans SC5314 (ATCC MYA 2876), Saccharomyces cerevisiae 
YPH499 (MA Ta ade2-101 trp-63 leu2-1 ura3-52 his3-∆200 lys2-801), 
S. cerevisiae BY4741 (MA Ta his3∆1 leu2∆0 met15∆0 ura3∆0) and 
Yarrowia lipolytica (P01a MATA leu2-270 ura3-302) (Y. lipolytica was 
provided by A. Domínguez, University of Salamanca, Spain). They were 
cultured on YPD agar plates. One colony of each strain was suspended in 
YPD broth medium (Yeast, Peptone, Dextrose) (Conda-Pronadisa) and 
incubated at 30 ºC for 20 h, and then they were diluted to achieve 
absorbances at 600 nm; corresponding to 4x106 CFU/mL based on 
1 absorbance unit to 2.5 x 107 CFU/mL for C. albicans and 1 absorbance 
unit at 600 nm to 1 x 107 CFU/mL for S. cerevisiae YPH 499 and 
S. cerevisiae BY4741 and Y. lipolytica for experimental conditions. 
6. Antimicrobial activity  
6.1 Microwell dilution assay 
Minimal inhibitory concentration (MIC) and minimal bactericidal 
concentration (MBC) were determined through broth micro-well dilution 
assay (Fig. 8). The lyophilized plant extracts were dissolved in Mueller-
Hinton broth (MHB) with serial dilution at specific concentrations w/v of 
each extract. 96-well microtiter plates were prepared by dispensing into 
each well 95 µl of each dilution of the lyophilized plant extract and 5 µL of 
inoculum (104 CFU; final concentration 105 CFU/mL) was added to each 
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tested dilution. The final volume in each well was 100 µL. Control wells 
were prepared with culture medium without inoculum, medium with 
bacterial inoculum and medium with plant extract without inoculum and 
plant extract alone, in same concentrations than used in the assay. Each 
concentration of the extract had a negative and positive control. The plate 
was incubated at 37 ºC on a shaker at 200 rpm for 16-18 h. Microbial 
growth in each concentration was determined by reading the respective 
absorbance at 600 nm using a standard microplate reader. Microbial 
growth was assessed by taking samples at 16-18 h and plating on MHA by 
using a replicator (drop assay) that were allow to grow for 24 h at 37 ºC.   
 
Figure 8. Microwell dilution assay.  
The tested bacteria are incubated in MHB media at 37 ºC overnight. In a microwell 
plate, MH represent the negative control of inoculum (C-), MH+i represent the 
positive growth control of inoculum (2x104 CFU/well) (C+), Ext. represent the 
extract dissolved in MH without inoculum at specific concentration, Ext+i represent 
the extract dissolved in MH with inoculum (2x104 CFU/well) at the specific 
concentartion. Each microwell contains100 µl as final volume. The microwell plate 
is incubated at 37 ºC for 16-18 h. The microbial growth was determined by 
measuring the absorbance at 600 nm of each concentration to determine the 
minimal inhibitory concentration (MIC). Afterward, 1.5 µl of each microwell were 
droped onto Mueller-Hinton Agar (MHA) plate by using replicator to assess the 
minimal bactericidal concentration (MBC) and the rest of the microwell was mixed 
with 5 ml of broth MH media and incubated at 37 ºC with agitation for 16-18 h then 
the MBC was determined. 
For assurance of the drop assay results, the rest of the microwell was 
mixed with 5 mL of MHB medium and incubated at 37 ºC with agitation for 
16-18 h, then the MBC was determined by direct observation of presence 
or absence the turbidity. MIC is defined as the lowest concentration of the 
antimicrobial compound that inhibits the growth of microorganisms after 
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incubation. MBC is the lowest concentration of the compound that kills the 
bacteria. 
6.2 Disc diffusion test 
Antibiotic susceptibility by disc diffusion test was realized according to the 
Kirby-Bauer test (Cona, 2002). Two sterile discs (6 mm diameter) were 
soaked separately on the aqueous extract to obtain 35 and 70 mg/disc and 
then the discs were allowed to dry. These discs were placed on the surface 
of MHA plates, previously prepared with the selected bacteria. Each disc 
was pressed down to ensure complete contact with the agar surface and 
maintained at a distance no closer than 24 mm from each other (center to  
center). The plates contained EPEC and E. coli ATCC 25922 at 
a concentration of 108 CFU/mL (McFarland 0.5). The target bacteria EPEC 
and E. coli ATCC 25922 were added to melted MHA at 45 ºC in absence 
and presence of 0.5 % Tween 80 (Sigma) to facilitate the aqueous extract 
diffusion through the agar. This preparation was incubated at 37 ºC for 
a period of 24 h. Discs commercially prepared with an antibiotic (Ampicillin 
10 µg/disc) (BD BBL) were used as a positive control. Antibacterial activity 
was determined as the lowest concentration of plant extract that produced 
an inhibition zone (halo) around a disc following the 24 h incubation. 
Antibacterial activity was evaluated from the diameter (mm) of the halo 
formed around the discs after 24 h incubation. 
7. Time-kill curve studies 
7.1 Time kill curves 
Time-kill curve were done at 1% w/v (10 mg/mL) (MIC) and 2.5% w/v 
(25 mg/mL) (MBC) of plant extract. Overnight fresh culture bacteria were 
inoculated into MHB media at starting density of 4x106 CFU/mL for both 
sample and control culture media. Cultures were incubated at 37 ºC for 
24 h. Aliquots for the determination of viable counts were taken from test 
culture and growth control flasks at 0, 2, 4, 6, 8, 10, 12 and 24 h. Viable 
counts were determined by plating 100µl of known dilutions of the culture 
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samples on to MHA plates in duplicate. Cell count plates were incubated at 
37 ºC for up to 48 h to allow bacterial growth. The number of colonies was 
multiplied by the assayed dilution. The growth curve was analysed by 
plotting log CFU/mL versus time and the bactericidal effect can be seen by 
a 3 log units decrease at the time specified (Cantón and Pemán, 1999). 
7.2 Time-kill kinetics. Mathematical model for 
bactericidal activity 
The killing kinetics of the bactericidal activity were analyzed by fitting the 
mean data at each time point to an exponential equation: Nt = N0 X e_Kt, 
where Nt expresses the number of viable bacteria at time t, N0 is the 
number of viable bacteria at the beginning of the experiment, K is the killing 
(or lethality) rate, and t is the incubation time. The exponential equation 
was transformed into a line by applying natural logarithms 
(log Nt=log N0+Kt). The K value was calculated, positive values of which 
indicate growth and negative values of which indicate killing. Thus, the time 
points of every killing curve were reduced to one value, K. The following 
parameters were derived from the killing equation: the mean times to 
achieve reductions in the proportions of viable cells of 50% (t50=0.30103/K), 
90% (t90 = 1/K), and 99% (t99 = 2/K) and the time to reach the bactericidal 
endpoint 99.9 % (t99.9 = 3/K) for each concentration (Cantón, et al., 2004). 
8. Microbial quality assays 
To investigate the presence of Salmonella spp. 25 grams of plant calyces 
were transferred to a filter bag (Seward (Nessler), Stomacher lab system) 
under sterile conditions and 225 mL of buffered peptone was added. After 
10 min of hydration at RT, the sample was homogenized for 1min in a 
homogenizer (Stomacher Lab Blender 400, Seward, Warthing, UK). Then 
the supernatant was transferred into a flask for incubation at 37 ºC for 24 h 
(pre-enrichment procedure).  
To assess the presence of Salmonella spp., after 24 h 1mL aliquots of the 
enrichment culture were added to two different types of broth culture media: 
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Selenite Brilliant Green broth media (Conda-Pronadisa) at 37 ºC and 
Rappaport-Vassiliadis broth media (Conda-Pronadisa) at 42 ºC for 24 h. 
Afterwards, a sample of the incubated selenite brilliant green broth media 
was laid over Salmonella-Shigella agar (SS) (Conda-Pronadisa) and Xylose 
Lysine Desoxycholate agar (XLD) (Conda-Pronadisa) for incubation at 
37 ºC for 24 h. In parallel a sample of Rappaport-Vassiliadis liquid media 
(Conda-Pronadisa) was surface plated on the Brilliant Green Agar (BGA) 
(Conda-Pronadisa) for incubation at 37 ºC for 24 h.  
To assess the presence of aerobic mesophilic bacteria, Enterobacteria, 
S. aureus, B. cereus, E. coli, L. monocytogenes and fungi: 10 grams of 
plant calyces were transferred to a homogenizer bag under sterile 
conditions and 90 mL of buffered triptone were added.  
For counting the total viable aerobic or mesophilic bacteria, the pour-
plate method was used.1mL aliquots of 10-4, 10-5 and 10-6 dilutions in 
peptone broth were mixed with 20 mL of Plate Count Agar (PCA) (Conda-
Pronadisa) and plated by duplicates for each dilution. After incubation at 
30 ºC for 24 h, plates were counted. 
For detection of enterobacteria 1 mL aliquots of the homogenate (10-1) 
were serially diluted up to 10-6. 1mL of 10-1, 10-2 and 10-3 were mixed with 
Violete-Red-Bile-Glucose (VRBG) (Conda-Pronadisa) in duplicate and were 
incubatedat 30 ºC for 24 h. For detection of E. coli 1mL of 10-1 and 10-2 
dilutions were mixed with Coli-ID agar (bioMèrieux) in duplicate at 37 ºC for 
24-48 h. 
For detection of S. aureus, the Most Probable Number (MPN) method was 
used.1mL 10-1, 10-2 and 10-3 dilutions by triplicate each one were mixed 
with Chapman-Mannitol broth (Conda-Pronadisa) media by triplicate of 
each dilution for detection after incubation at 37 ºC for 24 h. To confirm the 
presence of S. aureus, samples from incubated Chapman-Manitol broth 
media were plated on Baird-Barker agar (Difco) media and incubated at 
37 ºC for 24 h.  
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To detect the presence of B. cereus, a sample of 10-1 initial dilution was 
laid over Mossel agar (Conda-Pronadisa) and incubated at 30 ºC for 48 h.  
To assess the presence or absence of L. monocytogenes,: 10 g of the 
H. sabdariffa calyces were homogenized with Fraser broth media 
(bioMèrieux) and incubated at 30 ºC for 24-48 h, then a sample was laid 
over ALOA agar (bioMèrieux) and incubated at 37 ºC for 24 h. For fungi 
detection, duplicated samples of 10-1 and 10-2 dilutions were laid over 
Sabouraud agar (Conda-Pronadisa) to incubate for 2 to 4 days at 24 ºC. 
9. Cell culture 
HeLa, a human cervical epithelial cancer cell line was obtained from the 
American Type Culture Collection (ATCC). Cells were cultured in Iscove's 
Modified Dulbecco's Media (IMDM, Invitrogen) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS, Lonza BioWhittaker, Fisher 
Scientific) and antibiotics (penicillin 100 U/ml and streptomycin 100 μg/ml, 
Invitrogen) at 37 ºC in a humidified atmosphere with 5% CO2. Cell lines 
were routinely subcultured twice a week by detaching the monolayer with 
0.25% trypsin - 0.03% ethylene diamine tetra acetic acid (EDTA) solution. 
The cell passage was recorded and cells were discarded at the 25th 
passage. Frozen cell stocks were stored in liquid nitrogen using a freezing 
solution containing 20% of dimethyl sulfoxide (DMSO) as a cryoprotectant. 
10. EPEC infection of HeLa cells and pedestal 
formation 
For infections, HeLa cells were grown to 70-80 % confluence in tissue 
culture P100 plates in 5% CO2 at 37 ºC. Cells were seeded at a density of 
150,000 cells/well onto 6 well cell culture plates containing four heat-
sterilized glass cover slips in each well and allowed to attach for 24 h. 
EPEC was grown overnight as previously mentioned. 
For preactivation experiments, the bacteria was diluted 1:100 with Iscove´s 
modified Dulbecco`s media supplemented with 10 % fetal bovine serum 
without antibiotics in a P60 plate and were kept at 37 °C with 5% CO2 for 
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2 h. After the incubation period, the absorbance at 600 nm was adjusted at 
0.2. Then, 25 µl EPEC were added to each well of 6 well plates which 
contained HeLa cells and incubated for the indicated times at 37 °C in 
5% CO2. The Multiplicity of Infection (MOI) is defined as the number of 
bacteria added per cell at the beginning of the infection, and was calculated 
by considering that an absorbance at 600 nm of 1 is equivalent to 109 and 
that the number of HeLa cells per well counted the day of the infection. 
After the indicated time of infection, unattached bacteria were removed by 
washing cells three times with D-PBS, then the aqueous plant extract were 
added at the indicated concentrations and incubated for 1, 2 and 3 h, or 
cells were left uninfected as a control for the treatments.   
11. Immunoflourescence experiments 
Hela cells were fixed with formaline buffer solution (containing 4% w/v 
formaldehyde, Sigma) for 20 min at RT and then washed twice with D-PBS. 
The fixed cells were permeabilized with 0.05% Triton X-100 for 5 min. After 
washing with PBS three times, the cells were blocked with PBS containing 
2% BSA for 10 min. The cells were stained with 1 μg / mL tetramethyl-
rhodamine-isothiocyanate (TRITC)-phalloidin (Sigma) for 15 min at RT to 
visualize the actin cytoskeleton, and the pedestals. After three washes with 
PBS, the cells were stained with 4'-6-diamidino-2 phenylindole (DAPI, 
300 nM) for 5 min at RT to visualize bacteria. After three washes with PBS 
the coverslips were allowed to dry at RT during 20 min and mounted using 
5 μl of mounting medium (100 mM Tris-HCl pH 8.5, 10% Mowiol 4-88 
(Calbiochem), 25% Glycerol with phenylnediamine (Sigma)). Micrographs 
were taken using a Nikon Eclipse TE 200-U fluorescence microscope 
equipped with a Hamamatsu camera. Images were processed with Adobe 
Photoshop. Quantification of pedestals was done by counting the number 
of pedestals of attached bacteria for a total of 40 infected cells in 
representative microscope fields.  
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12. Cell viability assays 
12.1 Determination of cytotoxicity of the extract using the 
Rezasurin reduction test in J774 Macrophages 
J774 murine macrophages were seeded (7x104 cells/well) in 96-well-flat-
bottom microplates (Nunc) in 100 μL of RPMI 1640 medium (Sigma) 
supplemented with 10% of heat-inactivated fetal bovine serum (FBS). The 
plates were incubated at 37 C, 5% CO2 to allow for cell attachment during 
24 h. After the incubation time, the medium was replaced with 200 μL of the 
extract dissolved in RPMI medium at different concentrations, for another 
24 h. 
Rezasurin reduction test was used as an indicator for cell viability. Blank 
controls with the extracts dissolved in RPMI medium without cells and 
growth controls (untreated macrophages) were also included in each 
microplate. Afterwards, cytotoxicity was determined by addition of 1mM of 
the redox dye resazurin (20 μL/well) (resazurin sodium salt, Sigma) and 
measures were taken after 3 h of incubation by using a spectrofluorometer 
(λex 535 nm - λem 590 nm). Resazurin reduction test was used as an 
indicator of cell viability. Resazurin dye (blue and non-fluorescent) is 
reduced to resarufin (pink and highly fluorescent) by mitochondrial 
enzymes, which are carriers of diaphorase activities. These enzymes are 
probably responsible for the transference of electrons from NADPH+ H+ to 
resazurin, which is reduced to resorufin. The reduction of resazurin 
correlates with the number of alive macrophages.  
12.2 Determination of cytotoxicity of the extracts on 
HeLa cells 
HeLa cells were seeded at 150 000 cells per well of 6-well plates in IMDM 
medium supplemented with 10% heat-inactivated fetal bovine serum and 
antibiotics and incubated at 37 ºC in a humidified atmosphere with 5% CO2 
for 24 h. Then, the cells were treated with the aqueous plant extract of 
H. sabdariffa at different concentrations (5, 7 and 10 mg/mL) for 24 h; 
MA
TE
RI
AL
S 
AN
D 
ME
TH
OD
S 
 
  
101 
 
afterwards, cells were washed and harvested in 10 mL of medium. Equal 
volumes (50 µL) of trypan blue and cell suspensions were mixed well and 
5 µL were overlaid on a Neubauer chamber for cell counting under a light 
microscope. Live cells were counted per each well of the different 
concentrations and compared with the control of untreated cells. Trypan 
Blue is a blue acid dye that has two azo chromophores groups which 
cannot enter into the plasma membrane of live cells.  
13. Fractionation of the aqueous extract of Hibiscus 
sabdariffa calyces 
The lyophilized aqueous extract of H. sabdariffa (Fig. 9A) was fractionated 
using different organic solvents in order of increasing polarity: ethyl acetate, 
acetone and ethanol. First, lyophilized aqueous extract of H. sabdariffa 
calyces (40 g) were extracted with ethyl acetate (400 mL) at RT with 
magnetic stirring overnight (Fig. 9B). Then, the solvent (ethyl acetate) was 
filtered under vacuum (Fig. 9C), to obtain a supernatant and a residue. The 
supernatant was concentrated using a rotary evaporator (Rotavapor La 
BOROTA, 4000, Heidolph) (Fig. 10A) at 35 ºC, to obtain the ethyl acetate 
soluble extract (0.170 g) (EtOAc extract). The residue obtained was 
dipped in acetone (400 mL) at RT with magnetic stirring overnight, to obtain 
a supernatant and a residue. The supernatant after filtration was 
concentrated using a rotary evaporator at 35 ºC, to obtain the acetone 
soluble extract (1.1 g) (AC extract) (Fig. 10B). Afterwards, the residue 
was immersed in 400 ml of ethanol at RT with magnetic stirring overnight. 
The supernatant was concentrated after filtration using a rotary evaporator 
at 35 ºC to obtaine the ethanol soluble extract (20.6 g) (EtOH extract). 
This  ethanol extract was immersed in 200 ml of acetone  solvent. After 
filtration, the supernatant was concentrated using a rotary evaporator at 
35 ºC to get the acetone soluble extract from ethanol (AC-EtOH extract) 
(14.6 g). All extracts were stored at 4 ºC till further analysis. The extraction 
process is showed in scheme 1.  
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A B C 
 
Figure 9. Process of fractionation of the lyophilized H. sabdariffa extract 
calyces. (A) Lyophilized H. sabdariffacalyces extract in the lyophilization machine. 
(B) the lyophilized H. sabdariffa calyces extract with the organic solvent on the 
magnetic stirring plate. (C) Filtration under vacuum to obtain a supernatant and a 
residue. 
 
A 
  
B 
 
C 
 
Figure 10. Concentration of the supernatant and a fraction obtaining.(A) 
Rotary evaporator machine to concentrate the supernatant obtained after filtration. 
(B) Acetone soluble fraction after concentration. (C) Silica gel column 
chromatography. 
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Scheme 1. Fractionation process of the aqueous extract of H. sabdariffa 
calyces using different organic solvent in order of increase the polarity. 
 
Statistical Analysis were carried out using the two-tailed Student's t-test or 
Anova test and displayed graphically using GraphPad Prism software. 
Graphs represent mean ± SD of three or two separated experiments. All 
experiments were repeated three times separately.
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Results 
1.  Antibacterial activity of aqueous extracts 
One of our objectives is to study the in vitro antibacterial activity of aqueous 
extracts of five medicinal plants C. zeylanicum, O. vulgare, R. officinalis, 
T. vulgaris and H. sabdariffa against Gram-negative bacteria 
Uropathogenic E. coli (UPEC), Enteropathogenic E. coli (EPEC 
E 2348/69),  E.  col i  ATCC 25922,  P. aeruginosa,  
K.  pneumoniae, S. Typhimurium, S. Enteritidis and Gram-positive 
bacteria S. aureus ,  Methici l l in Resistant S. aureus (MRSA), 
E. faecalis ,  L. monocytogens ATCC 7644 and L. monocytogenes isolated 
from meat, by broth micro dilution assay. This method allows the 
determination of the MICs and MBCs. This method involve the 
incorporation of known concentrations of antimicrobial agents into the broth 
media then checking for the presence or absence of organism growth, after 
a suitable incubation period, general ly 16-18 h (MIC). And f rom 
each tested micro wel l,  1.5 µL was inoculated onto MHA plates then 
checking the presence or absence of the organism growth after the suitable 
incubation period (16-18 h) (MBC). 
1.1 Antibacterial activity of Cinnamomum zeylanicum 
extract 
The antibacterial activity of aqueous lyophilized extract of C. zeylanicum 
was diluted in MHB media at concentrations of 5, 10, 20, 35, 70 mg/mL. To 
determine the MICs and MBCs, the broth micro dilution assay was used. 
The results showed an inhibition of bacterial growth for both Gram-positive 
and Gram-negative bacteria. The MIC for S. aureus, E. faecalis and 
L. monocytogenes was 5 mg/mL, while for S. aureus (MRSA) was 
10 mg/mL (Fig. 11B). Regarding Gram-negative bacteria, we found that the 
MIC for EPEC, E. coli, UPEC and K. pneumoniae was 20 mg/mL except 
S. ser. Typhimurium and S. ser. Enteritidis was 10 mg/mL (Fig. 11A) 
(Table 4). 
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Figure 11. Antibacterial activity of aqueous extract of C. zeylanicum against 
Gram-negative and Gram-positive bacteria using drop assay. MIC of aqueous 
extract of C. zeylanicum against (A) Gram-negative bacteria and (B) Gram-positive 
bacteria by measuring the absorbance at 600 nm of bacterial growth after 
incubation at 37 ºC for 16-18 h. Graphs represent mean ± SD. Statistical analysis 
using two way ANOVA from two independent experiments ***, p˂0.0001. 
 
The MBC from extract of C. zeylanicum for Gram-positive bacteria 
S. aureus, Methicillin Resistant S. aureus (MRSA), L. monocytogenes and 
L. monocytogenes ATCC 7644 was 5 mg/mL. Regarding Gram-negative 
bacteria, it was founded that the MBC for enteropathogenic E. coli, 
Uropathogenic E. coli, S. ser. Typhimurium and S.ser.Enteritidis was 
20 mg/mL, except for E.coli ATCC 25922 was 35 mg/mL and K. pneumoni  
ae was 70 mg/mL (Fig. 12)  (Table 4). 
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Figure 12. Antibacterial activity of aqueous extract of C. zeylanicum against 
Gram-negative and Gram-positive bacteria using drop assay. 
MBC of aqueous extract of C. zeylanicum against Gram-positive and Gram-
negative bacteria was assesed by inoculating 1.5 µL of each micro well into MHA 
medium. 
Abbreviations: C= control, MH= Mueller Hinton, I= Inoculum, Ext= Extract, numbers 
as 5=5 mg/mL of the extract. 
(*)Listeria monocytogenes was isolated from meat 
 
Table 4. Cinnamomum zeylanicum 
  MIC MBC 
Bacteria Extract (mg/mL) Extract (mg/mL) 
 5 10 20 35 70 5 10 20 35 70 
S. aureus - - - - - - - - - - 
S. aureus MRSA - - - - - - - - - - 
E. faecalis - - - - - + + - - - 
L. monocytogenes - - - - - - - - - - 
L. monocytogenes ATCC 
7644 - - - - - - - - - - 
EPEC + + - - - + + - - - 
E. coli ATCC 25922 + + - - - + + + - - 
UPEC + + - - - + + - - - 
K. pneumoniae + + - - - + + + + - 
S. ser.Typhimurium + - - - - + + - - - 
S. ser. Enteritidis + - - - - + + - - - 
(+) means that there is growth of bacteria              (-) means that there is no growth of bacteria 
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1.2 Antibacterial activity of Origanum vulgare extract 
The antibacterial activity of O. vulgare extract was assessed by using micro 
well dilution method (Fig. 8). The O. vulgare extract was diluted in MHB 
media at concentrations of 35, 70, 140 mg/mL. The results showed 
an inhibition for Gram-positive and Gram-negative bacteria. The MIC for 
Gram-positive bacteria S. aureus, Methicillin Resistant S. aureus (MRSA) 
was 35 mg/mL and for E. faecalis and L. monocytogenes was 35 mg/mL 
(Fig. 13B) (Table 5). The MIC for S. Typhimurium, S. Enteritidis was 
70 mg/mL, and for UPEC was 140 mg/mL (Fig. 13A) (Table 5).  
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Figure 13. Antibacterial activity of O vulgare extract against Gram-negative 
and Gram-positive bacteria using drop assay. MIC of aqueous extract of 
O. vulgare against (A) Gram-negative bacteria and (B) Gram-positive bacteria by 
measuring the absorbance at 600 nm of bacterial growth after incubation at 37 ºC 
for 16-18 h. Graphs represent mean ± SD. Statistical analysis using two way 
ANOVA from two independent experiments **, p˂0.007. 
RE
SU
LT
S 
  
111 
 
The MBC for Gram-positive bacteria S. aureus, Methicillin Resistant S. 
aureus (MRSA), and L. monocytogenes and L. monocytogenes ATCC 7644 
was 35 mg/mL but for E. faecalis was 70 mg/mL. The MBC for S. ser. 
Typhimurium and S. ser. Enteritidis was 70 mg/mL and UPEC, E. coli 
ATCC 25922, EPEC and K. pneumoniae was 140 mg/mL. The aqueous 
extract showed no bactericidal activity against P. aeruginosa up to 
140 mg/mL (Fig. 14) (Table 5). 
 
Figure 14. Antibacterial activity of O vulgare extract against Gram-negative 
and Gram-positive bacteria using drop assay. 
 MBC of aqueous extract of O. vulgare against Gram-positive and Gram-negative 
bacteria  was assesed by inoculating 1.5 µL of each micro well into MHA medium. 
Abbreviations: C= control, MH= Müeller Hinton, i= Inoculum, Ext= Extract, numbers 
as 5= 5 mg/mL of the extract. 
(*)Listeria monocytogenes was isolated from meat 
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Table 5. Origanum vulgare 
  MIC MBC 
Bacteria Extract (mg/mL) Extract (mg/mL) 
 35 70 140 35 70 140 
S. aureus _ _ _ _ _ _ 
S. aureus (MRSA) _ _ _ _ _ _ 
E. faecalis + _ _ + _ _ 
L. monocytogenes _ _ _ _ _ _ 
L. monocytogenes ATCC 
7644 _ _ _ 
_ _ _ 
EPEC + + + + + _ 
E. coli ATCC 29522 + + + + + _ 
UPEC + + _ + + _ 
K. pneumoniae + + + + + _ 
S. ser. Typhimurium + _ _ + _ _ 
S.ser.Enteritidis + _ _ + _ _ 
P. aeruginosa + + + + + + 
(+) means that there is growth of bacteria   (-) means that there is no growth of bacteria 
1.3 Antibacterial activity of Rosmarinus officinalis extract 
R. officinalis extract was diluted at concentartions 12, 25, 50, 70, 
140 mg/mL. The extract showed an inhibition for Gram-positive and Gram-
negative bacteria. The MIC for Gram-positive bacteria S. aureus, Methicillin 
Resistant S. aureus (MRSA) and L. monocytogenes was 12 mg/mL, and for 
E. faecalis was 25 mg/mL (Fig. 15B) (Table 6). Regarding Gram-negative 
bacteria, we found the MIC for UPEC, E. coli ATCC 25922, EPEC and 
S. ser. Typhimurium was 140 mg/mL (Fig. 15A) (Table 6). The R. officinalis 
extract showed MBC for Gram-positive bacteria S. aureus, Methicillin 
Resistant S. aureus MRSA, L. monocytogenes and L. monocytogenes 
ATCC 7644 at 12 mg/mL. The MBC for E. faecalis was 25 mg/mL. 
Regarding Gram-negative bacteria, we found the MBC for S. ser. 
Typhimurium, S. ser. Enteritidis and UPEC was 140 mg/mL and showed no 
bactericidal activity against E. coli ATCC 25922, EPEC, K. pneumoniae and 
P. aeruginosa up to 140 mg/mL (Fig. 16) (Table 6). 
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Figure 15. Antibacterial activity of aqueous extract of R. officinalis against 
Gram-negative and Gram-positive bacteria using drop assay. MIC of aqueous 
extract of R. officinalis against (A) Gram-negative bacteria and (B) Gram-positive 
bacteria by measuring the absorbance at 600 nm of bacterial growth after 
incubation at 37 ºC for 16-18 h. Graphs represent mean ± SD. Statistical analysis 
using two way ANOVA from two independent experiments ***, p˂0.0001. 
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Figure 16. Antibacterial activity of aqueous extract of R officinalis against 
Gram-negative and Gram-positive bacteria using drop assay.  
MBC of aqueous extract of R. officinalis against Gram-positive and Gram-negative 
bacteria by inoculating 1.5 µL of each micro well into MHA medium. 
Abbreviations: C= control, MH= Mueller Hinton, i= Inoculum, Ext= Extract, numbers 
as 12 = 12 mg/mL of the extract. 
(*)Listeria monocytogenes was isolated from meat 
 
Table 6. Rosmarinus officinalis  
  MIC MBC 
Bacteria Extract (mg/mL) Extract (mg/mL) 
 12 25 50 70 140 12 25 50 70 140 
S. aureus _ _ _ _ _ _ _ _ _ _ 
S. aureus (MRSA) _ _ _ _ _ _ _ _ _ _ 
E.  faecalis + _ _ _ _ + _ _ _ _ 
L. monocytogenes _ _ _ _ _ _ _ _ _ _ 
L. monocytogenes 
ATCC 7644 _ _ _ _ _ _ _ _ _ _ 
EPEC + + + + _ + + + + + 
E. coli ATCC 
25922 + + + + _ + + + + + 
UPEC + + + + _ + + + + _ 
K. pneumoniae + + + + + + + + + + 
S.ser. Typhimurium + + + + _ + + + + _ 
S. ser. Enteritidis + + + + _ + + + + _ 
P. aeruginosa + + + + + + + + + + 
(+) means that there is growth of bacteria   (-) means that there is no growth of bacteria 
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1.4 Antibacterial activity of Thymus vulgaris extract 
T. vulgaris extract was diluted at concentrations of 35, 70, 140 mg/mL. 
T. vulgaris extract inhibited the bacterial growth for Gram-positive and 
Gram-negative bacteria. The MIC for S. aureus, Methicillin Resistant 
S. aureus (MRSA), L. monocytogenes and E. faecalis was 35 mg/mL 
(Fig. 17B) (Table 7). The MIC for UPEC, E. coli ATCC 25922, EPEC, 
S. ser. Typhimurium, S. ser. Enteritidis and P. aeruginosa was 35 mg/mL 
(Fig. 17A) (Table 7).  
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Figure 17. Antibacterial activity of aqueous extract of T. vulgaris against 
Gram-negative and Gram-positive bacteria using drop assay. MIC of aqueous 
extract of T. vulgaris against (A) Gram-negative bacteria and (B) Gram-positive 
bacteria by measuring the aborbance at 600 nm of bacterial growth after incubation 
at 37 ºC for 16-18 h. Graphs represent mean ± SD. Statistical analysis using two 
way ANOVA from two independent experiments ***, p=0.0001 and **, p˂0.001. 
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The MBC for Gram-positive bacteria S. aureus, Methicillin Resistant 
S. aureus (MRSA), and L. monocytogenes and L. monocytogenes 
ATCC 7644 was 35 mg/mL but for E. faecalis was 70 mg/mL. The MBC for 
S. ser. Typhimurium and S. ser. Enteritidis was 70 mg/mL and UPEC, 
E. coli ATCC 25922, EPEC and K. pneumoniae was 140 mg/mL. The 
aqueous extract showed no bactericidal activity against P. aeruginosa up to 
140 mg/mL (Fig. 18) (Table 7). 
 
Figure 18. Antibacterial activity of aqueous extract of T. vulgaris against 
Gram-negative and Gram-positive bacteria using drop assay. MBC of aqueous 
extract of T. vulgaris against Gram-positive and Gram-negative bacteria by 
inoculating 1.5 µL of each micro well into MHA medium. 
Abbreviations: C= control, MH= Müeller-Hinton, i= Inoculum, Ext= Extract, numbers 
as 35= 35 mg/mL of the extract. 
(*)Listeria monocytogenes was isolated from meat 
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Table 7. Thymus vulgaris 
 MIC MBC 
Bacteria Extract (mg/mL) Extract (mg/mL) 
 35 70 140 35 70 140 
S. aureus _ _ _ + + _ 
S. aureus (MRSA) _ _ _ + + + 
E. faecalis _ _ _ + + + 
L. monocytogenes _ _ _ + + _ 
L. monocytogenes ATCC 
7644 _ _ _ + + _ 
EPEC _ _ _ + + + 
E. coli ATCC 29522 _ _ _ + + + 
UPEC _ _ _ + + + 
K. pneumoniae _ _ _ + + + 
S. ser. Typhimurium _ _ _ + + + 
S. ser. Enteritidis _ _ _ + + + 
P. aeruginosa _ _ _ + + + 
(+) means that there is growth of bacteria   (-) means that there is no growth of bacteria 
 
1.5 Antibacterial activity of Hibiscus sabdariffa extract 
The H. sabdariffa extract showed significant inhibitory activity against 
Gram-positive and Gram-negative bacteria. The H. sabdariffa extract was 
diluted at concentartions of 5, 10, 20, 35 mg/mL. H. sabdariffa extract 
inhibited the bacterial growth of Gram-positive and Gram-negative bacteria. 
The MIC for Gram-positive bacteria S. aureus was 5 mg/mL, but for 
Methicillin Resistant S. aureus (MRSA) , E. faecalis, L. monocytogens 
ATCC 7622 and L. monocytogenes was 10 mg/mL (Fig. 19B) (Table 8). 
The MIC for UPEC, EPEC, E.coli ATCC 25922, P. aeruginosa, 
K. pneumoniae, S. Typhimurium, S. Enteritidis was 10 mg/mL (Fig. 19A) 
(Table 8) .  
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Figure 19. Determination of antibacterial activity of H. sabdariffa extract 
using drop assay: MIC of the aqueous extract against (A) Gram-negative bacteria 
and (B) Gram-positive bacteria by measuring the absorbance at 600 nm of the 
bacterial growth after incubation at 37 ºC for 16-18 h. Graphs represent mean ± 
SD. Statistical analysis using two way ANOVA from two independent experiments 
***, p˂0.0005 and**, p˂0.002. 
 
The MBC for Gram-positive bacteria S. aureus, E. faecalis, 
L. monocytogens ATCC 7644 and L. monocytogenes was 10 mg/mL, but 
for S. aureus (MRSA) was 20 mg/mL. The MBC for Gram-negative bacteria 
UPEC, E.coli ATCC 25922 and P. aeruginosa was 10 mg/mL, but for 
EPEC, K. pneumoniae, S. Typhimurium, S. Enteritidis was 20 mg/mL (Fig. 
20C) (Table 8). 
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Figure 20. Determination of antibacterial activity of H. sabdariffa extract 
using drop assay: MBC of the aqueous plant extract on Gram-negative and 
Gram-positive bacteria by inoculating 1.5 µL of each micro well into Mueller-Hinton 
Agar (MHA) medium. 
Abbreviations: C= control, MH= Müeller-Hinton, I= Inoculum, Ext= Extract, numbers 
as 5= 5 mg/mL of the extract. 
(*)Listeria monocytogenes was isolated from meat 
 
Table 8. Hibiscus sabdariffa 
 MIC MBC 
Bacteria Extract (mg/mL) Extract (mg/mL) 
 5 10 20 35 5 10 20 35 
S.  aureus _ _ _ _ + _ _ _ 
S. aureus MRSA + _ _ _ + + _ _ 
E. faecalis + _ _ _ + _ _ _ 
L. monocytogenes + _ _ _ + _ _ _ 
L. monocytogenes ATCC 
7644 + _ _ _ + _ _ _ 
EPEC + _ _ _ + + _ _ 
E. coli ATCC 25922 + _ _ _ + _ _ _ 
UPEC + _ _ _ + _ _ _ 
K. pneumoniae + _ _ _ + + _ _ 
S. ser. Typhimurium + _ _ _ + + _ _ 
S. ser. Enteritidis + _ _ _ + + _ _ 
P. aeruginosa + _ _ _ + _ _ _ 
(+) means that there is growth of bacteria   (-) means that there is no growth of bacteria 
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To determine the accurate MIC of H. sabdariffa against Gram positive and 
Gra m-negative bacteria, microdilution assay was used with low 
concentrations of H. sabdariffa extract at 5, 5.5, 6, 6.5 and 7 mg/mL against 
EPEC, E. coli ATCC 25922 (Gram-negative), S. aureus and S. aureus 
MRSA (Gram-positive). It was observed that the MIC for S. aureus, 
S. aureus MRSA and E. coli ATCC 25922 is 6 mg/mL, while for EPEC is 
6.5 mg/mL (Fig. 21). 
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Figure 21. Determination of MIC of H. sabdariffa extract using drop assay.  
(A) MIC of H. sabdariffa against EPEC. (B) MIC of H. sabdariffa against two Gram-
negative and two Gram-positive bacteria. (C) MBC of H. sabdariffa against Gram-
negative and Gram-positive bacteria. Abbreviations: C= control, MH= Müeller 
Hinton, i= Inoculum, Ext= Extract, numbers as 5= 5 mg/mL of the extract. 
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The antibacterial activity of H. sabdariffa was determined dublicated in the 
same microwell plate using microdilution assay against EPEC, E. coli 
ATCC 25922 (Gram-negative), S. aureus and S. aureus MRSA (Gram-
positive). The used concentrations are 5, 7, 10, 20 and 25 mg/mL. It was 
observed that the MIC is 7 mg/mL for EPEC, E. coli ATCC 25922, 
S. aureus and S. aureus MRSA in the two panels. But for the MBCs in the 
two panels were different, in the upper panel, the MBCs for EPEC, E. coli 
ATCC 25955, S. aureus and S. aureus MRSA are 25, 20, 10 and 
20 mg/mL, respectively. In the lower panel, the MBCs for EPEC, E. coli 
ATCC 25922, S. aureus and S. aureus MRSA are 20, 20, 20 and 
10 mg/mL, respectively (Fig. 22). This difference might due to the number 
of bacteria that was seeded by drop assay (replicator instrument).  
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Figure 22. Determination of MIC and MBC of H. sabdariffa using drop assay. 
(A) MIC of H. sabdariffa against two Gram-negative and two Gram-positive 
bacteria. Graph represent mean ± SD. Statistical analysis using two way ANOVA 
from two independent experiments ***, p˂0.0001. (B) MBC of H. sabdariffa extract 
against two Gram-negative and two Gram positive bacteria dublicated. 
Abbreviations: C= control, MH= Müeller Hinton, i= Inoculum, Ext= Extract, numbers 
as 5= 5 mg/mL of the extract. 
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H. sabdariffa extract showed the best antibacterial activity. It presented the 
lowest MICs and MBCs of the screened medicinal plants in our study 
(Fig. 2 3 and 24) (Table. 9). In addition, it does not form precipitates and 
thus it does not interfere with the used methods. For those reasons it has 
been selected for further characterization studies. 
 
Table 9. MIC and MBC of plant extracts 
 
Bacteria 
C. zeylanicum O. vulgare R. officinalis T. vulgaris H. sabdariffa 
mg/mL mg/mL mg/mL mg/mL mg/mL 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
S. aureus 29213 ≤ 5 ≤ 5 ≤35 < 35 ≤ 12 ≤ 12 35 140 ≤ 5 10 
S. aureus MRSA ≤ 5 10 ≤ 35 < 35 ≤12 ≤12 35 >140 10 10 
E. faecalis ≤ 5 20 ≤ 70 70 25 25 35 >140 10 10 
L. monocytogenes ≤ 5 ≤ 5 <35 < 35 ≤ 12 ≤ 12 35 140 10 10 
L. monocytogenes 
ATCC 7644 
≤ 5 ≤5 <35 < 35 ≤ 12 ≤ 12 35 140 10 10 
EPEC 20 20 > 140 140 140 >140 35 >140 10 25 
E. coli ATCC 25922 20 35 >140 140 140 >140 35 >140 10 10 
UPEC 20 20 ≤140 140 140 140 35 >140 10 10 
K. pneumoniae 20 70 >140 140 >140 >140 35 >140 10 10 
S. ser. Typhimurium 10 20 70 70 140 140 35 >140 10 10 
S. ser. Enteritidis 10 20 70 70 140 140 35 >140 10 10 
P. aeruginosa 10 30 >140 >140 >140 >140 35 >140 10 10 
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Figure 23. MBC of plant extracts against G-positive and G-negative bacteria. 
(A) MBC of O. vulgare, R. officinalis and T. vulgaris extracts against all tested 
Gram-negative and Gram-positive bacteria. (B) MBC of H. sabdariffa, 
C. zeylanicum against all tested Gram-negative and Gram-positive bacteria. 
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Figure 24. MBC of plants extract against Gram-positive and Gram-negative 
bacteria. MBC of H. sabdariffa, C. zeylanicum, O. vulgare, R. officinalis and 
T. vulgaris extracts against S. aureus and E. coli.  H. sabdariffa showed the best 
antibacterial activity against both Gram-positive and Gram-negative bacteria. The 
sensitivity of Gram-positive bacteria to the natural extracts are higher than Gram-
negative bacteria. 
 
Table 9 and figures 23 and 24 showing that H. sabdariffa extract is the 
most potent antibacterial extract followed by C. zeylanicum extract, as they 
are effective against Gram-positive and Gram-negative. While the 
R. officinalis, O. vulgare and T. vulgaris extracts showed lower antibacterial 
activity than H. sabdariffa and C. zeylanicum against Gram-positive more 
than Gram-negative, which shows that Gram-positive bacteria are more 
sensitive to those natural extracts than Gram-negative bacteria.  
1.5.1 Antibacterial activity of Hibiscus sabdariffa against EPEC 
using disc diffusion assay 
The Kirby-Bauer agar diffusion test is the standardized method for 
determining antimicrobial susceptibility. The disc diffusion assay was used 
to assess the antibacterial activity of H. sabdariffa extract against EPEC 
(Fig. 25). Two paper discs (6 mm in diameter) (B and C) were impregnated 
with the H. sabdariffa extract (70 mg/disc) and one disc with 10 µg 
ampicillin commercially prepared. The impregnated discs were placed on 
an inoculated MHA plate. The H. sabdariffa extract showed zone of 
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inhibition represents 10.5 mm in MHA and compared with ampicillin 
antibiotic zone of inhibition which represents 11 mm. 
 
Figure 25. Antibacterial activity of the H. sabdariffa extract against EPEC 
growing on agar Müeller-Hinton by disc diffusion assay. (A) Ampicillin disc 
(10 µg/disc) showing zone of inhibition of EPEC bacterial growth (halo). 
(B-C) Aqueous extract discs (70 mg/disc) also showing zone of inhibition against 
EPEC bacterial growth (halo) after incubation at 37 ºC for 24 h. 
 
1.5.2 Antibacterial activity of Hibiscus sabdariffa extract against 
Burkholderia cenocepacia 
In addition the effect of H. sabdariffa extract was tested against 
B. cenocepacia. B. cenocepacia is a Gram-negative bacteria, which is 
an opportunistic pathogen and human infections are common in patients 
with cystic fibrosis and chronic granulomatous disease, and are often fatal. 
In cystic fibrosis, it can cause "cepacia syndrome" which is characterized 
by a rapidly progressive fever, uncontrolled broncho pneumonia, weight 
loss, and possibly death. The MIC and MBC of H. sabdariffa extract against 
B. cenocepacia represent 4 and 5 mg/mL, respectively (Fig. 26A and B).  
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Figure 26. Determination of antibacterial activity of the H. sabdariffa extract 
against B. cenocepacia using drop assay. (A) MIC of the aqueous extract is 
determined by measuring the absorbance at 600nm of the bacterial growth after 
incubation at 37 ºC for 24 h. Graphic represent results from two independent 
experiments that were analyzed by Student´s t-test **, P=0.005. (B) MBC of the 
aqueous extract is determined by inoculating 1.5 µL aliquots of each microwell on 
MHA plates,at 37 ºC for 24 h. 
 
1.5.3 MIC and MBC of Hibiscus sabdariffa extract against 
Enteropathogenic E. coli EPEC E 234/69 
Because of EPEC is the main cause of the infantile diarrhea in developing 
countries, which is responsible for the children death, we determined the 
MIC of H. sabdariffa extract on EPEC using lower concentrations of 5, 7, 
10, 20, 25 mg/mL of H. sabdariffa extract. The MIC against EPEC was 
7 mg/mL (Fig. 27A), and MBC against EPEC was 25 mg/mL 
(Fig. 27B and C). 
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Figure 27. Determination of minimal inhibitory concentration (MIC) and minimal 
bactericidal concentration (MBC) of H. sabdariffa extract on Enteropathogenic 
Escherichia coli (EPEC). (A) Graph showing the MIC of the aqueous plant extract 
on EPEC by measuring the absorbance of EPEC growth by using broth micro-well 
dilution assay. Graph represents results from two independent experiments that were 
analyzed by Student´s t-test**, P= 0. 001; ***, P= 0.0008 for 5 mg/mL and the rest of 
concentrations, respectively. (B) Drop (spot) assay showing the MBC by plating 1.5 
µL from each tested microwell of multiwell dilution plate onto MHA. (C) Macrodilution 
assay showing the MBC by adding the rest of microwell after drop assay to 5 ml of 
broth MH media and the growth of bacteria was checked after incubation for 16-18 h 
with agitation at 37 ºC.  
Abbreviations: C= control, MH= Müeller Hinton, i= Inoculum, Ext= Extract, numbers 
as 5= 5 mg/mL of the extract. 
 
1.5.3.1 Time-kill curves and time-kill kinetics  
Lethality-time or time-kill curves provide important information on the 
dynamics of the microbicidal action of an antimicrobial agent and on 
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relationship between the concentration of the antimicrobial agent and its 
microbicidal activity. These time-kill studies are important parameters for 
the assessment of the bactericidal compounds efficacy. 
Time kill curves were performed for EPEC using different concentrations of 
H. sabdariffa extract 10 mg/mL (1.4 x MIC) and 25 mg/mL (3.6 x MIC). The 
bactericidal activity is considered as the time needed to achieve a 3-log 
decrease in viability respect to the initial time of the used antibacterial 
concentration. This parameter is an acceptable index of bactericidal activity 
(Cantón and Pemán, 1999).  
The results obtained in figure 28 shows that the 3-log decrease in cell 
viability occurred at 10 h. This is the time at which the extract concentration 
25 mg/mL (MBC) is bactericidal. 
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Figure 28. Time Kill kinetics of EPEC using H. sabdariffa extract. Time-killing 
curves representing the growth of EPEC versus time in absence (●: control) or 
presence of H.sabdariffa extract (■: 10 mg/mL; ▲: 25 mg/mL) in Müeller Hinton 
liquid media. Graphic represent results from two independent experiments that 
were analysed by two way ANOVA **, P<0.0001.. 
 
According to the calculation from figure equation, K values are: 
K25=0.131h1, K10=0.018 h-1. For 25 mg/mL (MBC), the following parameters 
are derived from the killing equation: the mean times to achieve reductions 
in the proportions of viable cells of 50% (t50)=2.3h, 90% (t90)=7.6h, and 
99% (t99)=15.3 h, and the time to reach the bactericidal endpoint 99.9% 
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(t99.9)=23 h. For 10 mg/mL (MIC), the mean times to achieve reductions in 
the proportions of viable cells of 50% (t50)=16.5 h, 90% (t90)=55 h, and 
99% (t99)=110 h and the time to reach the bactericidal endpoint 99.9% 
(t99.9)=165 h. These results suggest that the H. sabdariffa extract at MIC 
(10 mg/mL) the endpoint of bactericidal activity would be reached in 6 9 
days. Whereas with the MBC (25 mg/mL) the endpoint is reached in 23 h. 
Nevertheless, it should be notice that we are working with a crude extract 
and not with a pure active principle. 
 
2. Activity of Hibiscus sabdariffa extract on Fungi 
 
In order to investigate the potential antifungal activity of the H. sabdariffa 
extract, two different fungi (yeasts) were used. The pathogenic yeast (fungi) 
Candida albicans and two strains of the non-pathogenic yeast 
Saccharomyces cerevisiae: S. cerevisiae YPH 499 and S. cerevisiae 
BY4741. The extract concentrations assayed were 5, 10, 20, 35, 70, 140 
and 250 mg/mL by microwell and drop assays, as described in Material and 
Methods. The MICs were determined by measuring the absorbance of 
fungal growth at 600 nm in YPD liquid media (Fig. 29A). 
The MBCs were determined by drop assay inoculating 1.5 µl aliquots of 
each microwell on YPD agar plates after incubation at 30 ºC for 24 h 
(Fig. 29B). We observed that the H. sabdariffa extract inhibits the growth of 
S. cerevisiae BY4741 at 10 mg/mL and C. albicans, S. cerevisiae YPH 499 
at 70 mg/mL (Fig. 29A). The H. sabdariffa extract does not have fungicidal 
activity on C. albicans and S. cerevisiae BY4741 even up to 250 mg/mL. 
However at 140 mg/mL the extract has fungicidal activity against 
S. cerevisiae YPH 499 (Fig. 29B), but this concentration is too high to be 
considered as useful (or no toxic). These results imply that H. sabdariffa 
extract can not be used for treatment of fungal infections. 
 
RE
SU
LT
S 
130 
 
A 
Ctr 5 10 20 35 70 140 250
0.0
0.2
0.4
0.6
0.8
1.0
* *
C. albicans
S. cerevisiae YPH499
S. cerevisiae BY4741
P= 0.009
 9xtract (mg/ml)
Ab
so
rb
an
ce
 (6
00
 n
m
)
 
B 
 
 
Figure 29. Effect of H. sabdariffa extract on Fungi. (A) Determination of the MIC 
of the H. sabdariffa extract against C. albicans, S. cerevisiae YPH499 and 
S. cerevisiae BY4741 using drop assay at 5, 10, 20, 35, 70, 140 and 250 mg/mL 
concentrations of the aqueous extract in Yeast Extract-Peptone-Dextrose (YPD) 
broth media at 30 ºC for 24 h. Graphs represent mean ± SD. Graph represent 
results from two independent experiments that were analyzed by two way 
ANOVA**, P= 0.009. (B) Determination of MBC and growth on YPD agar plates 
after incubation at 30 ºC for 24 h. 
2.1 Effect of H. sabdariffa on the morphology of Candida 
albicans 
Although it was not observed antifungal activity on the dimorphic yeast 
C. albicans, the potential effect on the morphology was investigated. 
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C. albicans undergoes the transition from blastospores which are round 
budding cells, to filamentous forms, which are elongated cells in response 
to high temperature (37 ºC) at neutral pH or in the presence of serum at 
30 ºC (Kadosh and Johnson, 2005). It was observed at acidic pH of 
H. sabdariffa extract filamentous forms of C. albicans at different 
concentrations of the extract. We observed that the H. sabdariffa extract 
(pH= 4 at 5 mg/mL, pH=2.5 at 10 mg/mL and pH=2 at 20, 35 and 
70 mg/mL) induces filamentous forms of C. albicans when they were 
incubated overnight in MHB medium at various concentrations, at 30 ºC 
(Fig. 30). The filamentous morphology was observed at 5, 10, 20, 
35 mg/mL, although the cultures presented mixed morphologies 
(Fig. 30B, C, D and E). However, we could not detect filaments at higher 
concentrations of 70 mg/mL (Fig. 30F). 
A B C 
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Figure 30. Effect of H. sabdariffa extract on C. albicans cells morphology. 
(A) C. albicans growth control without treatment of the aqueous extract. Treated 
C. albicans with the aqueous extract at (B) 5 mg/mL (C) 10 mg/mL (D) 20 mg/mL 
(E) 35 mg/mL (F) 70 mg/mL. All treated C. albicans transformed from blastospore 
to filament transition after incubation overnight (18 h) in Müeller-Hinton liquid 
medium at 30°C. Micrographs of phase contrast 400X. Scale bar is 10 µm. 
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2.2 Effect of H. sabdariffa on the morphology of 
Yarrowia lipolytica 
In order to clarify if the observed effect of the extract on C. albicans cell 
morphology was a common effect to other dimorphic yeast, the 
H. sabdariffa extract was assayed with the non pathogenic yeast Yarrowia 
lipolytica. 
In our study, we observed that in cultures of Y. lipolytica (4x105 CFU/mL) in 
YPD broth medium at 30 ºC, for 16-18h, the extract induces the mycelium 
form of Y. lipolytica in a dose response manner at concentration ranging 
from 5, 10, 20, 35 mg/mL (Fig. 31B, C, D and F). In this case, the culture 
cell morphology was more homogenous, and hypha were predominant. As 
previously observed with C. albicans, in Y. lipolytica the formation of 
mycelium was not produced at higher concentrations of 70 mg/mL of the 
aqueous extract (Fig. 31F). 
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Figure 31. Effect of H. sabdariffa extract on Y. lipolytica cells morphology. (A) 
Y. lipolytica in absence of the aqueous extract (growth control).Treated Y. lipolytica 
with the aqueous extract at (B) 5 mg/mL (C) 10mg/mL (D) 20mg/mL (E) 35mg/mL 
(F) 70mg/mL in YPD liquid medium al 30 oC, 18h. Micrographs of phase contrast 
400X. Scale bar represents 10 µm. 
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3. Microbial quality of the dried calyces of Hibiscus 
sabdariffa 
The most potent antibacterial extract assayed was the aqueous extract of 
H. sabdariffa, both against Gram-negative and Gram-positive bacteria, 
especially against enteric pathogens, as showed previously. For this 
reason, the H. sabdariffa extract was selected for further studies and 
potential use as natural product to prevent or treat infectious diarrhea. 
Nevertheless, it is necessary to analyze the microbial quality of the plant 
material used before its potential oral use and further microbiological, 
molecular and chemical characterizations. 
Medicinal herbs and plants can be considered either as pharmaceutical 
preparations or as food and beverages in terms of their microbial quality, 
in compliance with the European Pharmacopoeia (Ph. Eur.) and the Royal 
Spanish Pharmacopoeia (Ph.R.Sp.) on one hand; or in compliance with the 
Spanish Regulations on Food and Beverages (Codex Alimentarius) 
(Anderson and Calderón, 1999). 
In addition other microorganisms have been investigated because their 
clinical and public health importance, such as S. aureus, B. cereus and 
L. monocytogenes, using standard microbiological methods. The results 
(Table 10) show that the calyces of H. sabdariffa that are used in our study 
did not have Salmonella, E. coli, S. aureus, L. monocytogenes, neither 
B. cereus; but it have Enterobacteria (18 CFU/10 g), and fungi 
(5x102 CFU /g). Although the dry calyces of H. sabdariffa have some 
Enterobacteria, and fungi, this batch can be used for human consumption 
because it complies with the microbial criteria for this type of products 
according to the European and Spanish regulations. 
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Table 10. Microbial quality of H. sabdariffa calyces 
Total viable aerobic count 3x105 CFU/g  
Salmonella absence /25 g 
Enterobacteria 18 CFU/10 g 
E. coli absence / 10 g 
S. aureus MPN<3/g 
B. cereus <102 /g 
L. monocytogenes absence /10 g 
Fungi 5x102 /g 
 
4. Determination of total phenolic compounds 
content (TPC) 
Phenolic compounds are a class of plant secondary metabolites. They are 
characterized by presence of one or more of six carbon rings and two or 
more phenolic hydroxyl group. For example, caffeic acid is a common 
representative of simple phenolic compounds that is present in tarragon 
and thyme, and is active against bacteria, viruses and fungi (Cowan, 1999; 
Karou, 2005). Polyphenols have direct antioxidant activity through 
inactivating harmful free radical such as lipid peroxides and by chelation of 
divalent metal ions, and have antioxidant activity indirectly through the 
induction of endogenous protective enzymes. Polyphenols content of 
aqueous plant extracts has been related to antibacterial activity due to their 
cytotoxic action on microorganisms, which include enzyme inhibition by the 
oxidized compounds (Cowan, 1999; Stevenson, 2007). Furthermore, it is 
well known that the phenolic compounds contribute to quality and nutritional 
value of plants in terms of modifying color, taste, aroma and flavor. 
Therefore we determined the TPCs content as described in Material and 
Methods (Point 3) of different aqueous plant extracts Cinnamomun 
zeylanicum, Origanum vulgare, Rosmarinus officinalis, Thymus vulgaris 
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and Hibiscus sabdariffa. The results obtained (Table 11) show that 
O. vulgare and R. officinalis extracts contain higher polyphenol compounds 
content (28 and 27.12 mg/g, respectively) than the rest of extracts, while 
C. zeylanicum and T. vulgaris have lower phenolic compounds content (9.9 
and 8.9 mg/g, respectively) than the rest of extracts. H. sabdariffa contains 
12.7 mg/g which is considered a moderate content of total phenolic 
compounds. Sirag et al., (2014) determined the total phenolic compounds 
in ethanolic extract of H. sabdariffa. The phenolic content represents 
41.07 mg/g. Their study determined phenolic compounds content higher 
than our value may be due to the extracts are different as our extract is 
aqueous extract and his extract is ethanolic (Sirag, et al., 2014). 
Table 11. Total phenolic compounds content of the aqueous plant  
extracts 
Plant extracts 
Total phenolic compounds content 
(mg/g) 
(as mg gallic acid equivalents) 
O. vulgare 28 
R. officinalis 27.12 
H. sabdariffa 12.7 
C. zeylanicum 9.9 
T. vulgaris 8.9 
 
5. Cytotoxicity determination 
5.1 Cytotoxicity of Hibiscus sabdariffa extract on 
Macrophages 
In order to investigate the cytotoxicity effects of the H. sabdariffa extract, 
we measured cell viability as previously described (O'Brien, 2000), as 
mentioned in Materials and Methods. The J774 murine macrophage cell 
line was used to evaluate the cytotoxicity of the aqueous plant extracts by 
using the Rezasurin reduction test. It is considered that the cytotoxic 
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concentration is the one that reduces the cell viability of macrophages from 
100% to 80-75%. In consequence, the cytotoxicity effect on viability of 
macrophages was assessed by determining the concentration of 
H. sabdariffa extract that reduced cell viability to 80-75 % compared to the 
cell viability of control untreated cells. The results which are presented in 
figure 32, indicate that the H. sabdariffa extract has no toxic effects on J774 
murine macrophages cell line at 10, 50 and 100 µg/mL. Concentrations of 
the H. sabdariffa extract such as 1 mg/mL induce a pH change that was 
appreciable by the change in the color of culture medium. This change 
could contribute to macrophages death, and therefore we discard this 
concentration. All together these results indicate that the H. sabdariffa 
extract has not cytotoxic effects at concentrations of 10, 50 and 100 µg/mL.  
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Figure 32. Effect of H. sabdariffa on cell viability. The H. sabdariffa extract did 
not show a significant decrease in cell viability of the J774 cell line (murine 
macrophages) at 10, 50 and 100 µg/mL concentrations. White bar represents the 
log of absorbance of resazurine in the presence of macrophages without the 
extract (blank). The black, dark grey and light grey bars represent the absorbance 
of resazurine in the presence of macrophages plus the aqueous plant extract at 10, 
50 and 100 µg/mL, respectively. Results of three independent experiments 
analyzed by Student´s t-test 
 
5.2 Cytotoxicity of Hibiscus sabdariffa extract on 
HeLa cells 
Alteration of cell growth is another indicator of cytotoxicity. In other words, 
the capability of cells to divide is used as an index of toxicity. The 
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concentration of a given plant extract at which 50 percent of HeLa cells do 
not divide is called the median inhibitory dose (ID50) (Ekwall 1990). We 
measured the cytotoxicity effect of the H. sabdariffa extract on HeLa cells 
by using trypan blue exclusion assay. HeLa cells were plated at 150 000 
cells per well of 6-well plate. After 24 h, cells were treated with the 
H. sabdariffa extract at 5, 7 and 10 mg/mL concentrations for 24 h. Then, 
the cells were harvested by trypsinization and counted under a microscope 
by adding trypan blue dye, which only enters dead cells. We observed that 
the H. sabdariffa extract did not show a significant decrease of growth of 
HeLa cells at 5 and 7 mg/mL concentrations. However, it showed a 
significant cell growth inhibition at 10 mg/mL. At such concentration HeLa 
cell growth was inhibited by approximately 50 % (Fig. 33). 
 
5.3 Cytotoxicity of Cinnamomum zeylanicum on 
Macrophages 
Similarly, in order to investigate the cytotoxicity effects of the C. zeylanicum 
extract, we proceed as before (Point 12.1 of Material and Methods). The 
results which are presented in figure 34 showed that the cell viability of 
macrophages is decreased from 100 % to 82 % and to 81.5 % at 
concentrations of 50 and 100 µg/ml, respectively. These results indicate 
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Figure 33. Cytotoxicity effect of H. sabdariffa extract on cell growth. White bar 
represents the numbers of HeLa cells without treatment (control). The black, dark 
grey and light grey bars represent the numbers of HeLa cells in the presence of 
H. sabdariffa extract at 5, 7 and 10 mg/mL, respectively. Results of two 
independent experiments are shown. Analysis was done by Student´s t-test 
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that the C. zeylanicum extract is not toxic at 10, 50 and 100 µg/ml 
concentrations on J774 murine macrophages cell line, compared with the 
control, although it is close to the limit considered as cytotoxic, as 
previously mentioned.  
 
6 Effect on pedestal formation induced by EPEC 
6.1 Effects of the Hibiscus sabdariffa extract on 
pedestal formation induced by EPEC 
Since the H. sabdariffa extract shows antibacterial activity (Fig. 19 and 20) 
and does not have significant toxic effects on cells at concentrations up to 
100 µg/mL (Fig. 32), we aimed to investigate its effect on pedestal 
formation induced by enteropathogenic Escherichia coli (EPEC) in HeLa 
cells. To that purpose, HeLa cells were seeded at 150 000 cells/well in 6 
well plates and incubated for 24 h. Then, cells were infected at a MOI of 10 
with preactivated EPEC for 3 h. After removing the unattached bacteria by 
washing 3 times with D-PBS, the cells were treated with the H. sabdariffa 
extract for 1, 2 and 3 h. The number of pedestals of treated and untreated 
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Figure 34. Effect of C. zeylanicum extract on cell viability. The aqueous plant 
extract of C. zeylanicum does not affect the cell viability of J774 cell line murine 
macrophages at 50 and 100 µg/mL. White bar represents the log of absorbance of 
resazurine in presence of macrophages without the extract (blank). The black, dark 
grey and light grey bars represent the absorbance of resazurine in presence of 
macrophages plus the aqueous plant extract at 10, 50 and 100 µg/mL, 
respectively. Results of three independent experiments analyzed by Student´s t-
test. 
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cells were quantified in 40 HeLa cells stained with TRITC-phalloidin and 
DAPI, to label the actin pedestals and the bacteria respectively.  
The results obtained are shown in Fig. 35, where it can be observed that 
cells treated with the aqueous plant extract show a significant inhibition of 
pedestal formation while untreated cells show increase numbers of 
pedestals along time (Fig. 35 and 36).  
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Figure 35. Quantitation of the number of pedestals after treatments with 
H. sabdariffa extract. HeLa cells were infected with EPEC for 1, 2 and 3 h. After 
washing off the unattached bacteria the number of pedestals formed was counted 
in cells treated with 10 mg/mL of aqueous extract of H. sabdariffa (black bars) and 
non-treated (white bars) cells. Graph represent results from two independent 
experiments that were analyzed by 2 way ANOVA test *, P=0.014.  
These results indicate that the treatment with H. sabdariffa extract at 
10 mg/mL of EPEC infected HeLa cells decreases the numbers of 
pedestals in a time dependent manner. 
After demonstrating that the numbers of pedestals formed at 3 hours are 
decreased by treatments with the aqueous plant extract at 10 mg/mL 
concentration for 1, 2 and 3 h post-infection, we hypothesized that the 
aqueous plant extract could prevent pedestal formation. Two strategies 
were applied to test the hypothesis. Firstly, HeLa cells were treated with the 
aqueous plant extract for 3 h. After removing the aqueous plant extract, 
HeLa cells were washed 3 times before infection by EPEC for 3 additional 
hours (preinfection treatments, Fig. 37). Secondly, the aqueous plant 
extract and EPEC infection to HeLa cells were added simultaneously 
(simultaneous treatments, Fig. 38). In both strategies, we observed that the 
plant extract at 10 mg/mL concentration prevents pedestal formation. 
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Figure 36. Effect of the treatment with the aqueous extract of H. sabdariffa on 
pedestal formation by EPEC. Visualization of pedestals after treatments. HeLa 
cells were infected with EPEC at a MOI of 10 for 3 hours. After washing off the 
unattached bacteria, the cells were treated with the aqueous plant extract of 
H. sabdariffa at 10 mg/mL or left untreated as a control for the indicated times. 
Then pedestals were visualized by fluorescence staining with TRITC-phalloidin 
(red pictures) to stain actin and DAPI to stain bacteria (blue pictures), respectively. 
Pictures were taken on an epifluorescence microscope at 1000X magnification. 
Images were merged with the Adobe Photoshop software. Scale bar represents 10 
µm. 
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The first strategy is shown in Fig. 37 where it can be observed that 
pedestals are not formed by EPEC in HeLa cells, when the cells are 
previously treated with the aqueous extract at 10 mg/mL concentration, 
compared with untreated-infected cells for 3 h as a control of pedestal 
formation.  
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Figure 37. Effect of the treatment of the H. sabdariffa extract on pedestal 
formation by EPEC. HeLa cells were treated with the H. sabdariffa extract or left 
untreated, as a negative control, for 3 hours. After washing the cells, they were 
infected with EPEC at a MOI of 10 for 3 h. Then pedestals were visualized by 
fluorescence staining with TRITC-phalloidin (red pictures) to stain actin and DAPI 
to stain bacteria (blue pictures) respectively. Pictures were taken on an 
epifluorescence microscope at 1000X magnification. Images were merged with the 
Adobe Photoshop. Scale bar represents 10 µm. 
 
The second strategy is shown in Fig. 38 where it can be observed that 
pedestals are not formed by EPEC in HeLa cells, when the H. sabdariffa 
extract at 10 mg/ml concentration and the bacteria (EPEC) were added to 
HeLa cells simultaneously and allow to proceed for 3 h. Untreated-infected 
HeLa cells are shown as a control of pedestal formation. 
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Figure 38. Effect of the treatment with the H. sabdariffa extract on pedestal 
formation by EPEC. The aqueous plant extract and EPEC were added to HeLa 
cells simultaeneously and infections were allow to proceed for 3 h. As a control, 
HeLa cells were infected by EPEC for 3 h without pretreatment. EPEC was 
added at a MOI of 10. Pedestals were visualized by flourescence staining with 
TRITC-phalloidin (red pictures) to stain actin and DAPI to stain bacteria (blue 
pictures) respectively. Picture were taken on an epifluorescence microscope at 
1000X magnification. Images were merged with the Adobe Photoshop software. 
Scale bar represents 10 µm 
 
6.2 Effect of Cinnamomum zeylanicum extract on 
pedestals induced by EPEC 
After observing that the C. zeylanicum extract has antibacterial activity 
against Gram-negative and Gram-positive bacteria (Fig. 11 and 12), we 
decided to investigate its effect on pedestal formation induced by 
enteropathogenic Escherichia coli (EPEC) in HeLa cells. For that purpose, 
we proceed as before (Fig. 36). The results obtained are shown in Fig. 39, 
where it can be observed that cells treated with the aqueous plant extract of 
C. zeylanicum at 20 mg/mL show a significantly decreased number of 
pedestals compared to untreated cells (Fig. 39). 
These results indicate that treatments of EPEC infected HeLa cells with the 
C. zeylanicum extract at 20 mg/mL decrease the numbers of pedestals in a 
time dependent manner. 
 
10 µm 
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Figure 39. Effect of treatments with the C. zeylanicum extract on pedestal 
formation by EPEC. HeLa cells were infected with EPEC at a MOI of 10 for 3 
hours. After washing-off the unattached bacteria, the cells were treated with the 
aqueous plant extract of C. zeylanicum at 20 mg/mL or left the cells untreated as a 
control for the indicated times. Then pedestals were visualized by fluorescence 
staining with TRITC-phalloidin (red pictures) to stain actin and DAPI to stain 
bacteria (blue pictures) respectively. Pictures were taken on an epifluorescence 
microscope at 1000X magnification. Images were merged with the Adobe 
Photoshop software. Scale bar represents 10 µm.  
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7. Effect of Hibiscus sabdariffa extract on 
morphology of E. coli EPEC E 234/69 a 
While we were doing EPEC infection experiments of HeLa cells in the 
experiments where EPEC and the extract were added simultaneously, we 
observed the preparations under a fluorescence microscope and noticed 
a filamentous morphology of EPEC after they were exposed to the 
H. sabdariffa extract at 10 mg/mL for 3 h compared to control (Fig. 40A). 
A B C 
   
D 
 
Figure 40. Effect of the H. sabdariffa extract on the morphology of EPEC. 
Simple staining with crystal violet of (A) Untreated EPEC (Control). (B) EPEC 
treated with the aqueous extarct of H. Sabdariffa at 10 mg/mL for 3 h. (C) EPEC 
treated with ceftazidime antibiotic at 0.5 µg/mL for 3 h. (D) EPEC stained with DAPI 
after exposure to the aqueous plant extract of H. sabdariffa for 3 h. Micrographs of 
phase contrast and epifluorescence. Scale bar represents 10 μm. 
It was reported (Buijs, et al., 2007) that ceftazidime, a β-lactam antibiotic, 
induces a filamentous morphology of Gram-negative bacteria E. coli at 
sub-MIC or MIC concentrations. For this reason, using Gram´s and DAPI 
staining (Fig. 40D). We compared the effect of H. sabdariffa extract 
(10 mg/mL for 3 h) to the effect of ceftazidime (0.5 µg/mL for 3 h) on EPEC 
at 4 x 105 CFU/mL. Ceftazidime was used as a positive control of the 
induction of the filamentous morphology of EPEC (Fig. 40C). These results 
can be useful to investigate the mechanism of action of H. sabdariffa as 
an antibacterial agent. 
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8. Chemical fractionation of Hibiscus sabdariffa 
extract 
8.1 Yield of fractions of Hibiscus sabdariffa extract 
calyces 
10 g of H. sabdariffa is soaked overnight in 100 ml of mili Q water then is 
filtered, and subjected to lyophylisation. Thus from 100 mL of 10 % 
aqueous extract of H. sabdariffa calyces we obtained 5.4-5.6 g (55%). The 
yield of the other fractions was as follows: EtOAc fraction extract 
represented 0.42 %, the AC fractions extract represented 2.8 %, the EtOH 
represented 51.5 %, while the AC fraction from EtOH (initially originated 
from the EtOH extract) (AC-EtOH) extract represented 36.5 % (Scheme 1). 
8.1.1 Antibacterial activity of fraction extracts 
First, the different fractions were concentrated under vacuum using a rotary 
evaporator. The antibacterial activity was done using broth microdilution 
assay against two Gram-negative bacteria, EPEC and E. coli ATCC 25922. 
The growth of the bacteria in MHB media without extract was the bacterial 
growth control (Ctr) and the growth of bacteria in MHB media in presence 
of the extract was the experimental test (10 mg/mL) (Fig. 41). 
Each extract (EtOAc, AC, EtOH, EtOH insoluble extract, AC-EtOH, and the 
AC insoluble extract from EtOH extract) was used at a concentration of 
10 mg/mL against EPEC and E. coli ATCC 25922. We observed that the 
AC, EtOH and AC-EtOH extract showed an inhibitory (Fig. 41 B, C and H) 
and bactericidal (Fig. 41 E, F and K) concentrations against EPEC and 
E. coli ATCC 25922 at 10 mg/mL. While the EtOAc extract, EtOH insoluble 
extract and AC insoluble extract from EtOH extract showed no antibacterial 
activity (Fig. 41A, D, G, J, I and L). 
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Figure 41. Antibacterial activity of different organic solvent fractions 
obtained from the initial aqueous extract of H. sabdariffa calyces. Minimal 
inhibitory concentrations of (A) Ethyl acetate soluble fraction. (B) Acetone 
soluble fraction. (E) Ethanol soluble fraction. (F) Ethanol insoluble fraction. (I) 
Acetone soluble fraction from ethanol. (J) Acetone insoluble fraction from 
ethanol. Minmimal bactericidal concentrations of (C) Ethyl acetate soluble 
fraction. (D) Acetone soluble fraction. (G) Ethanol soluble fraction. (H) Ethanol 
insoluble fraction. (K) Acetone soluble fraction from ethanol. (L) Acetone 
insoluble fraction from ethanol against Gram-negative bacteria by seeding 1.5 µL 
of each micro well into Mueller-Hinton Agar (MHA) medium. 
Abbreviatons: MH= Mueller Hinton broth media, Ccontrol, i,inoculum, fra, 
Fraction, 10= 10 mg/mL 
 
8.2 MIC and MBC of the active fraction extracts 
We used the broth micro dilution assay to determine the MICs and MBCs of 
the AC and EtOH extracts at 2, 5, 8 and 10 mg/mL against two Gram-
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positive bacteria S. aureus and Methicillin Resistant S. aureus (MRSA) and 
two Gram-negative bacteria enteropathogenic E. coli E 2348/69 (EPEC) 
and E. coli ATCC 25922. 
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Figure 42. MIC and MBC of the active fractions by drop assay. MIC of (A) AC 
extract. (C) EtOH extract. (E) AC-EtOH extract. MBC of (B) AC extract. (D) EtOH 
extract. (F) AC-EtOH extract by seeding 1.5 µL of each micro well into MHA 
medium. 
Abbreviations: MH= Mueller Hinton broth media, C = control, i= inoculum, fra.= 
Fraction, numbers as 5= 5 mg/mL 
 
The MIC and MBC of AC-EtOH extract against EPEC were also determined 
using 5, 10, 20 and 25 mg/mL concentartions of the extract (Fig. 42). 
We observed that the AC extract showed a MIC for S. aureus and MRSA at 
2 mg/mL and against EPEC and E. coli ATCC 25922 at 5 mg/mL 
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(Fig. 42A), while the MBC against all of them was at 5 mg/mL except for 
EPEC that was 8 mg/mL (Fig. 42B) (Table 11).  
Table 11. MIC and MBC of the active fractions 
Bacteria 
AC extract EtOH extract AC-EtOH 
MIC MBC MIC MBC MIC MBC 
Concentrations (mg/mL) 
EPEC 5 8 5 8 5 10 
E. coli ATCC 25922 5 5 5 5   
S. aureus 2 5 5 5   
S. aureus (MRSA) 2 5 2 5   
 
EtOH fraction extract exhibited a MIC against MRSA at 2 mg/ml and for 
EPEC, E. coli ATCC 25922 and S. aureus at 5 mg/ml, while the MBC 
against all of them was at 5 mg/mL except for EPEC that was 8 mg/mL 
(Fig. 42C and D). The AC-EtOH extract showed a MIC against EPEC at 5 
mg/mL (Fig. 42E) and a MBC at 10 mg/mL (Fig. 42F) (Table 11). 
According to results presented in Figs. 41 and 42, we concluded that there 
are two active antibacterial extracts obtained from the initial aqueous 
extract of H. sabdariffa calyces: the AC extract and AC-EtOH extract. We 
decided to proceed to a further fractionation of them. 
9. Fractionation of acetone soluble extract (AC 
extract)  
1.1 grams of AC extract was fractionated using column chromatography 
(silica gel 60, 0.04-0.06 mm, 230-240 mesh), using as eluent a gradient 
mixture from dichloromethane (DCM)-methanol (MeOH) (20:1 v/v) to 
MeOH, increasing the polarity up to 100% of methanol. Silica gel weight 
was 156 g and a column with 4.7 cm of diameter and 30 cm of hight 
(Fig. 43A). As the solvent passed through the column and become in 
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contact with the sample (extract), it causes a separation of different 
compounds which were collected in galss tubes (Fig. 43A). The fractions 
collected were analyzed using Thing Layer Chromatography (TLC) 
(Fig. 43B and C). It was obtained six fractions (Table 12).  
Table 12. The gradient mixture of eluent solvent used in the 
fractionation of AC extract. 
Fraction Eluent DCM:MeOH (v:v) 
Tubes                
(15 mL / tube) Weight (mg) 
1 20 : 1 1-60 50 
2 15 : 1 61-120 108 
3 10 : 1 121-170 42 
4 5 : 1 171-207 100 
5 1 : 1 208-243 200 
6 MeOH 244-280 576 
 
A B C 
 
Figure 43. Fractionation of the acetone extract and subsequent analysis by 
TLC. (A) Collection of the fractions from silica gel column chromatography in tubes. 
(B) Spotting each tube on TLC. (C) TLC inside a special chamber with a specific 
mixture of eluent solvent to analyze the content of each tube. 
9.1 Antibacterial activity of the fractions obtained from 
the fractionation of AC extract 
We determined the minimal inhibitory and minimal bactericidal 
concentrations using the broth micro dilution assay (drop assay) of the six 
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acetone fractions at 5 and 10 mg/mL against two Gram-positive bacteria 
S. aureus and Methicillin Resistant S. aureus (MRSA) and two Gram-
negative bacteria enteropathogenic E. coli E 2348/69 (EPEC) and E. coli 
ATCC 25922. We observed that the MICs of fraction 1 is 10 mg/mL (Fig. 
44A) (Table 13), fraction 2, 3, 4 and 5 is 5 mg/mL and fraction 6 did not 
show an inhibition against any tested bacteria at the used concentrations 
(Fig 44C, 45A and C, 46A and C) (Table. 13). And the MBC of fractions 2, 3 
and 4 is 5 mg/mL. MBC of fraction 5 is 10 mg/mL for EPEC, 
E. coli ATCC 29522 and S. aureus (MRSA). Fractions 1 and 6 showed no 
bactericidal activity against tested bacteria at the used concentrations 
(Fig. 44B and 46D) (Table 13). We concluded that the highly active 
fractions of AC extract are fractions 2, 3 and 4. 
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Figure 44. Antibacterial activity of fractions obtained from acetone soluble 
extract fractionation using drop assay. MIC of (A) Fraction 1. (C) Fraction 2. MBC 
of (B) Fraction 1. (D) Fraction 2 by seeding 1.5 µl of each micro well into Mueller-
Hinton Agar (MHA) medium.  
Abbreviations: MH= Müeller Hinton broth media, C = control, i= inoculum, fra.= 
Fraction, numbers as 5= 5 mg/mL. 
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Figure 45. Antibacterial activity of fractions obtained from acetone soluble 
extract fractionation using drop assay. MIC of (A) Fraction 3. (C) Fraction 4. MBC 
of (B) Fraction 3. (D) Fraction 4 by seeding 1.5 µL of each micro well into Mueller-
Hinton Agar (MHA) medium. 
Abbreviations: MH= Müeller Hinton broth media, C = control, i= inoculum, fra.= 
Fraction, numbers as 5= 5 mg/mL. 
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Figure 46. Antibacterial activity of fractions obtained from acetone soluble 
extract fractionation using drop assay. MIC of (A) Fraction 5. (C) Fraction 6. 
MBC of (B) Fraction 5.(D) Fraction 6 by seeding 1.5 µL of each micro well into 
Mueller-Hinton Agar (MHA) medium. 
Abbreviations: MH= Müeller Hinton broth media, C = control, i= inoculum, fra.= 
Fraction, numbers as 5= 5 mg/mL. 
RE
SU
LT
S 
152 
 
 
 
 
Figure 47. Thin layer chromatography stained with phosphomolybdic acid 
showing the acetone soluble extract and the antibacterial active fractions 2, 3, 4 
and 5 obtained from acetone soluble extract using a gradient mixture of 
DCM:MeOH 20:1 and 15:1 as a mobile phase. 
 
10. Fractionation of AC-EtOH extract 
AC-EtOH extract (14 g) was fractionated by silica gel column 
chromatography. The eluent solvent was a gradient mixture of 
dichloromethane and methanol (DCM:MeOH, 10:1 to MeOH) increasing the 
polarity up to 100% of methanol. Silica gel weight was 445 g and was 
added to a column of 8 cm of diameter and 30 cm of hight. The fractions 
collected were analyzed on a TLC plate using the gradient mixture of 
DCM:MeOH (20:1 to MeOH) as the solvent system depends on the fraction 
polarity. 10 fractions were obtained (Table 14).  
Table 13. MIC and MBC of AC fractions. 
 
Bacteria 
Fraction 1 Fraction 2 Fraction 3 Fraction 4 Fraction 5 Fraction 6 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
Concentrations (mg/mL) 
EPEC 10 >10 5 5 5 5 5 5 5 10 >10 >10 
E. coli 
ATCC 25922 10 >10 5 5 5 5 5 5 5 10 >10 >10 
S. aureus 10 >10 5 5 5 5 5 5 5 >10 >10 >10 
S. aureus 
(MRSA) 10 >10 5 5 5 5 5 5 5 10 >10 >10 
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Table 14. The gradient mixture of eluent solvent used in the 
fractionation of acetone soluble extract from ethanol 
(AC-EtOH extract). 
Fraction Eluent  DCM:MeOH (v:v) 
Tubes                 
(15 mL / tube) Weight (mg) 
1 10 : 1 1-26 142 
2 10 : 1 27 – 29   47 
3 10 : 1 30 – 42      88.9 
4 10 : 1 43 – 50 186 
5 10 : 1 51 – 54 184 
6 5 : 1 55 – 64  888 
7 5 : 1 65 – 69     953.8 
8 2 : 1 70 – 87 3700 
9 1 : 1 88 – 100 1200 
10 MeOH 100 – 130 3600 
10.1 Antibacterial activity of fractions obtained from the 
fractionation of AC-EtOH extract. 
Using broth microdilution assay the antibacterial activity of 10 fractions 
obtained from AC-EtOH extract was evaluated against EPEC by using 5, 
10, 20, 25 mg/mL concentrations of each fraction. We observed that 
fractions 1, 7 and 10 have lower antibacterial activity than the rest of 
fractions.  
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Figure 48. Antibacterial activity of fractions obtained from the AC-EtOH extract. 
MIC of (A) Fraction 1. (C) Fraction 2. MBC of (B) Fraction 1. (D) Fraction 2 by 
seeding 1.5 µL of each sample from a micro well into MHA plates. 
Abbreviations: MH=Mueller Hinton, C = control, i= inoculum, fra.= Fraction 
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Fractions 1, 7 and 10 showed MIC at 10, 10 and 20 mg/mL, respectively 
(Fig. 48A, 51A and 52C). They showed MBC at 25, 10 and 20 mg/mL, 
respectively (Fig. 48B, 51B and 52D). While fractions 2, 3, 4, 5, 6, 8 and 9 
showed MIC at 5 mg/mL (Fig. 48C, 49A, 49C, 50A, 50C, 51C and 52A) and 
exhibited MBC at 10 mg/mL (Fig. 48D, 49B, 49D, 50B, 50D, 51D, and 52B) 
(Table 15). 
 
 
   
Table 15. MIC and MBC of AC from EtOH fractions 
Bacteria 
Fraction 1 Fraction 2 Fraction 3 Fraction 4 Fraction 5 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
Concentrations (mg/ml) 
EPEC 10 25 5 10 5 10 5 10 5 10 
Bacteria 
Fraction 6 Fraction 7 Fraction 8 Fraction 9 Fraction 10 
MIC MBC MIC MBC MIC MBC MIC MBC MIC 
MB
C 
Concentrations (mg/ml) 
EPEC 5 10 10 10 5 10 5 10 20 20 
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Figure 49. Antibacterial activity of fractions obtained from the AC-EtOH extract. 
MIC of (A) Fraction 3. (C) Fraction 4. MBC of (B) Fraction 3. (D) Fraction 4by 
seeding 1.5 µL of each micro well into MHA medium. 
Abbreviations: MH= Mueller Hinton broth media, C = control, i= inoculum, fra.= 
Fraction, numbers as 5= 5 mg/mL. 
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Figure 50. Antibacterial activity of fractions obtained from the AC-EtOH extract. 
MIC of (A) Fraction 5. (C) Fraction 6. MBC of (B) Fraction 5. (D) Fraction 6 by 
seeding 1.5 µL of each micro well into MHA medium. 
Abbreviations: MH= Mueller Hinton broth media, C = control, i= inoculum, fra.= 
Fraction, numbers as 5= 5 mg/mL. 
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Figure 51. Antibacterial activity of fractions obtained from the AC-EtOH 
extract. MIC of (A) Fraction 7. (C) Fraction 8. MBC of (B) Fraction 7. (D) Fraction 
8 by seeding 1.5 µL of each micro well into MHA medium. 
Abbreviations: MH= Mueller Hinton broth media, C = control, i= inoculum, fra.= 
Fraction, numbers as 5= 5 mg/mL. 
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Figure 52. Antibacterial activity of fractions obtained from the AC-EtOH 
extract. MIC of (A) Fraction 9. (C) Fraction10. MBC of (B) Fraction 9. (D) Fraction 
10 by seeding 1.5 µL of each micro well into MHA medium. 
Abbreviations: MH= Mueller Hinton broth media, C = control, i= inoculum, fra.= 
Fraction, numbers as 5= 5 mg/mL. 
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Discussion 
1. Antibacterial activity of aqueous plants extract
The interest in plants with antimicrobial properties has increased because 
of the current problems associated with the antibiotics and the appearance 
of bacterial resistance. There are needs for sustained efforts from 
government and pharmaceutical companies to develop new antimicrobial 
drugs to overcome bacterial resistance that cannot be faced by stewardship 
alone. The antibiotic resistance problem has been estimated to cost United 
States hospitals more than $ 20 billion annually and get patient to remain 
longer time in hospitals. Moreover, it was estimated that 2 million patients in 
the European Union get hospital acquired infections annually; leading to 
175 000 patient death (Cooper and Shlaes, 2011). The antibiotic resistance 
is a global health problem that requires global action. There are many plant 
extracts with antimicrobial activity which have been recently reported 
(Rodríguez-Rodríguez, et al., 2012; Karuppiah and Rajaram, 2012; Hindi, 
2013;  Hleba, et al., 2013). Consequently we analysed the antibacterial 
activity of five selected plants. In the present study, aqueous extract of 
H. sabdariffa, C. zeylanicum, R. officinalis, O. vulgare, T. vulgaris were 
studied. We analysed their antibacterial activity against 12 pathogenic 
bacteria. Gram-negative bacteria: E. coli ATCC 25922, Enteropathogenic 
E. coli (EPEC E 2348/69), Uropathogenic E. coli (UPEC), P. aeruginosa, 
K. pneumoniae, S. ser. Typhimurium, S. ser. Enteritidis and against Gram-
positive bacteria: S. aureus, Methicillin Resistant S. aureus (MRSA), 
E. faecalis, L. monocytogens ATCC 7622 and L. monocytogenes (strain 
isolated from meat). 
There are different bioassays that can be used to evaluate the antibacterial 
activity of different plants extracts. In our study, we used both disc diffusion 
test and microwell dilution assay. Disc diffusion test is not appropriate for 
non-polar samples, because they do not diffuse well through the agar. This 
method does not distinguish between bacteriostatic and bactericidal effects. 
Microwell dilution assay (Fig. 8) was used to evaluate the MIC of the 
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selected plants aqueous extracts. In order to determine the MBC, is 
necessary to verify if there is cell growth after removing the antimicrobial 
agent. In general, in the scientific literature the drop assay is the most used 
method; but this method alone has some limitations in terms of sensitivity. 
In our working group (Dpt. of Microbiology II, UCM) we have obtained lower 
MBC values when using drop assay alone than the ones obtained with 
another complementary method such as macrodilution. This 
methodological strategy was set-up earlier by B. Conde (Dpt. Microbiology 
II, UCM) working with natural compounds (Conde et al., 2013; Mohamed, 
Conde et al., 2013). 
For this reason, the MBC of H. sabdariffa extract against EPEC, was 
determined by both drop and macrodilution assays. For drop assays 1.5 µL 
aliquots from each microwell were inoculated on MHA plates. For 
macrodilution assay (Fig. 8), the remaining volume from each microwell 
was diluted in 5 mL of liquid media, incubated at 37 ºC with agitation and 
checking the bacterial growth by turbidity.  
1.1 Antibacterial activity of aqueous plants extract by 
agar diffusion assay 
Agar diffusion assay was used to evaluate the antibacterial activity of the 
aqueous extracts of the five selected plants. The aqueous extract of 
H. sabdariffa was the only aqueous extract that showed a zone of inhibition 
(halo) of 10.5 mm in Müeller-Hinton agar (MHA) inoculated with EPEC. The 
ampicillin control halo was 11 mm (Fig. 18). This result suggests that 
H. sabdariffa extract could have a potential inhibitory effect over EPEC that 
we further investigate. 
The agar diffusion assay was done with all the selected aqueous plants 
extract. The MHA was prepared with and without addition of Tween 80 
(0.5%) to facilitate the diffusion of the aqueous extracts through the agar. 
Furthermore, we used Hexane organic solvent to dissolve the lyophilized 
aqueous extract (after lyophilization) of the plants for the purpose of 
facilitating the diffusion process through the agar.  
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We observed that any of the aqueous extracts of C. zeylanicum, 
O. vulgare, R. officinalis and T. vulgaris, or lyophilized aqueous extracts 
dissolved in Hexane solvent induce zone of inhibition through MHA (data 
not shown). These results indicate that the H. sabdariffa extract is very 
polar, whereas it diffused into the Mueller Hinton agar easily; on the 
contrary, the lyophilized H. sabdariffa extract did not dissolve in hexane 
organic solvent. The others aqueous plants extract did not show zone of 
inhibition (halo), probably because they contain less polar compounds than 
H. sabdariffa and agar diffusion assay is not appropriate for non-polar 
samples. 
1.2 Antibacterial activity of aqueous plants extract by 
drop assay (Broth micro dilution assay) 
1.2.1 Hibiscus sabdariffa extract 
H. sabdariffa extract displayed the best antibacterial activity: all tested 
Gram-positive and Gram-negative bacteria were inhibited (MIC) at 
concentrations ranging between 5 and 10 mg/mL of the aqueous extract, 
and were killed (MBC) at concentrations ranging between 10 and 20 mg/mL 
of the aqueous extract (Fig. 19 and 20) (Table 8).  
Fullerton et al (2011) checked the antimicrobial activity of phenolic extract 
of H. sabdariffa calyces using disc diffusion method against Escherichia coli 
O157:H7 isolated from food, veterinary and clinical samples. The results of 
that study showed that sorrel was more effective at 10%, while at 5%, and 
2.5% showed lower activity, it induced a bacterial growth inhibition zones of 
12.66 mm, 10.75 mm and 8.9 mm, respectively. These results indicated 
that sorrel is effective at the different concentrations that were charged on 
the paper disc (Fullerton, Khatiwada et al. 2011). 
In addition, Elsayed and Elshafei (2011) evaluated the antimicrobial activity 
of aqueous extract of H. sabdariffa under different extraction conditions 
(cold, hot and autoclaved) using agar well diffusion method and different 
types of media against Bacillus mycoides, Escherichia coli and Candida 
albicans (Elshafei 2011). The results of this study revealed that the 
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H. sabdariffa extract has antimicrobial activity against the tested 
microorganisms with variable degrees depending on the extraction 
conditions, assay medium and the test strain under study. In addition, this 
study reveals that H. sabdariffa extracts contain stable and heat resistant 
components. 
Both of the previous studies determined the inhibitory effect of the extract 
against the tested microorganisms using agar diffusion method. They did 
not evaluate the bactericidal or fungicidal effect of the plant extracts. Our 
study is more comprehensive because we evaluated the inhibitory effect, 
the bactericidal and fungicidal effects against tested microorganisms. 
These two  studies are consistent with our study suggesting the possible 
use of the H. sabdariffa extract as antimicrobial agent.  
Other study by Ali et al (2011) evaluated different activities of the ethanolic 
extract of H. sabdariffa at 250 and 500 mg/kg body weight in young Swiss-
albino mice, including anti-inflammatory activity using xylene-induced ear 
oedema and antidiarrheal activity induced by castor oil ingestion. They 
suggested using calyces of H. sabdariffa in traditional medicine as 
anti-inflammatory and antidiarrheal agents (Ali, Ashraf et al. 2011). 
Although this study analyzed the antidiarrheal activity of the ethanolic 
extract it did not analyze the effect of the ethanolic extract of H. sabdariffa 
against microorganisms directly, as we have done. 
Taken together our results until this point, we think that is reasonable to 
conclude that the aqueous extract of H. sabdariffa can be potentially used 
as an antibacterial agent, and it will be a promise for treatment of 
gastroenteritis. 
Afterward, it was interesting to evaluate the antibacterial activity of 
H. sabdariffa against Burkholderia cenocepacia, Gram-negative bacteria 
that are important human pathogen. It is currently considered as one of the 
main causes of infections of hospitalized patients, especially for sickle cell 
disease patients, oncology and burn patients and chronic lung disease 
patients, particularly those suffering from cystic fibrosis that have 
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a weakened immune systems. B. cenocepacia are often resistant to most 
common antibiotics (Torbeck,  et al. 2011). We observed that the 
H. sabdariffa extract significantly inhibited the growth of B. cenocepacia 
with a MIC of 4 mg/mL and killed it with a MBC of 5 mg/ml (Fig. 26). These 
results indicated that the H. sabdariffa extract possess a potent 
antibacterial activity against B. cenocepacia and shows promise for his use 
for treatment of hospitalized patient infections produced by B. cenocepacia. 
1.2.2 Cinnamomum zeylanicum extract 
C. zeylanicum extract exhibited an antibacterial activity lower than the 
antibacterial activity that was showed by H. sabdariffa against the tested 
Gram-positive and Gram-negative. C. zeylanicum aquous extract showed  
MIC ranging between 5 - 20 mg/mL, and showed MBC at 5 - 70 mg/mL 
(Fig. 11 and 12) (Table 4). Maidment et al. 2006 using disc diffusion assay 
showed the antimicrobial activity of aqueous, alcoholic extracts and 
essential oil of C. zeylanicum against Escherichia coli B and 
Staphylococcus aureus and  the yeast Saccharomyces cerevisiae. They 
found that alcoholic extract had greater activity than aqueous extract and 
essential oil had greater activity than both aqueous and alcoholic extracts. 
These results are consistent with our study, as the C. zeylanicum extract 
showed antimicrobial activity (Maidment, 2006). 
Bayoub, et al., verified the antibacterial activity of ethanol extract of 13 
medicinal plants. C. zeylanicum, T. vulgaris and R. officinalis were among 
these 13 plants. The MIC of the ethanol extract was determined against 
L. monocytogenes using microdilution method. The MICs of C. zeylanicum, 
T. vulgaris and R. officinalis extracts were 0.4, 1.56 and 5.25 mg/mL, 
respectively. Furthermore, they used agar well diffusion method inoculating 
L. monocytogenes ATCC 19117, S. aureus ATCC 25923, E. coli ATCC 
25922, E. faecalis, K. pneumoniae, E. cloacae, and A. baumannii strains. 
The diameter of inhibition zone of the ethanol extracts tested against 
L. monocytogenes. The ethanol extract of C. zeylanicum, T. vulgaris and 
R. officinalis showed 22, 19 and 16 mm of inhibition zone. No inhibition 
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zone was detected of T. vulgaris and R. officinalis extract against 
K. pneumoniae. C. zeylanicum and R. officinalis showed no inhibition zone 
against E. faecalis (Bayoub et al., 2010).These results consistent with our 
results as C. zeylanicum water extract showed better activity than both 
water extract of R. officinalis and T. vulgaris. The antibacterial activity of 
C. zeylanicum extract probably can be attributed to its essential oil 
content (Baratta et al., 1998; Senhaji et al., 2007; Rana et al.,2011). 
Generally essential oils antibacterial activity is complex, but Ranasinghe et 
al. (2013) reported that the antibacterial activity of essential oils arise from 
their hydrophobic nature that lead to disruption of bacterial cell wall and 
consequently leakage of bacterial components (Ranasinghe, et al., 2013). 
1.2.3 Origanum vulgare extract 
O. vulgare extract presented moderate antibacterial activity against the 
Gram-positive and Gram-negative bacteria tested, as it exhibited MIC 
ranging between 35 - 140 mg/mL and MBC between 35 – 140 mg/mL 
(Fig. 13 and 14) (Table 5). We observed that the MIC for Gram-positive 
bacteria S.aureus, Methicillin Resistant S. aureus (MRSA) was 35 mg/mL 
and for E. faecalis and L. monocytogenes was 70 mg/mL (Fig. 13B). 
Regarding Gram-negative bacteria, we found the MIC for S. Typhimurium, 
S. Enteritidis was 70 mg/mL, and for UPEC was 140 mg/mL (Fig. 13A) 
(Table 5). The aqueous extract of O. vulgare showed minimal bactericidal 
concentration (MBC) for Gram-positive bacteria S. aureus, Methicillin 
Resistant S. aureus (MRSA), and L.monocytogenes and L. monocytogenes 
ATCC 7644 was 35 mg/mL but for E. faecalis was 70 mg/mL. Regarding 
Gram-negative bacteria The MBC for S. Typhimurium and S. Enteritidis 
was 70 mg/mL and UPEC, E. coli ATCC 25922, EPEC and K. pneumoniae 
was 140 mg/mL, but it did not show bactericidal activity against P. 
aeruginosa at the used concentrations (Fig. 14) (Table 5). 
Ashraf et al (2011) evaluated the antibacterial activity of chlorophorm, 
methanol and aqueous extract of O. vulgare by agar well diffusion assay. 
The study reported that the chlorophorm and methanol extracts has better 
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antibacterial and antifungal activity than aqueous extract (Ashraf 2011). 
This study is consistent with our study as both studies showed that the 
aqueous extract did not inhibit P. aeruginosa. And their study showed that 
the aqueous extract did not inhibite S. typhi, E. coli ATCC 25922 and 
S. aureus, while our aqueous extract inhibits those bacteria probably 
because of higher concentrations used in our study. They used various 
concentrations of the dried plant extracts including 1000 µg/mL, 500 µg/mL, 
250 µg/mL, 125 µg/mL and 62.5 µg/mL. Although the chlorophorm and 
methanol extracts of O. vulgare in Ashraf study showed better antibacterial 
activity than the aqueous extract of O. vulgare, we used the aqueous 
extract to compare its antibacterial activity with the aqueous extract of the 
other selected plants in our study. 
Abdul sattar et al. (2012) studied the antimicrobial activity of water extract 
of T. vulgaris, O. vulgare and R. officinalis at 100, 200, 300, and 400 
mg/mL concentrations using agar well diffusion method. The antimicrobial 
activity was evaluated against Streptococcus mutans, Lactobacillus 
acidophilus bacteria that cause dental caries and Candida albicans (Abdul 
sattar 2012). They reported that the water extract of these plants possess 
antimicrobial activity: the best one is T. vulgaris followed by O. vulgare and 
then R. officinalis. This study is consistent with our results in that the 
aqueous extracts of the three selected plants possess antibacterial activity. 
Although in our study O. vulgare had the greatest antibacterial activity 
compared to R. officinalis and T. vulgaris. However we should keep in mind 
that the microorganisms analysed in both studies were different. 
1.2.4 Rosmarinus officinalis extract 
R. officinalis extract render a lower antibacterial activity than O. vulgare 
against both the Gram-positive and Gram-negative bacteria tested. It 
displayed MIC ranged between 12 and 140 mg/mL, and MBC ranged 
between 12 and 140 mg/mL, but it did not show bactericidal activity against 
E. coli ATCC 25922, EPEC, K. pneumoniae and P. aeruginosa (Fig. 15 and 
16) (Table 6). 
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Several researchers have reported the antimicrobial activity of 
R. officinalis essential oil (Bozin 2007; Okoh et al. 2010; Zaouali et al. 
2010). Thus Moreno et al. (2006) reported that the antibacterial activity of 
R. officinalis is due to their polyphenol content, more specifically to 
carnosic acid C20H28O4 and rosmarinic acid C18H18O18 (Moreno, 2006). 
Abu-Shanab, 2004 investigated the antibacterial activity of hot water, 
methanol and ethanol extracts of five plants. The dried extracts of 
Syzygium aromaticum, Cinnamomum cassia, Salvia officinalis, Thymus 
vulgaris and Rosmarinus officinalis against S. aureus, Bacillus subtilis 
ATCC 6633 multi-drug resistant P. aeruginosa and enterohemorrhagic 
E. coli O157 EHEC. Agar diffusion method and microdilution method were 
used. The concentrations used for agar diffusion method was 100 mg/mL 
and for micro dilution method were from 0.781 to 6.25 mg/mL to determine 
the MIC of each plant extract. They observed that the water extract of all 
plants screened by disc diffusion method showed an inhibitory effect 
ranges between 10-13 mm against S. aureus MRSA and B. subtilis but no 
effect was detected against P. aeruginosa and E. coli (EHEC). Furthermore 
this water extracts did not inhibite any of the tested microorganisms at the 
concentrations used by micro dilution method. Ethanol extract of 
R. officinalis inhibited the growth of S. aureus MRSA and B. subtilis at 1.5 
and 3.125 mg/mL, respectively, and T. vulgaris inhibited them at 3.125 and 
6.25 mg/mL, respectively. No inhibition effect detected for the tested Gram-
negative. This study is consistent with our study, as their results indicated 
that the Gram-positive bacteria are more sensitive to the crude extracts of 
all the species studied than Gram-negative bacteria (Abu-Shanab, 2004). 
1.2.5 Thymus vulgaris extract 
T. vulgaris extract reported the lowest antibacterial activity of the selected 
plants. It showed MIC at 35 mg/mL for the Gram-positive and Gram-
negative bacteria tested (Fig. 17A and B), and MBC for three Gram-positive 
bacteria S. aureus, L. monocytogenes and L. monocytogenes ATCC 7622 
at 140 mg/mL. The aqueous extract of T. vulgaris showed no bactericidal 
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activity against all tested Gram-negative bacteria, UPEC, E. coli ATCC 
25922, EPEC, K. pneumoniae, P. aeruginosa, S. Typhymurium, 
S. Enteritidis, and two Gram-positive bacteria Methicillin Resistant 
S. aureus (MRSA) and E. faecalis (Fig.18) (Table 7). The bacteria were 
inhibited completely at 35 mg/mL, and at higher concentration of 70 mg/mL 
it seems that they grow and no inhibition which is not logic. We interpret 
that it is due to the precipitate was formed of the extract in each well 
contain it and interfere with OD reading. 
Kon and Rai (2012) demonstrated the antibacterial activity of essential oil of 
T. vulgaris using disc diffusion method against S. aureus and E. coli. 
S. aureus showed higher susceptibility to essential oil than E. coli (Kon, 
2012). These results are consistent with our results in the inhibition of both 
S. aureus and E. coli growth. However we did not find bactericidal activity 
against E. coli.  
Nzeako et al. (2006) evaluated the water extract of T. vulgaris using well 
agar diffusion technique against S. aureus, P. aeruginosa, E. coli, 
S. pyogenes, Corynebacterium species, Salmonella species, Bacteroides 
fragilis and Candida albicans. This study showed that the aqueous extract 
of T. vulgaris possess antibacterial activity only against S. aureus at 25% 
v/v (Nzeako 2006). They evaluated the essential oil of thyme against the 
previous microorganisms. The essential oil of T. vulgaris showed inhibition 
against all tested microoorganisms S. aureus, P. aeruginosa, E. coli, 
S. pyogenes, Corynebacterium species, Salmonella species, Bacteroides 
fragilis and Candida albicans at 0.39, 1.56, 0.78, 0.78, 0.39, 0.39, 1.56, and 
0.10 % v/v. These results are consistent with our results, as the aqueous 
extract showed no bactericidal activity for E. coli and S. species. But our 
study showed an inhibition for all tested microorganisms. This inhibition 
results is conflicting with Nzeako et al. (2006) results might be due to the 
method used for evaluation of the antibacterial activity. In their study was 
used only agar diffusion assay while in our study we used both agar 
diffusion and drop assays.  
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Based on the previous results, we concluded that the Gram-positive 
bacteria are more sensitive to plants extract than Gram-negative bacteria 
(Fig. 23 and 24). Consistent with our study, Mohamed Bokaeian et al, 
(2014) showed that Gram-positive S. aureus is more sensitive to 
H. sabdariffa extract than Gram-negative E. coli, as the highest MIC was 
20 mg/mL against two E. coli and the least MIC was 1.25 mg/mL against 
three S. aureus (Bokaeian, 2014). Furthermore,  Shan et al. (2007) study 
showed that Gram-positive bacteria (S. aureus, L. monocytogenes and 
B. cereus) were generally more sensitive to 46 extracts from dietary spices 
and medicinal herbs than Gram-negative bacteria (E. coli and S. anatum) 
(Shan, 2007).  
In general, comparing our results with the ones in the literature was quite 
difficult due to the heterogeneity of some factors that affect the 
experimental conditions such as the used CFU/mL, method used for 
extraction of the plant extract, the solvent used in the extraction method, 
the used extract is lyophilized (in case of aqueous extracts) or not, and the 
assay used for MIC and MBC determination. Additionally, the same plant 
from different countries shows different results due to the difference 
between the environmental conditions that lead to the difference in the 
active constituent’s content. 
2. Total phenolic compounds content of the plant 
aqueous extracts 
Generally, the antibacterial activity of plants extract is attributed to the 
presence of several secondary metabolites such as alkaloids, flavonoids, 
phenols and polyphenols, flavones, flavonols, terpenoids (Cowan, 1999) 
that can act individually or synergistically. 
Subsequently to the evaluation of the antibacterial activity of the selected 
aqueous plants extract, it was interesting to determine the polyphenol 
content of the selected plants as a parameter of plants quality and because 
it is documented that polyphenols have antibacterial activity (Cowan, 1999; 
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Karou, 2005). Therefore, we hypothesized that both parameters, 
polyphenol content and antibacterial activity could correlate. 
Total polyphenol content was determined using Folin-Ciocaltaeu method 
(Sharma, et al. 2011). As shown in table 11, O. vulgare and R. officinalis 
possessed the highest crude extract content of phenolic compounds with 
values of 28 and 27.12 mg/g, respectively. H. sabdariffa is considered to 
have a moderate crude extract content of polyphenols with a value of 
12.7 mg/g. While T. vulgaris presented the lowest crude extract content of 
polyphenols with a value of 8.9 mg/g. C. zeylanicum polyphenol content is 
slightly higher than that of T. vulgaris with a value of 9.9 mg/g (Table 11). 
These results reveal that the polyphenol content is not correlated with the 
antibacterial activity. Thus the aqueous plant extract with the highest 
polyphenol content did not present the highest antibacterial activity. In the 
present study O. vulgare presented the highest polyphenol content but it 
does not presented the highest antibacterial activity. As mentioned, 
H. sabdariffa presents moderate content of polyphenol but it possesses the 
highest antibacterial activity.  
Sirag et al. (2014) determined the total phenolic compounds in ethanolic 
extract of H. sabdariffa. The phenolic content represents 41.07 mg/g. Their 
study determined phenolic compound content higher than our plant extract 
content may be due to the extracts are different as our extract is aqueous 
extract and their extract is ethanolic ( Sirag 2014) .  
To summarize this part, the order of the plants extract in terms of 
polyphenol content is O. vulgare > R. officinalis > H. sabdariffa > 
C. zeylanicum > T. vulgaris. The order of the plants extract in terms of 
antibacterial activity is H. sabdariffa > C. zeylanicum > O. vulgare > 
R. officinalis > T. vulgaris. Stagos, et al. (2012) reported the same 
conclusion using 24 extracts from Greek domestic Lamieceae species: he 
found that the polyphenol content is not correlated with antibacterial and 
antioxidant activities (Stagos, Portesis et al., 2012). Mahboubi et al. (2014) 
study consistent with our results, they showed that the antibacterial activity 
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of five plants extract (Thymus vulgaris, Thymus caramanicus, Zataria 
multiflora, Ziziphora clinopodioides and Ziziphora tenuior) is not correlate 
with phenolic compounds contents (Mahboubi, et al., 2014). In contrast, the 
study of Shan et al., (2007) showed that the antibacterial activity of 46 
extracts from dietary spices and medicinal herbs was closely associated 
with their phenolic constituents (Shan, 2007). These results reveal that the 
phenolic compounds in our aqueous plants extract are not the major 
compounds responsible for the antibacterial activity. Therefore it is possible 
that other compounds (Cowan, 1999) are responsible for the antibacterial 
activity found acting individually or alternatively, they can synergize.  
After screening the antibacterial activity of the five aqueous plants extract, 
we decided to select H. sabdariffa aqueous extract as it showed the best 
antibacterial activity to complete the aims of our study. Therefore, we next 
determined the microbial quality of the dried calyces of H. sabdariffa. 
3. Microbial quality of Hibiscus sabdariffa calyces 
Naturally, plants have high level of microorganisms including bacteria and 
fungi. Microbial contamination of dried plants could be caused by 
inappropriate methods of cultivation, collection, harvesting, unsuitable 
transportation, prolonged drying and storage, inadequate hygiene of 
producers and climatic conditions. Microbial contamination can chemically 
transform some plants constituents to other metabolites not initially found in 
the herbal plants which may reduce or inactivate their therapeutic activity. 
Herbal plants which are used without boiling water have different limits of 
suitability regarding the presence of specific microorganisms than herbal 
plants used with boiling water (Table 16). Medicinal herbs and plants can 
be considered either as pharmaceutical preparations or as food and 
beverages in terms of their microbial quality, in compliance with the 
European Pharmacopoeia (Ph. Eur.) and the Royal Spanish 
Pharmacopoeia (Ph. R. Sp.) (Real Farmacopea Española, R. F. E.) on one 
hand; or in compliance with the Spanish Regulations on Food and 
Beverages (Codex Alimentarius). According to the Ph. Eur. and Ph. R. Sp. 
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medicinal plants are included in category 4 which states that herbal 
remedies consisting solely of one or more vegetable drugs (whole, reduced 
or powdered). 
When considered as food and beverages, most of medicinal plants are 
included into the group of stimulating food and derivatives, Codex 
Alimentarius Chapter XXV, under the epigraph of “plant species for use in 
feeding infusions”. This title groups the vegetal species, or their parts, used 
in feeding for their physiological action, because of the characteristic flavor 
and taste (Real Decreto 3176/1983 of November 16; B.O.E 28-12-83) 
(Table 17). 
Table 16. Microbial criteria for pharmaceutical preparation (European 
Pharmacopoeia) 
 
Herbal remedies to 
which boiling water is 
added before use 
Herbal remedies to which 
boiling water is not added 
before use 
Total viable aerobic 
count 
Not more than 107 /g or 
mLof aerobic bacteria 
Not more than 105 /g or 
mL of aerobic fungi 
Not more than 105 /g or mL 
of aerobic bacteria 
Not more than104 /g or mL 
of fungi 
E. coli 102 /g or mL Absence in 1g or 1mL 
Salmonella  Absence in 10 g or 10 mL 
Enterobacteria  Not more than 103 /g or mL 
 
Table 17. Microbial criteria for stimulating foods and derivatives. 
Microbial Regulation R.D. 1534/1483 of April 27; B.O.E. 27-5-
83(1). 
Total viable aerobic count Maximum 1x106 CFU/g 
Salmonella-Shigella Absence /25 g 
E. coli 1x104 CFU/g 
B. cereus 1x102 CFU/g 
Fungi Maximum 1x104 CFU/g 
(1) Microbial Regulation for tea and other plant infusions. Spanish Regulations on 
Food and Beverages. 
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The microbial contamination of herbal plants may reduce or inactivate their 
therapeutic activity and some plants sensitive constituents could be 
transformed chemically to poisonous compounds by contaminating 
microorganisms (Ahmed, 2006). The evaluation of the microbial quality was 
done by using the standard colony-count method which is commonly used 
for detecting and determining the number of microorganisms in plant 
materials to evaluate the food safety and commercial quality. The present 
study show that the calyces of H. sabdariffa that are used in our study did 
not present, E. coli, S. aureus, L. monocytogenes, but it has Enterobacteria 
(18 CFU/10 g), B. cereus (<102 CFU/10 g) and fungi (5x102 CFU/g). 
Although the calyces of H. sabdariffa have been contaminated with some of 
Enterobacteria, B. cereus and fungi, it can be used for human consumption 
due to its acceptable microbiological criteria that is consistent with the 
microbial criteria shown in table 16 and 17. According to the the European 
microbial criteria that is mentioned in table 16 and 17. Therefore, the results 
(Table 10) show that there are no faecal contaminations and suggested 
adequate measures during cultivation, collection, harvesting, drying, 
packaging and an adequate hygiene of producers. The implication of these 
results is that the dried H. sabdariffa calyces are appropriate for human 
consumption and can be used as a medicinal herbal plant. 
In 2009, Adebayo-tayo et al., isolated several microorganisms from the 
dried H. sabdariffa calyces collected from different markets in Uyo (Eastern 
Nigeria). They isolated S. aureus, B. subtilis, Bacillus spp. E. faecalis, 
Micrococcus spp. and Klebsiella spp. The associated fungi found were 
Aspergillus flavus, A. terreus, A. glaucus, Penicillium citrinum, Fusarium 
oxysporum, Rhizopus spp. and Mucor spp. A. glaucus had the highest 
frequency of occurrence among the isolated fungi (Adebayo-tayo, 2009). 
This study proved that the majority of the collected samples of dried 
H. sabdariffa calyces are below the acceptable limit for human consumption 
which conflicting with our study results. 
Another study of Omemu et al. (2005) in Nigeria, reported that the 
microorganisms isolated from the dried calyx and the juices included the 
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fungi, Aspergillus niger, Aspergillus flavus, Rhizopus oligosporus, 
Penicillium citrinum, Mucor spp., Saccharomyces cerevisiae, and Candida 
krusei, while Bacillus subtilis, Pseudomonas. spp., S. aureus, 
Streptococcus faecalis, Escherichia coli, Proteus mirabilis, Serratia spp., 
Lactobacillus brevis and Lactobacillus fermentum represented the bacterial 
isolates (Omemu, 2006). 
These two studies are contradicting our study probably due to the different 
origin of dried H. sabdariffa calyces. Our dried calyces were purchased 
from local herbalist of Egypt, accordingly soil, climatic conditions, 
cultivation, harvesting, drying, packaging and hygiene of producers could 
be different than in Nigeria.  
Afterwards, because of the good antibacterial activity presented by 
H. sabdariffa aqueous extract, it was relevant to evaluate the cytotoxicity in 
in vitro. So that, in order to evaluate the cytotoxicity of the aqueous extract 
of H. sabdariffa, the cell viability of both macrophages and HeLa cell lines 
was measured after their treatment with the aqueous extract as an index of 
cytotoxicity.  
4. Evaluation of the cytotoxicity 
4.1 Cytotoxicity of Hibiscus sabdariffa on macrophages 
We used the J774 macrophage cell line to assess the cytotoxicity of 
H. sabdariffa as previously described (O'Brien, 2000). The cytotoxicity was 
assessed by determining the concentration that decreases the cell viability 
of macrophages to 80-75 %. H. sabdariffa extract was used at 10, 50 and 
100 µg/mL. It was observed that the H. sabdariffa extract has not cytotoxic 
effects at the used concentrations (Fig. 32). We avoided using higher 
concentrations with macrophages due to the pH change that was 
appreciable by the change in the color of culture medium (that was 
corroborated by measuring the pH (pH= 4 at 1 mg/mL) that could lead to 
macrophages death. Therefore the H. sabdariffa extract can be used with 
safety and efficacy as antibacterial agent for human consumption. 
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4.2 Cytotoxicity of Hibiscus sabdariffa extract on HeLa 
cells 
The cytotoxicity of H. sabdariffa was also evaluated using infection 
experiemnts of HeLa cells because it is a frequently used infection model. 
First at all, we evaluated the cytotoxicity of the H. sabdariffa extract at 
different concentrations. We observed (Fig. 33) that the aqueous extract of 
H. sabdariffa at 5 and 7 mg/mL did not show any significant effect on the 
growth of HeLa cells. However, it shows a significant cell growth inhibition 
at 10 mg/mL. At such concentration HeLa cell growth was inhibited by 
approximately 50 %. These results at 5, 7 and 10 mg/mL concentrations 
were confirmed by using 4 different initiall cell densities (1x105, 2x105, 
3x105 and 4x105 cells/well) of HeLa cells. 
 Khaghani et al. (2011) evaluated the cytotoxicity of H. sabdariffa extract 
from calyces. They used two types of cell lines, namely human breast 
adenocarcinoma MCF-7 (a breast-cancer cell line) and normal human fetal 
foreskin fibroblast HFFF. The concentrations of the aqueous extract that 
were used ranged between 0.05 and 0.5 mg/mL (Khaghani, 2011). They 
observed that the H. sabdariffa extract significantly decreased by 45% the 
number of MCF-7 cells at 0.5 mg/mL after 72 h exposure. On the contrary 
the H. sabdariffa extract was not cytotoxic for the HFFF cell line after 
incubation of 24-72 h at all tested concentrations. These results reveal that 
the H. sabdariffa extract has a selective cytotoxicity. These results are 
consistent with our findings: we observed a significant decrease of HeLa 
cell numbers to approximately 50%, after 24 h incubation with the aqueous 
extract at 10 mg/ml. This cytotoxic effect on cancer cell lines is probably 
due to an anti-proliferative effect. Comparable results were obtained by 
Akim et al. (2011) showing that H. sabdariffa extract has antiproliferative 
effects on different cancer cell lines as Caov-3, MCF-7, MDA-MB-231 and 
HeLa cells (Akim, 2011) which further supports our results. 
Furthermore, Onyenkewe et al. (1999) and Ali et al. (2005) in an in vivo 
study using rats, reported that the LD50 of H. sabdariffa calyces extract was 
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above 5000 mg/kg, suggesting that the extract is substantially non-toxic 
(Onyenekwe,  et al. 1999; Ali, et al. 2005). From all these studies we 
concluded that the H. sabdariffa has potential safety for human 
consumption as an antibacterial agent. 
4.3 Cytotoxicity of Cinnamomum zeylanicum on 
macrophages 
Cytotoxicity of C. zeylanicum extract was assessed using the J774 
macrophage cell line as previously described (O'Brien, 2000). The 
cytotoxicity was assessed by determining the concentration that decreases 
the cell viability of macrophages to 80-75 %. C. zeylanicum extract was 
used at 10, 50 and 100 µg/ml. The results (Fig. 34) indicate that the 
C. zeylanicum extract is not toxic at 10, 50 and 100 µg/ml concentrations 
on J774 murine macrophages cell line, compared with the control, although 
it is close to the limit considered as cytotoxic, as previously mentioned.  
Singh et al. (2009) analyze the cytotoxic effect of an aqueous cinnamon 
extract from the bark of C. zeylanicum compared with that of commercially 
available cinnamaldehyde and was performed on various human and 
mouse cell lines as well as in primary cells. The aqueous cinnamon extract 
proved to be more cytotoxic to cancerous cells at concentrations just above 
0.16 mg/mL (containing 1.28 μM cinnamaldehyde) around which the 
commercial cinnamaldehyde (1.6 μM) had no cytotoxic effect. At a critical 
concentration of 1.28 mg/mL (containing 10.24 μM cinnamaldehyde), 
aqueous cinnamon extract treatment resulted in 35-85% growth inhibition of 
the majority of the cancerous cells, whereas at a similar concentration 
(10 μM) commercial cinnamaldehyde treatment resulted in 30% growth 
inhibition of only SK-N-MC cells with no effect on other cell lines (Singh, et 
al. 2009). These results suggest that aqueous cinnamon extract had 
a significant inhibitory effect on the majority of cancer cells and thus may 
suggest to be a chemotherapeutic agent and proved that lower 
concentrations than 0.16 mg/mL is not inducing cytotoxic effect to cancer 
cells. 
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Recently, because of recurrence outbreaks caused by E. coli worldwide, 
particularly the significant outbreak that occurred in Germany 2011 due to 
E. coli O104:H4 strain that possesses a new mixture of pathogenic features 
from both EHEC (Stx but not the type III secretion and Tir/intimin system) 
and EAEC (specially the adherence mechanisms). Enteropathogenic E. coli 
(EPEC) 2348/69 was selected instead of EHEC because our laboratory 
safety level authorization prevent using EHEC as it is a level 3 
microorganism. So that, we analysed the antibacterial activity of the 
H. sabdariffa extract against EPEC using 5, 7, 10, 20, 25 mg/mL 
concentrations. We observed that EPEC was inhibited (MIC) at 7 mg/mL 
and was killed (MBC) at 25 mg/mL (Fig. 27). These results imply that the 
H. sabdariffa extract as a potential antibacterial activity against EPEC and 
might be used for treatment of gastroenteritis induced by EPEC. 
5. Effect on pedestal formation induced by EPEC 
5.1 Effect of Hibiscus sabdariffa extract on pedestal 
formation 
EPEC adheres to intestinal cells, promotes characteristic A/E lesions and 
the formation of disease-associated actin-enriched structures called 
pedestals. A widespread in vitro model of infection is the use of HeLa cells. 
To investigate the effects of H. sabdariffa extract on pedestal formation, 
HeLa cells were treated for 3h with the aqueous extract after infection by 
EPEC for 3h; at this time point pedestals should have been readily 
detectable. 
We observed that the H. sabdariffa extract blocked pedestal formation 
while the infected untreated HeLa cells displayed an increase in the 
number of pedestals along time (Fig. 35 and 36). These results indicate 
that the H. sabdariffa extract can inhibit pedestal formation induced by 
EPEC even if the bacteria are already attached to the cells.  
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After observing that the H. sabdariffa extract decreases the number of 
pedestals, we hypothesized that the aqueous extract may prevent pedestal 
formation. To comprehend that purpose, two strategies were used 
1- Treating HeLa cell for 3h with the aqueous extract before infection 
by EPEC (preventive treatment).  
2- Treating HeLa cells for 3h with the aqueous extract during EPEC 
infection (simultaneous treatment). 
With the first strategy, we observed that pedestals were not formed which 
prove that the aqueous extract can prevent their formation (Fig. 37). With 
the second approach, we also observed that pedestals were not formed 
(Fig. 38). 
Importantly, while performing the infection experiments, we observed that 
H. sabdariffa extract induced a filamentous morphology of the bacteria. We 
interpret that the extract was inhibiting the final steps of the bacterial 
division and decided to further investigate the important finding, discussed 
in detail below. 
Our study represents the first of its class to address the effect of 
H. sabdariffa extract on pedestal formation by EPEC. Furthermore, we 
propose a previously unreported mode of action as antibacterial agent 
against EPEC: inhibition of cell division. We concluded that the aqueous 
extract of H. sabdariffa could have a potential use for treatment and 
prevention of gastroenteritis produced by EPEC. Future studies will aim to 
analyse the effect in vivo, using Citrobacter rodentium infection of mice. 
6. Probable mechanism of action of Hibiscus 
sabdariffa as antibacterial agent 
Surprisingly, using fluorescence microscopy while performing the HeLa cell 
infection experiments, we observed that treatments of EPEC with the 
H. sabdariffa extract induced a filamentous morphology; in which cells 
continue to elongate but do not separate (probably implying no septa 
formation).  
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Next Gram´s and DAPI staining was performed to compare this phenotype 
with the one produced by ceftazidime, an antibiotic known to induce 
filamentous morphology of Gram-negative bacteria. Thus, EPEC was 
treated with ceftazidime at MIC 0.5 µg/mL for 3h, and in parallel, we use the 
H. sabdariffa aquous extract at 10 mg/mL for 3h. We compared both 
conditions to untreated EPEC as a negative control (Fig. 40). We observed 
that the filamentous morphology of EPEC that is induced by H. sabdariffa is 
similar to the one induced by ceftazidime. However, at higher 
concentrations of aqueous extract of H. sabdariffa, such as 20 mg/mL 
(bactericidal concentration), the filamentous morphology was not observed.  
Buijs et al. in 2007 reported that ceftazidime and cefotaxime induce 
a filamentous morphology in bacteria. Ceftazidime is a β-lactamic antibiotic 
with affinity for penicillin-binding protein (PBP-3) and PBP-1. At low 
concentrations, ceftazidime inhibits PBP-3 leading to filament formation, but 
at higher concentrations inhibits PBP-1 resulting in rapid bacterial lysis. In 
addition, it was reported that the capacity to produce filaments correlates 
with the MIC (Buijs, 2007). Therefore, probably for that reason we could not 
observe the filamentous morphology of treated EPEC with H. sabdariffa at 
higher concentrations such as 20 or 25 mg/mL. 
It has been reported that this morphological change (filament induction) 
reduces the ability of bacteria to adhere to epithelial cells (Zhanel, 1992). 
This would explain why there was a significant inhibition of pedestal 
formation by EPEC in all conditions tested. We can conclude that the 
probable mechanism of action of our aqueous extract as antibacterial agent 
is similar to the one of ceftazidime. Collectively, H. sabdariffa extract 
antibacterial activity could be due to the interference of the active 
compounds with bacterial cell wall synthesis, inducing the filamentous 
morphology at lower concentrations and bacterial death, at higher 
concentrations. 
After proving that the H. sabdariffa extract is a very potent antibacterial 
agent against Gram-negative and Gram-positive bacteria that can 
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potentially be used for treatment and prevention of gastroenteritis induced 
by EPEC and establishing its safety for human consumption, it was 
interesting to study the rates of bacterial killing. Therefore we performed 
time kill analysis. 
7. Time kill studies 
Time kill curve is an accepted index of bactericidal activity which is used for 
assessment of the efficacy of bactericidal agents. The rates of bacterial 
killing after exposure to the antibacterial agents should achieve a 3-log 
decrease in viability. The concentrations used in time kill study were 
10 (1.4 x MIC) and 25 (3.5 x MIC) mg/mL of the H. sabdariffa extract 
against EPEC at 4x106 CFU/mL. The cell counts were determined at 0, 2, 4, 
6, 8, 10, 12, and 24 h of drug exposure compared to the cell counts of 
untreated EPEC as a control for growth. 10 mg/mL is the maximum 
concentration used for inhibition of pedestal formation without affecting 
immunostaining of HeLa cells, moreover its induction to filamentous 
morphology of EPEC was compared to ceftazidime antibiotic. For these 
reasons, it was decided using 10 mg/mL in this time kill study instead of 
7 mg/mL. From Fig. 28 the bactericidal activity of H. sabdariffa extract 
started at 10 h. As the 3-log decrease in cell viability is occurred at 
25 mg/mL (MBC) (Fig. 28). At 10 mg/mL is an inhibitory concentration, as 
no decrease in cell viability observed during 24 h. According to the 
calculation from figure equation, K values are: K25 = 0.131 h-1, 
K10 = 0.018 h-1. For 25 mg/mL (MBC), the following parameters are derived 
from the killing equation: the mean times to achieve reductions in the 
proportions of viable cells of 50% (t50) = 2.3h, 90% (t90) = 7.6 h, and 99% 
(t99) = 15.3 h, and the time to reach the bactericidal endpoint 99.9% (t99.9) 
= 23 h. For 10 mg/mL (MIC), the mean times to achieve reductions in the 
proportions of viable cells of 50% (t50) = 16.5 h, 90% (t90) = 55 h, and 
99% (t99) = 110 h and the time to reach the bactericidal endpoint 
99.9% (t99.9) = 165 h. These results suggest that the H. sabdariffa extract 
at MIC (10 mg/mL) the endpoint of bactericidal activity would be reached in 
6.9 days. Whereas with the MBC (25 mg/mL) the endpoint is reached in 
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23 h. Nevertheless, it should be notice that we are working with a crude 
extract and not with a pure active principle. These results can interpret the 
wide range between the MIC (7mg/mL) and the MBC (25 mg/mL) against 
EPEC is due to the time required for the bactericidal activity of H. sabdariffa 
is concentration dependent. This is the first study showing the bactericidal 
activity rate of H. sabdariffa extract against EPEC. It can be concluded that 
H. sabdariffa extract is a potential antibacterial agent specifically against 
EPEC. 
8. Effect of Hibiscus sabdariffa extract on Fungi 
After proving that the H. sabdariffa extract has a potent antibacterial activity 
against Gram-negative and Gram-positive bacteria, it was pertinent to 
investigate its antifungal activity. We tested the extract activity against 
C. albicans, and two strains of S. cerevisiae, YPH 499 and BY4741. Drop 
assay was performed using the aqueous extract at 5, 10, 20, 35, 70, 140 
and 250 mg/mL concentrations. It was observed that the H. sabdariffa 
extract inhibits the growth of S. cerevisiae BY4741 at 10 mg/mL. However 
the MIC for C. albicans and S. cerevisiae YPH 499 was 70 mg/mL (Fig. 
29A).  
Thereafter, it was found that the H. Sabdariffa extract has no fungicidal 
activity on Candida albicans and Saccharomyces cerevisiae BY4741, even 
at concentrations up to 250 mg/mL. However at 140 mg/mL concentration 
has fungicidal activity on Saccharomyces cerevisiae YPH 499 (Fig. 29B). 
Consistent with our results, the study by Elsayed and Elshafei (2011) 
recently reported that the H. sabdariffa extract is able to inhibit the growth 
of Bacillus mycoides, Escherichia coli and Candida albicans  in the ranges 
of 0.32 ± 0.13 - 1.50 ± 0.05 mg/mL using agar well diffusion method 
(Elshafei, 2011). However Olaleye (2007) reported that the methanolic 
extract of H. sabdariffa is not able to inhibit Candida albicans up to 
80 mg/mL (maximum concentration used in this study) using agar diffusion 
method.  
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Fitzgeralda et al. (2003) suggested that the H. sabdariffa extract can be 
used as a preservative agent for food (Fitzgeralda, 2003). Therefore, the 
H. sabdariffa extract could not be used for treatment of fungal diseases, 
due to its inability to induce fungicidal activity.   
8.1 Dimorphism in fungi 
The word dimorphism (Greek dis = two; morphe = form), is used in 
mycology to describe the property that is possessed by some fungi to adapt 
two different vegetative morphologies, depending on the growth conditions. 
However, the denotative value of this term, in our discipline, not reduced to 
duality of yeast-hypha phenotype, because under the heading dimorphic 
fungi includes a number of organizations with more than two 
interconvertible morphologies, distinct, coexisting in certain circumstances 
and some authors suggest the term pleomorphic or polymorphic 
(Rodríguez, 1987). 
The phenomenon of dimorphism is the capacity displayed by different fungi 
to grow in two forms: yeast and hypha (mycelium). The conditions that 
induce the dimorphic transition of yeast to hypha or vice versa are very 
diverse, including changes in temperature, pH, the gaseous atmosphere of 
growth, or the presence of specific compounds in the culture media 
(Coelho, 2010). Several fungal species display a morphological change 
called dimorphism and it is associated to pathogenesis. Dimorphism can be 
defined as the capacity of fungi to grow in two distinct morphological forms 
as yeast form or filamentous form. This phenomenon is induced as 
a response to the environmental conditions as pH, temperature, nutritional 
status, gaseous atmosphere of growth (CO2 content) or presence of specific 
compounds in the culture media. This ability of switching among these 
morphologies (yeast and mycelium forms) is required for virulence although 
both forms have been identified during infection (Ruìz-Herrera, 2012). 
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8.2 Effect of Hibiscus sabdariffa extract on Candida 
albicans morphology 
In C. albicans, the dimorphic transition can be induced by a range of 
environmental conditions and molecules including pH, temperature, 
nutritional factors, serum (Jacobsen, 2012) or quorum sensing 
(Albuquerque, 2012). At low pH, < 6, C. albicans cells predominantly grow 
in the yeast form, while at a high pH, > 7, hyphal growth is induced (Soll, 
1986). In contrast, in presence of H. sabdariffa extract (at low pH, ≤ 4) 
C. albicans undergoes the transition to hyphae (Fig. 30). In order to obtain 
more conclusive results and to understand the regulation of this 
phenomenon at the molecular level, further studies are needed.  
There are several virulence factors of C. albicans contributing to its 
pathogenicity. These properties include adhesiveness to host cells, 
secretion of degradative enzymes, and the ability to undergo a reversible 
morphological transition from the blastospore to filamentous forms 
(Ruìz Herrera, 2012). Therefore our results indicate that the induction of 
a filamentous morphology at low concentrations of 5, 10, 20, 35 mg/mL 
could be attributed to the increase of its virulence. At higher concentrations 
70 mg/mL (MIC) we could not observed the phenotype due to the growth 
inhibitory effect of the aqueous extract against C. albicans (Fig. 30). 
Alternatively, it is possible that H. sabdariffa contain an active constituent 
able to induce filamentation of C. albicans. Further studies are required to 
prove any of these two hypothesises. 
8.3 Effect of Hibiscus sabdariffa extract on 
Yarrowia lipolytica morphology 
Y. lipolytica is non-pathogenic dimorphic yeast. It has the capacity to 
metabolize hydrocarbons and lipids, to accumulate large amount of organic 
acids and to secrete heterologous proteins. It represents a very good model 
for studying fungal dimorphism. It has been described that the transition 
yeast to hypha in Y. lipolytica is induced as a response to neutral pH or 
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high temperature or presence of serum (Rodríguez and Domíngez, 1984) 
or in presence of N-acetylglucosamine as the only carbon source, as only 
induction factor (Rodríguez and Domínguez, 1990). Interestingly, we 
observed hypha formation of Y. lipolytica, although the pH of our 
H. sabdariffa extract was acidic (low pH < 4) at 30 ºC (Fig. 31). These 
conditions are non-filament inducing conditions. But at higher concentration 
70 mg/mL of the aqueous extract those filaments were not observed. These 
results are analogous to the observed with C. albicans. 
9. Fractionation of the Hibiscus sabdariffa extract 
The lyophilized H. sabdariffa extract was fractionated using different 
organic solvents. The fractionation process was carried out by using 
organic solvents according to their differential polarity. Due to the fact that 
the lyophilized H. sabdariffa extract is a very polar extract, we started the 
fractionation with the less polar organic solvent and continue with the 
higher polar organic solvents.  
Hexane was the first solvent used in our fractionation process and as 
expected we did not obtain an extract from the lyophilized H. sabdariffa 
extract. Then ethyl acetate, acetone and ethanol solvents were used. 
EtOAc extract presented the lowest yield (0.42 %) while EtOH extract 
presented the highest yield (51.5 %). Acetone extract presented law yield 
(2.8 %) and AC-EtOH extract presented moderate yield (36.5%) 
(Scheme 1). This implies that the compounds that H. sabdariffa calyces 
contain are highly polar. 
 The antibacterial activity of EtOAc, AC, EtOH extracts and the residue was 
evaluated against EPEC and E. coli ATCC 29522, AC-EtOH extract was 
evaluated against EPEC only, using micro dilution assay at 10 mg/mL as 
preliminary test. We observed that the active extracts are AC, EtOH and 
AC-EtOH extracts, as they showed antibacterial activity against EPEC and 
E. coli ATCC 29522 at 10 mg/mL and AC-EtOH extract showed 
antibacterial activity against EPEC at 10 mg/mL (Fig. 41).  
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We determined the MIC and MBC of the active extracts (AC and EtOH) 
against EPEC, E. coli ATCC 29522, S. aureus and Methicillin Resistant 
S. aureus (MRSA) at 2, 5, 8 and 10 mg/mL. But AC-EtOH extract used 
against EPEC only at 5, 10, 20 and 25 mg/mL. We observed that AC and 
EtOH extracts showed MIC against EPEC, E. coli ATCC 29522, S. aureus 
and Methicillin Resistant S. aureus (MRSA) at 5 mg/mL, and MBC at 
5 mg/mL for E. coli ATCC 29522, S. aureus and Methicillin Resistant 
S. aureus (MRSA) and 8 mg/mL for EPEC (Fig. 42) (Table 11). AC-EtOH 
extract showed MIC and MBC against EPEC at 5 and 10 mg/mL, 
respectively. 
AC-EtOH extract originates after thin layer chromatography (TLC) analysis 
to fractionate AC and EtOH extracts, we observed that EtOH extract 
contains bands similar to the AC extract bands. So that, we decided to treat 
EtOH extract with acetone solvent to obtain AC extract from EtOH extract 
(AC-EtOH). The antibacterial activity of both AC-EtOH extract and the 
residue of EtOH extract was evaluated against EPEC. We observed that 
the AC-EtOH extract has MIC at 5 mg/mL and MBC at 10 mg/mL, while the 
residue did not show antibacterial activity at 10 mg/ml (Fig. 41). All together 
we concluded that the antibacterial active constituents present in the AC 
extract as well as AC-EtOH extract. 
We continue the isolation process, therefore, AC extract was fractionated 
using column chromatography with silica gel as stationary phase and using 
gradient eluent of DCM:MeOH 20:1 increasing the polarity gradually up to 
MeOH 100% as mobile phase (Table 12). Six fractions of AC extract were 
obtained (Table 12). Their antibacterial activity was evaluated against two 
Gram-negative bacteria EPEC, E. coli ATCC 29522, and two Gram-positive 
bacteria S. aureus and Methicillin Resistant S. aureus (MRSA) at 5 and 
10 mg/mL concentrations. We observed that fractions 2, 3 and 4 showed 
the strongest antibacterial activity, as they exhibited MIC at 5 mg/mL and 
MBC at 5 mg/mL for all tested bacteria (Fig. 44 C, D, and 45A, B, C and D) 
(Table 13). Fraction number 5 showed fainter antibacterial activity than 
fractions 2, 3 and 4 (Fig. 46 A and B). Fractions 1 and 6 showed no 
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bactericidal activity against tested bacteria at the used concentrations (Fig. 
44B and 46D) (Table 13). 
Similarly the AC-EtOH extract was fractionated using column 
chromatography with silica gel as stationary phase and using gradient 
eluent solvent of DCM:MeOH 10:1 increasing the polarity gradually up to 
100% MeOH as mobile phase (Table 14). 10 fractions were obtained from 
AC-EtOH extract (Table 14). Their antibacterial activity was evaluated 
against EPEC only, because it is our research interest and to save fractions 
quantities for further fractionation, at 5, 10, 20 and 25 mg/mL. We observed 
that the fractions 2, 3, 4, 5, 6, 8, 9 showed the best antibacterial activity, as 
they exhibited MIC against EPEC at 5 mg/mL and MBC at 10 mg/mL 
(Fig. 48C, D, 49A, B, C, D, 50A, B, C, D, 51C, D and 52A, B)  (Table 15). 
But fractions 1, 7 and 10 displayed lower antibacterial activity than the rest 
of 10 fractions (Fig. 48A, B 51A, B and 52C, D) (Table 15). These results 
reveal that specifically fractions 2, 3 and 4 of AC extract displayed stronger 
antibacterial activity than the fractions of AC-EtOH extract which probably 
implies that the active constituents are more concentrated in AC extract 
than in the AC-EtOH extracts if we hypothesized that both extracts contain 
the same active constituents. 
TLC result of both extracts (AC and AC-EtOH extract) was observed under 
UV light to conclude that both extracts have similar bands on TLC using 
DCM:MeOH 10:1 as mobile phase (Fig. 53) implicating that both extracts 
could contain similar active compounds. DI
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Figure 53. Thin layer chromatography (TLC). TLC was marked showing the 
running pattern of compounds through TLC of AC extract (A) and AC-EtOH extract 
(A de E) using solvent mixture of DCM:MeOH 10:1 as a mobile phase. 
 
All together, we concluded that the stronger antibacterial activity of some 
fractions versus others is probably due to the presence of higher 
concentrations of active antibacterial compounds. Alternatively, they may 
contain specific compounds that act synergistically. Therefore, if these 
synergistic compounds are separated they loss their antibacterial activity. 
This could explaine the lack of antibacterial activity obtained in the last 
fractionation performed to get fractions A, B and C, although their parental 
fraction showed antibacterial activity (data not shown).  
The antibacterial activity of H. sabdariffa has been attributed to numerous 
compounds (secondary metabolites) found in the calyces. There are 
different secondary metabolites of calyces that have been identified as 
protocatechuic acid, phenolic acids, organic acids, saponins and alkaloids 
(Liu, Tsao et al. 2005; Olaleye 2007).  
Morales-Cabrera and others, (2013) examined the antimicrobial activity of 
five varieties of H. sabdariffa against S. Typhimurium and S. Choleraesuis. 
Aqueous, methanol and the ethanol extract were tested and it was 
determined that ethanol extracts were the most effective against 
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Salmonella (Morales-Cabrera 2013). However, the methanol extract of 
H. sabdariffa showed antibacterial activity against E. coli O157:H7 (EHEC) 
that was isolated from food, veterinary and clinical samples (Fullerton 
2011). In a different study, the ethanolic extract showed better 
antibacterial activity than the aqueous extract of H. sabdariffa against 
E. coli, S. aureus, P. aeruginosa and S. mutants (Al-Hashimi, 2012).  
In conclusion, the majority of currently published reports that ethanolic or 
methanolic extracts of H. sabdariffa calyces showed higher antibacterial 
activity than the aqueous extract. The present study is the first study 
reporting that the acetone soluble extract showed better antibacterial 
activity against tested bacteria than the aqueous extract. Our result could 
be of use for pharmaceutical formula preparation for treatment of enteric 
infections specifically induced by EPEC. Therefore, we conclude that the 
crude aqueous extract or the fractions of H. sabdariffa can be used for 
treatment of gastroenteritis even more considering that this plant is already 
used as a tea. 
10. Perspectives 
Future studies will aim to:  
To study the potential molecular target of H. sabdariffa in the bacteria cell 
wall to induce bacterial filamentation.  
Determination of the active compounds of H. sabdariffa as antibacterial 
agents. This in progress with prof. Angel Rumbero (Dpt. of organic 
chemistry, Fac. of Science, UAM).  
Determination of the in vivo antibacterial effect of the new natural extract in 
animal model (mice) infected with Citrobacter rodentium (etiologic agent 
equivalent to human infection with EPEC) by:  
(a) Determining the bacterial count in the stool of infected and 
infected/treated groups (collect stool at days 7 and 14, end of the 
experiment) and determine bacterial count. 
(b) Determining the amount of water in the stool.  
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(c) Determining the inflammatory store. 
(d) Staining for selected protein (tight junction and inflammation).  
To determine the effectiveness of H. sabdariffa extract in protecting barrier 
function of intestinal monolayers. The in vitro experimental study can be 
achieved by using a specific intestinal cell line (Caco 2) grown in transwells. 
These will be used to assess the new plant extract’s ability to protect 
intestinal barrier function (measuring transepithelial resistance) in 
monolayers infected with EPEC. Moreover, staining these monolayers for 
tight junction proteins (occluding, ZO1) will exhibit the efficiency of new 
plant extract in protection of tight junction structure.  
We will determine the efficiency of H. sabdariffa extract in protecting host 
intestinal cells with EPEC-induced inflammatory response. In the designed 
experimental groups, we will assess if the extract attenuates the 
inflammatory signaling pathway (NF-kB) and cytokine expression (IL-8) 
induced by EPEC infection.  
A collaboration with Dr. S. Savkovic (NorthShore University Healthsystem, 
Evanston, Illinois, USA) have been already stablished in order to 
address these aspects. 
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Conclusions 
The antibacterial activity of five natural plant extracts were assayed 
against Gram-positive (Staphylococcus aureus, Methicillin Resistant 
S. aureus (MRSA), Enterococcus faecalis, Listeria monocytogens 
ATCC 7644 and L. monocytogenes isolated from meat); and Gram-
negative bacteria (Uropathogenic Escherichia coli, 
Enteropathogenic E. coli (EPEC E 2348/69), E. coli ATCC 25922, 
Pseudomonas aeruginosa, Klebsiella pneumoniae, Salmonella 
Typhimurium and S. Enteritidis). 
1. The antibacterial Hibiscus sabdariffa extract has antibacterial activity
against all tested Gram-positive and Gram-negative bacteria.
Cinnamomum zeylanicum extract has antibacterial activity against all
tested Gram-positive and Gram-negative bacteria. Origanum vulgare
extract showed antibacterial activity against Gram-positive and
Gram-negative bacteria except P. aeruginosa. Rosmarinus officinalis
is only active against Gram positive bacteria. Also Thymus vulgaris is
only active against Gram positive bacteria.
The most active extracts are H. sabdariffa and C. zeylanicum. In
general, Gram-positive bacteria are more sensitive than Gram
negative bacteria. The sensitivity ranges are similar for both extracts,
except Klebsiella pneumonia, that is the less sensitive with
C. zeylanicum.
2. The bactericidal activity of H. sabdariffa is dose and time dependent,
with a bactericidal endpoint t99.9 of 23h, for EPEC.
3. H. sabdariffa calyces can be a source of antibacterial compounds
against Gram-negative and Gram-positive bacteria. But not for
antifungal compounds due to the lack of fungicidal activity against
Candida albicans.
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4. H. sabdariffa extract has an antiproliferative effect over HeLa cells, in 
agreement with previous results obtained with other transformed cell 
lines.  
 
5. H. sabdariffa total extract inhibits and prevents pedestal formation in 
treated Hela cells.  
 
6. The bactericidal action over EPEC and the inhibitory activity of 
H. sabdariffa extract over pedestal formation might be, at least in 
part, due to the induction of bacterial filamentation, which can be 
mediated through the interaction of some active constituents with a 
molecular target, inducing incomplete cell wall synthesis.  
 
7. The most active fractions obtained from H. sabdariffa extract are the 
fractions 2, 3 and 4 obtained from the “acetone extract”. Those 
fractions can be used for further isolation of active compounds as 
antibacterial agents, or for obtaining pharmaceutical preparations for 
the treatment of enteric infections, specifically those produced by 
EPEC. 
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